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 Proteomics is the large scale study of a set of proteins from a biological species to understand 
protein expression, post translation modifications, and protein-protein interactions.  Mass spectrometry 
(MS)-based proteomics allows large scale protein identification and quantitation in the same experiment.  
Quantitative proteomics reports abundance changes between multiple protein samples, which principally 
reflect a biological process or disease state.  Relative quantitation can be achieved using stable isotope 
chemical labeling of proteins or peptides using MS or tandem mass spectrometry (MS/MS).  Sample 
throughput is limited by the chemical tag and technique.  MS-based protein quantitation employs methods 
which generate a mass shift in MS to compare abundance changes between two to three samples.  An 
example of precursor quantitation is described using acetylation to study the spleen proteome of mice 
treated with Adriamycin.  Isobaric tags, such as tandem mass tags (TMT), achieve relative quantitation of 
up to ten samples in MS/MS.  In order to analyze additional biological samples beyond ten, multiple 
experiments must be performed separately, which leads to increased instrument time, higher cost, and 
variation due to additional preparation steps, sample handling, and MS injections.   
Herein, novel methods which enhance multiplexing in quantitative proteomics beyond the current 
limitations are presented.  Enhanced multiplexing is achieved by combining precursor MS labeling with 
isobaric tags, which is termed “combined precursor isotopic labeling and isobaric tagging” (cPILOT).  
Initially, cPILOT is used to identify and quantify 3-nitrotyrosine (3NT) containing proteins.  The 
biological significance and proteomic techniques employed to study 3NT are reviewed.  cPILOT is 
expanded to a global strategy by coupling low pH dimethylation with TMT.  Global cPILOT was applied 
iv 
 
to study the liver proteome of an Alzheimer’s disease mouse model, which revealed alterations in 
metabolism.  Finally, the versatility of cPILOT is demonstrated by incorporating N,N-dimethyl Leucine 
isobaric tags.  Overall, the work presented throughout the dissertation highlights novel strategies to 
enhance multiplexing in quantitative proteomics which are applied to study various diseases. 
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 1.0.  INTRODUCTION 
1.1.  PROTEOMICS 
Proteomics is the study and characterization of expressed proteins from biological fluids, tissue 
homogenates, cell lysates, and dried blood spots [1, 2].  Proteomics provides key information about 
protein abundance, post-translational modifications (PTM), protein-protein interactions, and differences 
in expression [3, 4].  Clinically, proteomics is applied to discover potential drug targets and identify 
disease biomarkers [5].  Traditional analysis of proteins employs two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) [6].  Proteins migrate through a gel based on mobility in the first dimension 
followed by isoelectric point separation in the second dimension.  Separated proteins are detected using 
fluorescence [7], chemiluminescence [8], and Coomassie blue or silver staining [9], however only protein 
abundance information is obtained with these methods.    Primary antibodies can be coupled with 2D-
PAGE for targeted protein identification, but this method is low throughput and impractical for large scale 
proteomic studies [6].  Gel-based proteomics offer several advantages in robustness, reproducibility, and 
straight-forward analysis of whole proteins, but limitations include the missed detection of hydrophobic 
and low abundant proteins (< 1-10 ng), low resolution, and a limited dynamic range.  Mass spectrometry 
(MS) provides in-depth protein identification, quantitation and sequencing information and has become a 
principal tool in proteomics [10].  2D-PAGE can be coupled with MS, where proteins are separated 
through gels, excised, then analyzed using MS [6, 11].       
Advances in proteomics are driven by the continuous developments in analytical techniques and 
MS instrumentation.  It is estimated that over 100,000 unique protein sequences, isoforms, and post-
translation modifications are encoded by the human genome, resulting in protein concentrations spanning 
several orders of magnitude [12].  MS-based proteomics and tandem mass spectrometry (MS/MS) 
provides the ability to detect thousands of proteins in a single experiment.  Multiple separation techniques 
are frequently coupled with MS to enhance proteome coverage, which includes liquid chromatography 
(LC) and capillary electrophoresis (CE) [13, 14].  Additionally, mass spectrometers routinely used in 
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proteomics offer high resolution, high mass accuracy and fast MS/MS scan rates, allowing for high 
throughput protein identification.  For example, the most advanced MS instrumentation can identify 
approximately 90% of the yeast proteome in one hour of LC-MS/MS analysis time [15] and over 10,000 
proteins in C. elegans [16].  While these numbers are impressive and were not possible with past 
technology, there is no standard experiment in proteomics and results vary depending on project goals and 
experimental conditions.  Choices in sample preparation, chromatographic separation, instrumentation, 
MS/MS fragmentation, data collection, and data processing must be considered when designing a 
proteomics experiment.  The following sections in Chapter 1 discuss options available for key 
experimental parameters used in proteomics.  Emphasis is placed on techniques employed throughout this 
dissertation. 
 
1.1.1.  Post-Translation Modifications 
Post-translation modifications (PTM) result from the covalent attachment of a chemical species to 
amino acid functional groups.  Proteins expressed in nature are rarely pure, but instead exist in various 
combinations of isoforms and PTMs.  Mapping protein PTM sites is critical to understand biological 
processes.  Approximately 300 PTMs are known in eukaryote proteins [17], however the most common 
PTMs studied in proteomics are phosphorylation [18], cysteine oxidation [19] and nitrosylation [20], 
acetylation [21], glycosylation [22], and ubiquitination [23].  PTMs are involved in cellular signaling, 
communication, and regulation of biological processes.  For example, protein phosphorylation can occur 
as O-phosphorylation on Ser, Thr, and Tyr residues and N- phosphorylation on Arg, Lys, and His residues 
[18].  Biologically, phosphorylation is a PTM controlled by protein kinases and phosphatase enzymes to 
regulate metabolism, proliferation, cell differentiation and cell survival [24].  MS and MS/MS are 
powerful tools in protein characterization to provide further insight to relationships between function and 
PTM location [25].  
Redox proteomics involves the study and characterization of PTMs caused by reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) under conditions of oxidative stress [26].  Examples 
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of ROS and RNS include the superoxide anion (O2.-), hydrogen peroxide (H2O2), hydroxide (OH-), and 
peroxynitrite (ONOO-).  Due to the high reactivity of ROS and RNS, these species cause oxidative 
damage by creating unnatural modifications on protein sites, which can alter function and biological 
pathways [27, 28].  Oxidative damage includes the formation of protein carbonyls [29, 30] and nitration 
[31, 32] and is observed Alzheimer’s and Parkinson’s diseases, cardiovascular diseases, diabetes, and 
aging [33].  Chapter 3 reviews the proteomic techniques and analytical challenges in studying 3-
nitrotyrosine and Chapter 4 presents a novel proteomics method to selectively identify and quantify 
protein nitration. 
 
1.1.2.  Shotgun Proteomics 
MS-based proteomics can be performed on intact proteins (top-down) or peptides resulting from 
enzymatic digestion of proteins (bottom-up).  Top-down methods provide PTM and protein isoform 
characterization, however limitations exist due to difficulties in reproducible protein ionization, 
fragmentation, and separation techniques [34].  Bottom-up (“shotgun”) proteomics performs liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis on peptides, which exhibit more 
efficient ionization, gas phase fragmentation, and versatility in quantitative experiments compared to top-
down methods [12].  The general procedure for bottom-up proteomics is illustrated in Figure 1.1.  
Proteins are extracted from cell cultures or tissue homogenates and digested into peptides using a 
protease.  Trypsin is the most common protease, which cleaves proteins at lysine or arginine residues 
[35], however other proteases such as LysC and chymotrypsin can be used if alternative cleavage sites are 
required [36].  Proteins are digested into a pool of peptides and separated using a chromatographic 
technique in order to collect MS spectra free of background interfering species.  LC [6], capillary 
electrophoresis (CE) [37] and isoelectric focusing [38] can be used to separate peptide mixtures in one or 
more dimensions to increase identification in large scale experiments.  For example, Chapter 6 presents a 
2D-separation of liver protein digests using strong cation exchange (SCX) coupled with RPLC [7].  
Peptides are separated according to charge state on a Polysulfethyl A column to collect multiple fractions  
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Figure 1.1.  Procedure for bottom-up proteomics. 
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of equal concentration.  Elution is performed by increasing a KCl salt gradient.  Each fraction is collected, 
desalted, and subject to reversed phase liquid chromatography (RPLC), which exploits the differences in 
peptide hydrophobicity for separation.  Eluted peptides are ionized and introduced into MS, where ions 
are separated according to their mass to charge ratios (m/z) and abundances recorded by a detector.  
Tandem mass spectrometry (MS/MS) is routinely incorporated in MS-based proteomics to provide 
sequence information, which is discussed in Section 1.1.4.  Database search algorithms, such as 
SEQUEST (Section 1.1.5) [39], match experimental and theoretical MS/MS spectra to identify peptide 
sequences.  This strategy is used throughout the dissertation to identify proteins.  Quantitation can be built 
into the bottom-up proteomics procedure and will be discussed in Section 1.2.  
 
1.1.3. MS Instrumentation in Proteomics 
Eluted peptides from RPLC separations must be ionized prior to MS and MS/MS analysis.   
Electrospray ionization (ESI) [40] and matrix assisted laser desorption ionization (MALDI) [41] are two 
popular ionization sources in shotgun proteomics due to their ability to ionize large molecules at 
atmospheric pressure.  In ESI (used throughout the dissertation), LC eluted peptides form charged 
droplets resulting from an applied potential and travel towards the MS inlet.  Solvent evaporates from the 
droplet, which increases the charge density until a coulombic explosion creates smaller droplets and ions.  
ESI typically results in peptide ions of multiple charge states and couples well with mass analyzers with a 
limited m/z range.  Recently, other ionization techniques have emerged in proteomics and include 
desorption ESI (DESI) [42], laserspray ionization (LSI) [43], and solvent assisted inlet ionization (SAII) 
[44], which results in enhanced sensitivity while generating ESI-like ions.   
New developments in mass spectrometry have driven the progress in proteomics in recent years.  
Quadrupoles, ion traps, time of flight, and high resolution mass spectrometers [45], such as the Orbitrap 
[46] and FT-ion cyclotron resonance (FTICR), [47] have been employed in proteomic analysis [10].  
Hybrid mass spectrometers utilize multiple mass analyzers in one instrument, which provide the most 
potential in proteomics due to their versatility and multi-dimensional analysis.  Orbitrap-ion trap hybrid 
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instruments couple high resolution (> 100,000) and high mass accuracy (< 2ppm) with fast, sensitive 
MS/MS scans creating an instrument suited for large scale discovery-based proteomics.  The principal 
instrument used throughout this dissertation is the LTQ-Orbirtap Velos shown in Figure 1.2 [48].  High 
resolution MS scans are performed in the Orbitrap to detect intact peptides.  Scan rates occur at 
approximately 700 ms per scan (R = 60,000), which can impact the duty cycle of LC-MS/MS 
experiments.  However, simultaneous MS/MS scans are performed in the dual ion trap, which performs 
four to five MS/MS scans during the high resolution Orbitrap analysis.  Additional MS/MS scan events 
can be performed resulting in an enhanced identification, but with a longer duty cycle.  Together, this 
creates an efficient method capable of collecting tens of thousands of peptide fragmentation spectra in a 
single LC-MS/MS experiment.   
When work for this dissertation began, the LTQ-Orbitrap Velos was the state-of-the-art mass 
spectrometer in proteomics.  Orbitrap hybrids have rapidly evolved in the last five years with the release 
of the Orbitrap-Elite [49] and the Q-Exactive [50].  Additionally, Orbitrap resolution has reached up to R 
= 1,000,000 using reduced mass analyzer dimensions and enhanced Fourier transform algorithms [51].  
The current-state-of-the-art is the Orbitrap Fusion, which is a tribred mass spectrometer containing a high 
resolution Orbitrap, a quadrupole mass analyzer, and a dual ion trap capable of performing 20 MS/MS 
scan events per second [52].  Emphasis with each new hybrid model is placed on increasing the scan 
speeds so that more spectra are collected in real time resulting in enhanced protein identification.  While 
newer Orbitrap instrumentation is impressive, the Orbitrap Velos is capable of identifying thousands of 
unique proteins in an experiment. 
 
1.1.4.  Peptide Fragmentation  
Large scale proteomic experiments typically operate using data dependent acquisition (DDA) 
[53], which results in isolation and MS/MS fragmentation of the most intense ions detected in MS.  
Peptides cleave at specific sites along the backbone into a series of a/x, b/y, and c/z type ions shown in 
Figure 1.3.  Different fragmentation techniques can affect the appearance of peptide MS/MS spectra [54].   
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Figure 1.2.  Schematic of the LTQ-Orbitrap Velos [52] (Thermo Scientific). 
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Figure 1.3.  Peptide fragmentation in MS/MS showing cleavage sites for a/x, b/y, and 
c/z ion pairs.   
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Collision induced dissociation (CID) occurs in the ion trap of the LTQ-Orbitrap Velos.  Selected ions of 
interest are isolated and exposed to an RF excitation to increase the kinetic energy.  Excited ions collide 
with helium gas causing fragmentation favored between the amide bond of peptides resulting in b-type 
and y-type ions.  CID-MS/MS is the principal fragmentation technique used throughout the dissertation to 
generate MS/MS spectra due to its robustness, reproducibility and fragmentation efficiency.  One 
disadvantage of CID in ion traps is a low mass cutoff of approximately one-third of the selected m/z in 
MS/MS spectra (due to the RF increase required for excitation) [55].  In order to detect low m/z ions in 
MS/MS, higher energy collisional dissociation (HCD) is employed where ions are fragmented in an 
octopole HCD collision cell (Figure 1.2) and detected using the Orbitrap [48, 56].  Ions are isolated in the 
linear ion trap and transferred to the HCD cell, where a DC offset is applied in the presence of nitrogen 
gas to cause fragmentation.  Quantitative proteomic experiments using isobaric tags (Section 1.2) require 
HCD fragmentation to detect ions from 100-150 m/z for quantitation.  HCD also provides reproducible 
and efficient fragmentation, however peptide coverage (i.e. b- and y-type ions) is impaired.  As a result, 
MS experiments use a combination of CID- and HCD-MS/MS scan events during data collection for 
peptide identification and quantitation, respectively [57]. 
 
1.1.5.  Database Searching and Protein Identification 
 Proteomic data files can contain > 50,000 total MS and MS/MS spectra from a single LC 
separation.  Database search algorithms and data processing software tools have been developed to 
streamline spectral interpretation in large scale studies.  Data files (.RAW) are searched with algorithms 
such as SEQUEST [39, 58] to generate a list of detected peptides and proteins in a shotgun proteomic 
experiment.  First, a FASTA file is uploaded from an online protein database such as Uniprot or 
SwissProt, which contain a list of protein sequences and accession numbers for a given species [59].  
SEQUEST performs in silico digestion of the protein database matching the user’s experimental criteria, 
which results in a list of theoretical peptides and corresponding MS/MS spectra.  Experimental and 
theoretical MS/MS spectra are compared, matched, and scored to identify peptide sequences [60, 61].  A 
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single SEQUEST search result contains a mix of correctly identified peptides and false positive 
identifications.  Misidentified peptides are filtered by searching the RAW data against a decoy database to  
measure the frequency of peptide identifications due to random matching [62].  False discovery rates 
(FDR) for peptide identification are set to 0.05 and 0.01 for 95% and 99% confidence, respectively.  
SEQUEST is built into the software package Proteome Discoverer (PD, Thermo Scientfic), which assists 
in processing data for protein identification and quantitation. 
 
 1.2.  MS-BASED QUANTITATIVE PROTEOMICS 
 Quantitative proteomics provides significant insight to disease states or other experimental 
conditions [63, 64].  Complex protein digests result in a pool of peptides with varying chemical and 
physical properties that differ in charge state, hydrophobicity, amino acid sequence, and PTMs [12, 65, 
66].  As a result, relative quantitation is employed by comparing the abundance changes between peptides 
originating from separate samples.  Relative quantitation can be performed using label free approaches or 
chemical tagging.  Label free quantitation uses spectral counting or comparisons of peptide peak area 
between multiple samples and has been extensively reviewed [67-69].  Quantitation is also achieved by 
modifying peptide functional groups with stable isotope chemical tags, which is divided into two groups:  
precursor isotopic labels and isobaric tags.  For purposes of this dissertation, only isotope chemical 
tagging techniques will be highlighted. 
 
 1.2.1.  Precursor Isotopic Labeling 
 Precursor isotopic labeling achieves relative quantitation between multiple samples in MS.  
Peptides or proteins are modified with the same chemical label, however one tag incorporates heavy 
atoms within the structure creating a “light” and “heavy” tag.  When samples are pooled and analyzed 
using LC-MS/MS, light and heavy peptide pairs co-elute to create an m/z shift in MS corresponding to the 
mass difference between the chemical tags.  Relative quantitation compares the peak areas between each 
peptide pair.  Table 1.1 shows common precursor isotopic labeling techniques.  Metabolic labeling  
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Table 1.1.  Common Stable Isotope Tags for Relative Quantitation
Tag Multiplex Reactive Site MS Order Mass Shift (Da) Reporter Ions (m/z)
SILACa 3 Arg, Lys MS 0, +6, +8, +10 n/a
SILAMb 2 All AA MS > 10 n/a
Acetylation 2 N-term, Lys MS 0, +3 n/a
Dimethylation 5 N-term, Lys MS 0, +2, +4, +6, +8 n/a
ICATc 2 Cys MS 0, +8 n/a
ICPLd 2 Lys MS 0, +6 n/a
Oxygen 18 2 C-term MS 0, +2, +4 n/a
iTRAQe 8 N-term, Lys MS/MS n/a 113-119, 121
TMTf 6 N-term, Lys MS/MS n/a 126-131
DiLeug 8 N-term, Lys MS/MS n/a 114-119, 121-122
DIARTh 6 N-term, Lys MS/MS n/a 114-119
aStable isotopic labeling of amino acids in cell cultures
bStable  isotopic labeling of amino acids in mammals
cIsotope coded affinity tags
dIsotope coded protein labels
eIsobaric tags for relative and absolute quantitation
fTandem mass tags
gDimethyl leucine tags
hDeuterium isobaric anime reactive tags
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incorporates stable isotopes at the earliest point in sample preparation [65].  For example, stable isotopic 
labeling of amino acids in cell cultures (SILAC) [70] employs a cell medium rich in heavy arginine or 
lysine, which incorporates heavy amino acids on the protein primary structure during expression.  Since 
the chemical labeling occurs at the earliest point in the experiment, variation is minimal [64], however 
SILAC techniques are limited to cell cultures.  Metabolic labeling can be achieved in vivo by feeding 
animals fortified heavy lysine food pellets [71, 72], however this technique is highly expensive, requires 
multiple animal generations to achieve >95% labeling efficiency, and is not compatible with all species.  
  Alternatively, precursor isotopic labeling can employ chemical tags, which target reactive amino 
acid functional groups.  Common precursor chemical tagging techniques (Table 1.1) include acetylation 
[73], dimethylation [74, 75], isotope-coded affinity tags [76], isotope-coded protein labels [77], and C-
terminal oxygen 18 labeling [9, 78].  Precursor quantitation provides versatility, modifies large peptide 
quantities, and provides a dynamic range approximately three orders of magnitude [12, 79, 80].  
Multiplexing is limited to two or three samples per experiment due to increasing MS spectra complexity 
as quantitation channels are added.  Dimethylation can achieve multiplexing up to five samples with mass 
shifts of +2 Da per precursor channel [81],  however significant peptide overlap is observed at peptide 
charge states of +3 or higher.  Precursor labeling strategies used in the dissertation are acetylation 
(Chapters 2,4) and dimethylation (Chapters 5, 6, and 7).   
 
1.2.2.  Isobaric Tags 
Isobaric tags are an alternative chemical labeling approach in quantitative proteomics and are 
capable of analyzing up to 10 samples in a single experiment using MS/MS.  Tandem mass tags      
(TMT) [11], the isobaric tag for relative and absolute quantitation (iTRAQ) [13], deuterium isobaric 
amine-reactive tags (DiART) [82] and dimethyl leucine tags (DiLeu) [83] are available for multiplexed 
protein quantitation.  Figure 1.4 illustrates the TMT 6-plex isobaric reagents used throughout the 
dissertation in Chapters 4-6.    Isobaric tags consist of three regions:  a reporter ion group, a mass balance 
group, and a reactive site that targets a peptide functional group such as amines.  Heavy isotopes  
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Figure 1.4.  Chemical structure for 6-plex tandem mass tags (TMT) showing reporter ion, 
mass balance, and peptide reactive groups.  Samples are pooled for LC-MS analysis 
resulting in a single peak in MS.  Isolation and fragmentation generates six reporter ion 
signals in MS/MS corresponding to the mass of each reporter ion. 
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(13C, 15N) are incorporated into the reporter ion and mass balance regions of the tag to retain the same 
mass (Figure 1.4).  For TMT tags, reporter ions span from m/z 126 through 131, while the respective 
balance group ranges from m/z 103 through 98.  When samples are modified with different TMT reagents 
and pooled for LC-MS/MS analysis, peptide sequences have similar retention times, ionization, and 
precursor mass resulting in a single peak in the MS spectrum.  However, upon isolation and MS/MS 
fragmentation of the peptide ion, the TMT tag cleaves between the mass balance and reporter ion group 
resulting in six unique signals corresponding to the mass of the reporter ions (m/z 126-131 for TMT tags).  
Relative quantitation is achieved by comparing reporter ion signals in MS/MS.  Isobaric tags provide the 
advantage of performing multiplexed experiments without creating additional precursor MS complexity 
since all peptides have the same mass.   TMT tags can multiplex up to 10 samples using isotopologues, 
which take advantage of the difference in mass shift caused by 15N and 13C [84, 85].  These tags require 
high resolution Orbitrap scans of at least R = 35,000 to obtain accurate quantitation and separate all 10 
reporter ions.  While this dissertation primarily uses the TMT 6-plex tag, the methods can easily 
incorporate TMT 10-plex tags since the reaction chemistry is identical. 
Quantitation using isobaric tags is accurate and linear up to two orders of magnitude with 10-30% 
relative standard deviation (RSD) depending on the fold change ratios [66].  Limitations to isobaric 
quantitation include ratio compression due to the isolation and fragmentation of background peptides [86, 
87].  In quantitative proteomic experiments, it is expected that a majority of proteins are equimolar in 
which only a small percentage of detected proteins yield a significant change.  Co-isolation and co-
fragmentation occurs when a background ion is detected within the isolation window of the peptide of 
interest.  Since the background ion is also likely modified with an isobaric tag due to the global nature, 
MS/MS spectra contains the combined reporter ion signal originating from all fragmented precursor ions.  
This results in inaccurate quantitation using isobaric tags and underestimates the true value [88].  Charge 
state reduction in the gas phase [89], analysis of TMT clusters in MS/MS [90], ion mobility [91, 92], 
DDA optimization [93], and isobaric isotopologues [17] have solved this issue to provide accurate 
quantitation.  However, these techniques require additional MS hardware or specialized data processing 
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software scripts.  Ting and Gygi presented a higher order MS data collection method by HCD 
fragmentation to generate reporter ion spectra (MS3) [94].  This technique can be easily implemented 
using the LTQ Orbitrap Velos and is employed in Chapters 5 and 6 to perform protein quantitation using 
isobaric tags.   
 
1.2.3.  Multiplexing 
 Current relative quantitation techniques can multiplex up to ten samples in a single experiment.  
While an impressive number, this does not meet the demands in clinical laboratories [5, 95].  Figure 1.5 
outlines the challenges in performing large scale proteomic experiments which exceed an N of ten.  
Multiple samples must be prepared and analyzed separately, which extends instrumental analysis time, 
increases cost, and increases variation due to additional preparation steps, instrument injections, and 
sample handling (i.e. pipetting errors) [95].  Optimization in protein buffers, digestion procedures, and 
instrumental parameters (i.e. Orbitrap overfill, extended gradients, longer columns, etc.) have helped 
achieve ~20% RSD across 24 samples [96] and 60 samples [97].  The tradeoffs include highly exhaustive 
sample preparation procedures and individual injections of each sample creating an instrument analysis 
experiment lasting over 20 days.  Novel enhanced multiplexing techniques can create higher sample 
throughput, reduce variation, and analyze large N simultaneously in one LC-MS/MS injection. 
Two strategies have been developed to enhance multiplexing.  The first is presented in Figure 1.6, 
which develops methods that combine precursor labeling techniques with isobaric tags.  This dissertation 
presents combined precursor isotopic labeling and isobaric tagging (cPILOT) to enhance multiplexing of 
protein nitration [98, 99] (Chapter 4) and global quantitative proteomics [100, 101] (Chapters 5 and 6).  
Using cPILOT, peptides are modified with a precursor labeling reagent creating light and heavy peaks 
solely to generate a mass shift in MS.  Light and heavy peptides are further modified with isobaric tags 
targeting a different functional group.  HCD-MS/MS or MS3 fragmentation of both light and heavy 
peptides results in two unique reporter ion spectra, thus quantifying additional samples simultaneously.  
Other multiplexing techniques using a similar approach include the combination of SILAC and TMT tags  
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Figure 1.5.  Illustration showing the need for enhanced multiplexing in quantitative 
proteomics.  Precursor MS quantitation multiplexes two to three samples in a single 
experiment while isobaric tagging can analyze up to six samples at once using TMT 
tags.  Enhanced multiplexing expands sample throughput. 
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Figure 1.6.  Strategy for combined precursor isotopic labeling and isobaric tagging. 
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[102] and the synthesis of novel TMT tags [103].  An alternative strategy to enhance multiplexing takes 
advantage of isotopologues that expands 6-plex TMT isobaric tags to 8-plex [104] and 10-plex [85]. 
NeuCode labeling can multiplex 12 samples in precursor MS, but requires ultra-high resolution Orbitrap 
mass analyzers (R = 480k) to distinguish 6 mDa mass shifts for relative quantitation at higher m/z ratios 
[105].  Recently, TMT tags were combined with iTRAQ in a single experiment since both sets of tags 
result in unique m/z reporter ions offering further potential in multiplexing [106].  Chapters 4-7 discuss 
the development of various cPILOT strategies to expand multiplexing in quantitative proteomics. 
 
1.3.  OVERVIEW OF DISSERTATION 
 This dissertation focuses on the method development of novel multiplexing strategies in 
quantitative proteomics to study disease.  First, an acetylation precursor labeling technique is applied in 
Chapter 2 to study the effects of an anti-cancer drug, Adriamycin, on the spleen proteome to uncover 
changes in the immune system of healthy mice.  Chapter 3 reviews proteomic techniques to quantify 3-
nitrotyrosine (3NT).  Chapter 4 introduces combined precursor isotopic labeling and isobaric tagging 
(cPILOT), which selectively quantifies 3NT peptides and enhances multiplexing in protein quantitation.  
Chapter 5 extends cPILOT from a PTM selective approach to a global approach and also experiments 
with alternative data collection techniques to acquire more efficient multiplexed data in real time.  
Twelve-plex global cPILOT is analytically characterized in Chapter 6 and applied to study the effects of 
Alzheimer’s disease in the liver of a mouse model.  Chapter 7 demonstrates the versatility of cPILOT by 
incorporating N,N-dimethyl leucine tags to provide a more cost effective cPILOT method.  Finally, 
Chapter 8 summarizes the dissertation and presents the future outlook, goals, and current challenges in 
multiplexing.  Chapters 2-6 are primarily written from published papers or submitted manuscripts. 
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2.0.  GLOBAL EFFECTS OF ADRIAMYCIN TREATMENT ON MOUSE SPLENIC PROTEIN 
LEVELS* 
(*Reprinted with permission from Evans, A. R.; Miriyala, S.; St. Clair, D. K.; Butterfield, D. A.; 
Robinson, R. A. S.  Journal of Proteome Research.  2012.  11,  1054-1064.  Copyright 2014.  
American Chemical Society.) [107] 
2.1.  INTRODUCTION 
Adriamycin [(ADR), also known as doxorubicin] is an anthracycline drug used to treat 
hemopoietic and a wide range of  solid tumors in lung, breast, ovarian, prostate, and bladder cancers, 
amongst others [108, 109].  Although the mechanisms of ADR drug action in non-cancerous tissues are 
not completely understood, there are two widely supported phenomena.  The first primary action involves 
the intercalation of DNA and inhibition of topoisomerase II enzymatic activity, which results in the 
termination of DNA replication and transcription [110, 111].  Clinically, ADR is very effective as an 
anticancer treatment, however some patients can suffer from major side effects such as cardiomyopathy 
and heart failure [112], dizziness, lack of concentration, and cognitive deficits characterized as 
“chemobrain” [113, 114].  In other cases, patients develop a resistance to ADR and treatment fails [115].   
The second primary action of ADR involves the generation of toxic free radical species such as 
the superoxide anion.  The structure of ADR contains a quinone, which is converted to a semi-quinone 
through a one electron reduction.  In the presence of oxygen, the semi-quinone is converted back to the 
quinone resulting in the formation of reactive oxygen species causing oxidative stress [116], which 
become detrimental to nontargeted cells, in addition to cancerous cells [117].  Oxidative stress can result 
in protein oxidation, DNA damage, and lipid peroxidation which disrupt cellular functions.  Several 
reports have demonstrated that ADR leads to elevated oxidative stress in plasma [118], brain [119], heart 
[120], cardiomyocytes [121],  liver [122], testes [123], and kidney [124].  The cytotoxicity of ADR also 
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causes alterations to apoptotic pathways, lipid membrane structure and function [125], Ca2+ homeostasis 
[126], and cellular arrest and differentiation [127].     
Proteomic methods have been employed to study the effects of ADR treatment in different cell 
lines and tissues, including brain [119, 128, 129], plasma [130], heart [131], MCF-7 human breast cancer 
cells [132], hepatoma cells [133], Jurkat T cells [134], Raji cells [135], and thymus [136].  Proteomic 
studies of ADR-resistant cells lines [137] have been performed on K562/ADM cells [138, 139], 
K562/ADR cells [140], DLKP cell lines [141], and MCF-7/ADR cells [142-144].  It has been shown that 
cellular populations in spleen tissue undergo substantial changes after ADR treatment, which may have 
global effects on immunity in ADR-treated patients [145].  To-date no quantitative proteomics studies of 
spleen tissue from ADR-treated mice has been reported.    Herein is the first report that has examined the 
effects of ADR treatment on protein expression in spleen.  The proteomics method employs global 
internal standard technology (GIST), which is a post-digestion precursor isotopic labeling approach 
(Chapter 1) [73].  Nanoflow reversed phase liquid chromatography (RPLC)-tandem MS (MS/MS) was 
used to detect relative changes in splenic protein expression in control and ADR-treated mice.   
2.2.  EXPERIMENTAL  
2.2.1.  Animal Housing and Treatment 
Approximately three month old male B6C3 mice were housed at the University of Kentucky 
Central Animal Facility with 12 hour light/12 hour dark cycle.  Animals were fed standard Purina rodent 
chow ad libitum.  The animal protocol was approved by the University of Kentucky Animal Care and Use 
Committee.  Animals used in these studies were the same as those previously reported [136].  Mice were 
divided into two groups and injected with either saline (hereafter referred to as control mice) or 
adriamycin (25mg/kg body weight; hereafter referred to as ADR-treated mice).  Spleen tissue was 
harvested 72 hours post injection from saline-perfused mice.  For these studies, an N = 5 was used for 
each treatment group. 
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2.2.2.  Spleen Homogenization 
Spleen tissues were homogenized in an ice-cold phosphate buffer saline (PBS) solution 
containing 8 M urea with 100 passes of a Wheaton homogenizer.  Homogenate solution was collected, 
sonicated, and centrifuged at 13000 RPM for 10 minutes (4 °C).  Supernatants were collected and protein 
concentrations determined using the BCA assay according to the manufacturer’s instructions (Pierce 
Thermo; Rockford, IL).  Samples were stored at -80 °C until further use. 
2.2.3.  Protein Digestion 
For individual samples, 100 µg of spleen protein was spiked with 1 µg of bovine β-lactoglobulin 
(Sigma Aldrich; St. Louis, MO) and subject to tryptic digestion as follows.  0.25 M dithiothreitol 
(Thermo Fisher; Pittsburgh, PA) was added in a 1:40 protein:reagent molar excess and incubated at 37 °C 
for two hours.  0.25 M iodoacetamine (Acros Organics; Morris Plains, NJ) was added in a 1:80 
protein:reagent molar excess and incubated at 0 °C for two hours in the dark followed by the addition of 
0.25 M L-cysteine in a 1:40 protein:reagent molar excess at room temperature for 30 minutes.  Tris buffer 
solution (0.2 M Tris, 10 mM CaCl2, pH 8.0) was added to reduce the urea concentration to 2 M.  TPCK-
treated trypsin from bovine pancreas (Sigma Aldrich) was added to each sample in a 2% w:w 
enzyme:protein ratio and incubated at 37 °C for 24 hours.  Samples were flash-frozen with liquid nitrogen 
and cleaned using Waters Oasis HLB C18 cartridges. 
2.2.4.  Synthesis of N-acetoxy-H3-succinimide and N-acetoxy-2H3-succinimide 
The procedure for synthesis of N-acetoxy-H3-succinimide and N-acetoxy-2H3-succinimide is 
described elsewhere [146].  Briefly, 1.9478 g of N-hydroxysuccinimide (NHS, Sigma Aldrich) was added 
to 4.8 mL of >99% acetic anhydride (Sigma Aldrich) or  1.9451 g of NHS was added to 4.4 mL of 99% 
atom 2H6-acetic anhydride (Sigma Aldrich).  Both reactions occurred at room temperature for 15 hours 
under nitrogen.  White crystals products were collected, washed thoroughly with hexane, and dried under 
vacuum.  Product purity was confirmed with NMR analysis (>95% purity).   
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2.2.5.  Isotopic Labeling of Peptides  
Stock solutions (0.25 M) of N-acetoxy-H3-succinimide and N-acetoxy-2H3-succinimide were 
prepared in 50 mM phosphate buffer (pH = 7.5).   Tryptic peptide samples (1 mg⋅mL-1) were reconstituted 
in 50 mM phosphate buffer and reacted with 100 molar excess of the N-acetoxy-H3-succinimide (light) 
and N-acetoxy-2H3-succinimide (heavy) for control and ADR-treated mice, respectively.  Reactions 
occurred at room temperature for 5 hours under constant stirring.  Control and ADR-treated samples were 
pooled and treated with excess 0.25 M hydroxylamine hydrochloride (Sigma Aldrich) and adjusted to pH 
10.  After 20 minutes at room temperature the samples were adjusted to pH 7 and were cleaned, dried, and 
stored at -80°C.   
 
2.2.6.  LC-MS/MS 
Isotopically labeled peptide samples were reconstituted in formic acid solution (0.1% in water) to 
a concentration of 0.5 µg⋅µL-1 and injected onto a trapping column (2 cm × 100 µm i.d.) packed with 200 
Å C18 material (Michrom Bioresources Inc.; Auburn, Ca) using an autosampler on a  nanoflow Eksigent 
2D LC system.  Buffers A and B were composed of water:acetonitrile (97:3) and acetonitrile, 
respectively, each with 0.1% formic acid.  Samples were washed with buffer A and eluted onto an 
analytical column (13.2 cm × 75 µm i.d.) packed with 100 Å C18 material (Michrom Bioresources Inc.).  
Gradient elution was performed as follows (%A/%B):  90:10 for 2 minutes, ramp to 85:15 over 4 minutes, 
hold for 4 minutes, ramp to 70:30 over 120 minutes, ramp to 40:60 over 30 minutes, ramp to 20:80 over 
five minutes, hold for 10 minutes followed by column re-equilibration.  Eluted peptides were detected on 
an LTQ-Orbitrap Velos MS using data-dependent acquisition with the following parameters:  full FT 
parent scan at 60,000 resolution over the m/z range of 300-1800, positive ion mode, the top 6 most intense 
ions were selected for CID fragmentation (35% collision energy, 10 ms activation time, 5000 minimum 
ion count threshold) and mass analyzed using the LTQ.  Each pooled isotopically labeled sample (N = 5) 
was analyzed with three technical LC-MS/MS replicates. 
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2.2.7.  Database Searching and Analysis 
.RAW files were searched against the mouse International Protein Index (IPI) database (56957 
total sequences on 4/26/2010) using the SEQUEST algorithm embedded in Proteome Discoverer 1.2 
software (Thermo).   The FASTA sequence for bovine β-Lactoglobulin (National Center for 
Biotechnology Information Accession Number:  gi4388846) was manually added to the database.  Search 
parameters included:  precursor mass tolerance of 15 ppm, fragmentation tolerance of 1.0 Da, dynamic 
modifications of light and heavy acetyl groups on lysine residues and the N-terminus and oxidation of 
methionine, and a static modification of carbamidomethyl on cysteine.  All files were searched against a 
decoy database with false discovery rates set at p<0.05 and p<0.01 so that only medium and high 
confidence peptides, respectively, were used for further analysis.  Proteome Discoverer 1.2 provided peak 
intensity and area information for light and heavy labeled peptides and protein ratio calculations.   
2.2.8.  Statistics for Differentially-Expressed Proteins 
The search results were treated as follows in order to generate a confident and conservative list of 
differentially-expressed proteins.  After calculation of protein ratios, the protein list was filtered to include 
only proteins that were detected in a minimum of any six LC-MS/MS analyses.  One-way ANOVA (p < 
0.05) was carried out in Origin 8.0 to assess statistical differences in the ADR/control (CTR) ratios across 
biological (N = 5) and technical (N=3) replicates for each protein.  Proteins were considered 
differentially-expressed if the following two criteria were met:   1) a calculated F score < the tabulated F 
score (α = 0.05) and, 2) a ADR/CTR or CTR/ADR ratio > 1.5.   
2.2.9.  Western Blot Verification 
Protein samples (50 µg) were denatured in an appropriate sample buffer and electrophoretically 
separated on a Criterion TGX gel (Biorad Laboratories; Hercules, CA) at 250 V.  Protein from the gel was 
transferred onto a nitrocellulose membrane paper using a Fast-Transfer Blot System (Biorad).  Blots were 
washed three times in Wash blot.  BSA blocking solution was added to the membrane and incubated on a 
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rocker for one hour.  A 1:1000 dilution of rabbit polyclonal anti-annexin A2 primary antibody (Sigma 
Aldrich) and 1:2000 dilution of rabbit polyclonal anti-actin primary antibody (Sigma Aldrich) was added 
and incubated at 4 °C overnight.  The blot was rinsed and incubated with a 1:8000 dilution of anti-rabbit 
IgG alkaline phosphatase secondary antibody (Sigma Aldrich) for one hour on a rocker.  The blot was 
rinsed and colorometrically developed as described above for protein carbonyls.  The dried blot was 
scanned using a Canon scanner, saved as a .TIFF file, and densitometry analyses carried out with Scion 
Image Software. 
 
2.3.  RESULTS 
2.3.1.  Effects of ADR Treatment on Spleen Tissue 
In order to better understand the effects that ADR treatment has on spleen tissue we initially 
began by measuring spleen weights.  The ADR-treated mice used in these studies exhibited an ~11% 
decrease in body weight and an ~68% decrease in thymus weight [136].  Additionally, this work reports 
an ~66% loss in spleen weight of ADR-treated mice relative to controls (Table 2.1).  Because lower body 
weight and thymus size are correlated with lower numbers of lymphocytes [136], we hypothesize that 
there is also a lower number of splenic lymphocytes based on smaller spleen sizes in ADR-treated mice.   
 
2.3.2.  GIST Proteomics Workflow  
The quantitative proteomics workflow, shown in Figure 2.1, was used to determine differences in 
protein expression after ADR treatment as follows.  Protein samples extracted from homogenized spleen 
tissue of control and ADR-treated mice were spiked with an internal protein standard (i.e., bovine β-
lactoglobulin) prior to trypsin digestion.  Tryptic peptide samples from control and ADR-treated mice 
were isotopically labeled with either a light or heavy GIST reagent, respectively, and pooled in a 1:1 ratio.  
Isotopically labeled peptide mixtures (N = 5 for biological replicates) were analyzed with triplicate 
nanoflow LC-MS/MS experiments using a LTQ-Orbitrap Velos MS.  Identified proteins were filtered (as 
discussed above) in order to generate a list of differentially-expressed proteins.   
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Table 2.1.  Masses of Spleen Tissues Collected from 
Control and ADR-treated Mice. 
Animal Control (g) ADR (g) 
1 0.0814 0.0297 
2 0.0909 0.0346 
3 0.0859 0.0378 
4 0.115 0.0269 
5 0.0840 0.0278 
Ave. ± SD .0914 ± .0135 .0314 ± .0047 
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Figure 2.1. Schematic of the proteomics workflow showing internal standard spiking, GIST labeling, 
and nanoflow RPLC-MS/MS to determine differentially-expressed proteins in the spleen proteome of 
ADR-treated mice. 
26 
 
2.3.3.  Internal Standard Normalization 
Figure 2.2a shows an example parent mass spectrum obtained for a doubly-charged peptide pair 
at m/z 509.289 and 512.308 that eluted from the column at tr = 80.8 minutes.  The observed mass shift of 
6 Da between the light and heavy labeled peptide peaks indicates that the peptide contains the addition of 
two acetylations to the peptide sequence.  The CID-MS/MS spectrum for the light labeled peptide is 
shown in Figure 2.2b displaying a consecutive series of b- and y-type fragment ions.  The CID-MS/MS 
spectrum for the heavy labeled peptide is similar (data not shown).  This peptide pair has been assigned as 
the [(Acetyl)LIVQTMK(Acetyl)+2H]2+ peptide of β-lactoglobulin.  The ratio of heavy/light labeled 
peptides for the internal standard should be unity as 1 µg of β-lactoglobulin was spiked into protein 
extracts of both control and ADR-treated spleen samples.  The measured ratio for heavy/light labeled 
peaks shown in Figure 2a is 1.0 based on peak areas, which agree with the expected values.  The ratio 
values for other tryptic peptides of β-lactoglobulin are similar and an average protein ratio value of 
0.98±0.10 is observed across all 15 injected samples.  β-lactoglobuin ratio values within each technical 
replicate were used to normalize ratio values of mouse splenic proteins. 
As previously discussed, isotopically labeled peptide mixtures were subject to triplicate LC-
MS/MS analyses.  Figure 2.3 shows a bar graph of the total number of proteins identified in each 
individual analysis.  The average number of proteins detected in a single injection is 189± 29.  The total 
number of proteins identified increases with each new sample injection such that, after accounting for 
redundant entries, we identified a total of 388 unique proteins across the 15 injections.  This accounts for 
a total of 70,033 spectral peptide counts.  
 
2.3.4.  Differentially-Expressed Proteins in ADR-Treated Mice 
Using a conservative set of criteria (see section 2.2.8), 59 proteins were assessed as differentially-
expressed in ADR-treated mice (Table 2.2).  These proteins are involved in processes such as cell 
signaling, protein translation, defense response, metabolism, Ca2+ binding and apoptosis, and structural 
27 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Example mass spectra a) of a peak pair [L(acetyl)IVTQTMK(acetyl)+2H]2+ that eluted at tr 
80.8 minutes with m/z 509.289 and 512.308 for the light and heavy labeled peaks, respectively, and b) 
of the CID generated fragments obtained upon isolation of the light labeled peak at m/z 509.289.  The 
peptide assigned belongs to β-lactoglobulin 
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Figure 2.3.  Bar graph of the total number of proteins identified in individual LC-MS/MS analyses and 
the total number of newly assigned proteins identified with each consecutive experiment (diamonds).  
The values shown include redundant protein assignments that arise due to isoforms. 
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stability.  In total, 37 proteins are upregulated (ADR/CTR > 1.5) and 21 proteins are downregulated 
(CTR/ADR > 1.5).  Most of the upregulated proteins and all of the down-regulated proteins change by a 
factor of 1.5-4.0.  Four upregulated proteins (i.e., complement C3 protein, tropomyosin 2, peptidyl-
cis/trans-isomerase, and hemopexin) were expressed by a factor of >4 in spleen tissue as a result of ADR 
treatment.   
2.3.5.  MS/MS and Western Blot Analysis of Annexin A2 
Figure 2.4a shows an example MS/MS spectrum for a doubly-charged peptide pair at m/z 792.934 
and 794.445.  The isotopically labeled peaks have a ADR/CTR ratio of 2.0, indicating the upregulation of 
this species in ADR-treated mice.  The MS/MS spectrum in Figure 2.4b shows fragment ions that 
correspond to the peptide sequence [(Acetyl)GVDEVTIVNILTNR+2H]2+ that belongs to the protein, 
annexin A2.  Annexin A2 has an average ADR/CTR ratio of 2.5 ± 0.4 as measured across 11 injections 
(Table 2.2).  Western validation was carried out in order to confirm protein changes measured with our 
proteomics workflow for annexin A2.  Figure 2.5 shows an example Western blot obtained for control 
and ADR-treated splenic proteins for annexin A2 and actin (loading control).  A 50% increase in annexin 
A2 levels is observed in ADR-treated mice supporting upregulation of this protein, which is consistent 
with proteomics results (Figure 2.5).   
2.4.  DISCUSSION 
This work reports the first investigation of the effects of ADR treatment on splenic protein levels 
in mice.  The spleen is involved in innate and adaptive immunity and helps to regulate immune 
homeostasis [147].  The spleen consists of lymphocytes such as T-cells, B-cells, and macrophages with 
functions that include blood filtering, iron recycling, pathogen response, and immune induction, 
activation, and proliferation [147].  These functions are critical for normal conditions and even more so in 
diseased states, such as cancer.  The smaller spleen weight measured in this work (Table 2.1) is consistent 
with other reports of reduced body weight and spleen size in ADR-treated mice [136, 148-150] and   
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Figure 2.4.  Example mass spectra a) of a peak pair [(Acetyl)GVDEVTIVNILNR+2H]2+ that eluted at tr 
117.5 minutes with m/z 792.934 and 794.445 for the light and heavy labeled peaks, respectively, and b) 
of the CID generated fragments obtained upon isolation of the light labeled peak at m/z 792.934.  The 
peptide belongs to the annexin A2 protein. 
35 
Figure 2.5. Example Western blot image of annexin A2 and actin (loading control) protein 
expression.  The percent annexin A2 in control and ADR-treated mice obtained after normalization 
of annexin A2 levels to actin levels are listed underneath the image, N = 3. 
36 
supports the notion that altered cell differentiation [127] as well as decreased lymphocyte proliferation 
[148, 151] persist with ADR treatment.  Reduced spleen size is also reflective of lower numbers of 
lymphocytes, which occurs with aging [152] and could result in a weakened immune response in ADR-
treated patients.   
Following acute ADR treatment in mice, 59 splenic proteins were differentially-expressed (Table 
2.2).  Figure 2.6 shows a graphical illustration of the major pathways affected by ADR treatment, which 
we discuss below.  These proteins are involved in a number of biological processes such as Ca2+ binding 
and apoptosis, DNA transcription and repair, cellular signaling, redox maintenance, metabolism, 
immune/defense response, and structural maintenance.   
 
2.4.1.  Ca2+Binding/Apoptosis Proteins 
Proteins involved in Ca2+-binding, apoptosis, and chaperone activity were upregulated in ADR-treated 
mice. Annexins 2 and 5 belong to a class of Ca2+-dependent membrane binding proteins.  Annexin binds 
to both free Ca2+ and the phospholipids of the membrane structure [153] and may be a key moderator of 
apoptosis.  Annexin A2 has been reported as upregulated in ADR resistant cells [138, 154] suggesting its 
importance for chemoresistance.  Annexin A5 has been found to inhibit apoptosis of phagocytes [155].  
Upregulation of annexin A5 in ADR-treated mice is consistent with upregulation in the thymus [136], 
ADR-treated HepG2 cells [133], and in MCF-7/ADR resistant cells [143, 156].   
Calreticulin, is a Ca2+-binding chaperone protein that is localized to the endoplasmic reticulum.  
Although calreticulin has a number of biological functions its primary roles involve modulation of Ca2+ 
homeostasis and molecular chaperone activity.  Upregulation of calreticulin can lead to elevated levels of 
free Ca2+ that is housed in intracellular stores [157].  Additionally this protein is localized to the cell 
surface and is critical for initiating immune response [158].  In ADR-treated cells calreticulin migrates 
from the ER and localizes to the surface of pre-apoptotic and cancerous cells, which will undergo 
clearance by lymphocytes [159].  Calmodulin is another Ca2+-binding protein, which is involved in Ca2+ 
homeostasis, cellular growth, proliferation, and transport processes and has been implicated in  
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Figure 2.6. Illustrative depiction of differentially-expressed splenic proteins (pathways) that are affected 
from ADR-treatment. 
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chemoresistance of cancer therapies [160].  Ca2+ ion flux is important in modulating cell death in the 
immune system [161], thus overexpression of Ca2+-binding proteins observed in ADR-treated mice could 
alter free Ca2+ levels and lead to irreversible cell injury and death.   
2.4.2.  Transcription and Translation 
Several transcriptional and translational-related proteins were downregulated in ADR-treated 
mice.  Histone proteins oligomerize to form the nucleosome, which is the core component of chromatin, 
and help to recruit proteins to DNA.  Nucleolin is a histone chaperone protein that is found on the surface 
of cancerous cells [162].  Downregulation of nucleolin and histones H1.5 and H3.2 may be directly 
related with ADR’s mechanistic action of DNA intercalation and inhibition of topoisomerase II, which 
results in disrupted transcription.  Other histone proteins have been reported as upregulated in human 
Jurkat T-cells treated with ADR [134].  It is not clear why there are differences in histone expression 
between these studies but it may be because transcription is affected by ADR treatment.   
The 40S ribosomal proteins SA, S3, and S14 were downregulated in ADR-treated mice, which is 
consistent with studies in ADR-treated Jurkat T-cells [134].  Heterogeneous nuclear ribonucleoproteins 
(HNRP) in this work differed in expression levels.  For example, HNRP A1 is downregulated, whereas 
HNRP F is upregulated (Table 2.2) in ADR-treated mice.  In Raji cells treated with ADR, HNRP C1/C2 
was downregulated, whereas in ADR resistant cells HNRP D is upregulated [138].  Polyadenylate-
binding protein 1, another protein involved in protein translation, is downregulated in these studies. 
Overall, it appears that ADR treatment reduces protein translational activity which may be related with 
oxidative damage and altered transcription.     
2.4.3.  Cytoskeletal/Structural Proteins 
Proteins involved in integrity of the cytoskeleton or other structures represent the largest group of 
differentially-expressed proteins in ADR-treated mice.  Cytoskeletal proteins have been implicated as 
potential targets for chemotherapeutic treatments in cancer [163]. Cytoskeletal and structural related 
39 
proteins in these studies were all found to be upregulated, with the exception of F-acting-capping protein, 
which is downregulated in ADR-treated mice.  Upregulation of filamin, tropomyosin, spectrin, and 
tubulin is consistent with studies in ADR-treated HepG2 cells [133].   Vimentin is upregulated in these 
studies and in ADR-treated human Jurkat T cells [134] but has also been reported as downregulated in 
ADR-treated Raji cells [135].   
Tubulin proteins are the base unit of microtubules in the cell, which are needed for cellular 
transport and structural integrity.  Both α- and β-tubulin were upregulated in the thymus of ADR-treated 
mice [136], which is consistent with these results.  However, β-tubulin has also been observed to be 
downregulated following ADR treatment [133].  α-actinin is a ubiquitously expressed cytoskeletal protein 
that is comprised of an actin-binding domain, a calmodulin-like domain, and a calponin-homology 
domain [164].  Actinin belongs to a family of F-actin cross linking proteins that also includes spectrin.  α-
actinin-1 and -4 are found in nonmuscle tissues and are necessary for T-cell migration and activation 
[164].  
The proteins described above as well as transgelin, transgelin-2, and dihydropyrimidinase-related 
protein 2 detected in these studies, each has a key role for normal maintenance of the cytoskeletal 
structure.  Upregulation of cytoskeletal proteins following ADR treatment could occur due to a 
compensatory mechanism to maintain structural stability.  In addition to detrimental effects caused by 
cancerous cells, chemotherapeutic compounds (e.g., ADR) have been suggested to be a major cause of 
disruption of cytoskeletal proteins [165].  Consequences of disrupted cytoskeletal integrity include 
alterations to cell shape, growth, and transport which may lead to cell destruction and failure.      
2.4.4.  Chaperone/Immune and Defense Response/Antioxidant 
Differential regulation of proteins involved in cellular defense processes indicates that cells are 
under attack or there is cellular dyshomeostasis, particularly in these studies as a result of ADR treatment. 
Glucose-regulated 78 kDa (GRP78) protein belongs to the class of heat shock 70 proteins, which serve as 
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molecular chaperones.  GRP78 is endoplasmic reticulum resident and involved in misfolded protein 
response.  Other functions of GRP78 include Ca2+ homeostasis, apopotosis, and cellular signaling related 
with cancer cell proliferation and survival [166].  GRP78 overexpression is associated with a number of 
cancers and may be indicative of cellular stress or favorable survival outcomes due to the removal of 
cancerous cells [166].  Upregulation of GRP78 in these studies may suggest that ADR treatment provides 
cells with additional defenses against misfolded proteins that are likely to occur in cancer patients.  
Downregulation of T-complex protein 1-a cytosolic chaperone protein[167] suggests that there is an 
imbalance in the overall cellular chaperone machinery in the presence of ADR.   
Immune response proteins: complement C3, α-1-antitrypsin 1-1, and thrombospondin 1 were 
upregulated in ADR-treated mice.  Thrombospondin 1 inhibits tumor cell progression and angiogenesis 
and has been investigated as a potential target for cancer therapy [168].  Due to the multifunctional roles 
of thrombospondin 1, it is possible that upregulation of this protein following ADR treatment results in 
reduced tumor growth in normal and cancerous cells.  Complement C3 is directly involved in the 
complement system that is a part of the innate immune response.  α-1 antitrypsin 1, a proteinase inhibitor, 
is also involved in immune response by protecting cells in inflammatory conditions.  Hemopexin, is a 
scavenger of free heme that is used to transport molecular oxygen.  It belongs to the acute-phase proteins, 
which can be activated in the immune system under inflammatory conditions and is sometimes localized 
to the surface of macrophages in spleen for receptor binding [169].  ADR treatment, based on 
upregulation of these splenic proteins, may help to increase immune response by initiating compensatory 
inflammation mechanisms.  
Superoxide dismutase (SOD) is an endogenous antioxidant defense enzyme that eliminates 
superoxide anion through catalyzing the dismutation of superoxide anion to oxygen and hydrogen 
peroxide.  Manganese SOD has been heavily implicated in cancer [170], however we detected 
upregulation of Cu-Zn SOD (or SOD1) in ADR-treated mice.  St. Clair et al. demonstrated that an 
overexpression of SOD2 in heart tissue helps protect the heart from oxidative damage and ADR 
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cardiotoxicity [171].  Due to the antioxidant nature of SOD, upregulation of this enzyme may be in result 
to the free radicals generated from ADR redox recycling and thus serves to protect cells from oxidative 
damage.   
2.4.5.  Metabolism 
Metabolic proteins in these studies had varying expression in response to ADR treatment (Table 
2.2).  Serine protease inhibitor A3K, isoform 2 of phospholipase D4, sulfated glycoprotein 1 preprotein, 6 
–phosphogluconate dehydrogenase, fructose-bisphosphate aldolase A, nucleoside diphosphate kinase, and
aldehyde dehydrogenase were upregulated in ADR-treated mice, whereas δ-aminolevulinic acid 
dehydratase, probable ATP-dependent RNA helicase DDX5, GTPase IMAP family member 4, aldose 
reductase, and flavin reductase were downregulated.  Alterations to metabolic proteins were also observed 
in thymus from ADR-treated mice [136].  Alterations to metabolism in peripheral immune organs (i.e., 
spleen, and thymus) can be compared with reports describing changes to myocardial energy metabolism 
[172].  Differential-expression of metabolic splenic proteins shows that ADR treatment has downstream 
effects in glycolysis, glucogenesis, and other metabolic pathways.   For example, aldose reductase, which 
converts glucose to fructose during impaired glycolysis, also functions to reduce toxicity of lipid 
peroxidation products, such as 4-hydroxy-trans-nonenal.  Downregulation of this particular enzyme may 
be detrimental to spleen in ADR-treated mice.  Normal energy production is critical to help cells have a 
better defense response against cellular toxicity and cancer and to maintain normal cellular homeostasis.     
2.4.6.  Redox/Cellular Signaling/Transport 
The redox system in the cell is crucial to maintaining a balance between reactive oxygen species 
and antioxidants, which keeps cells free from oxidative stress and damage.  Redox processes are altered 
following ADR treatment in cancer cells [137].  Splenic proteins involved in cellular signaling and 
transport processes were differentially-expressed in ADR-treated mice (Table 2.2) and have been 
implicated in other proteomic studies investigating effects of ADR treatment [128, 133-135].  Peptidyl-
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prolyl cis-trans isomerase B belongs to the family of PPIase enzymes that isomerize proline residues in 
target proteins and assist in protein folding.   This particular PPIase is upregulated in spleen whereas Pin 1 
is downregulated in the brains of ADR-treated mice [128].  Myosin proteins (i.e., Myosin, Myosin-11, 
Myosin-9) are ATP-dependent proteins which regulate actin-based cell motility and were detected as 
upregulated in these studies.  Myosin-9 and Myosin-11 were downregulated in mitochondrial Raji cells 
after ADR treatment [135].  The differences observed in expression of myosin, Pin1, and 14-3-3 may be 
tissue specific.  Upregulation of these proteins following ADR treatment could be related to upregulation 
of cytoskeletal proteins, which would be necessary for maintenance of cellular structure and hence 
cellular transport.      
2.5.  CONCLUSIONS 
ADR treatment is reported to have detrimental effects on a number of tissues in animal models 
and in cell cultures.  Downstream effects of ADR-treatment on mouse spleen tissue include reduced 
spleen size and alterations to the global splenic proteome for proteins involved in cellular processes such 
as cytoskeletal structural integrity, Ca2+ binding, immune response and others.  It is possible that ADR 
treatment through alterations to protein expression leads to weakened immunity.  Insights gained from 
these studies will be useful for understanding toxic mechanisms of ADR treatment, which is necessary to 
minimize drug side effects and improve quality of life in cancer patients undergoing ADR treatment.  In 
this work, we perform differential analysis of ADR-treated mice using the precursor quantitation 
technique global internal standard technology.  Control and ADR-treated mice were treated with light and 
heavy acetyl groups, respectively creating a mass shift of 3 Da.  While effective at providing accurate 
quantitation and determination of differentially-expressed proteins, five samples were prepared and 
analyzed individually.   
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3.0.  PROTEOMICS QUANTIFICATION OF PROTEIN NITRATION* 
(*De Gruyter Proteomics Quantification of Protein Nitration, Walter De Gruyter GmbH Berlin 
Boston, 2013.  Copyright and all rights reserved.  Material from this publication has been used with 
the permission of Walter De Gruyter GmbH.) [99] 
3.1.  INTRODUCTION 
Protein nitration is a post-translational modification (PTM) that can occur under oxidative stress 
(Section 1.1.1) [33].  Nitration is mediated by an increased concentration of reactive oxygen and nitrogen 
species (ROS and RNS, respectively) such as O2.-, ONOO-, and NO2..  An overabundance of cellular RNS 
levels can result in the formation of 3-nitrotyrosine (3NT) and 3NT-modified proteins [173].  Protein 
nitration may result in altered enzymatic activity [174, 175], reduced cellular signaling, disruption of 
phosphorylation pathways [176], and protein degradation [177].  In addition, this PTM has been linked to 
various diseases such as cancer, cardiovascular disease [178], arthritis [179], and neurodegenerative 
disorders such as Alzheimer’s (AD) disease [180] and Parkinson disease (PD) [181, 182].   
Elevated protein nitration has been observed in the brains of AD patients and is correlated with 
disease hallmarks such as amyloid-β peptide levels, senile plaque deposition, and neurofibrillary tangles 
(composed of tau proteins) as well as physiological symptoms such as memory loss, decreased motor and 
language skills, and other behavioral changes [26].  Furthermore, protein nitration is linked to AD disease 
progression and is detected in mild cognitive impairment (MCI), early AD, and advanced stages of AD 
[183-186].  The primary effects of protein nitration in AD are manifested in energy metabolism.  For 
example, glyceraldehyde 3-phosphate dehydrogenase and α-enolase, proteins involved in the glycolytic 
pathway are nitrated [180, 187] leading to reduced enzymatic function [188] potentially limiting ATP 
production [189].  Nitration of tau proteins has been observed in MCI and may influence the early onset 
of AD [190].  Other pathways such as cytoskeletal integrity [191], pH buffering [192], mitochondrial 
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dysfunction [193], and lipid abnormalities [194] are also affected by protein nitration in AD and indicate 
the importance of this PTM for disease pathogenesis [190].   
Other neurodegenerative disorders such as PD [195], Down’s syndrome [196], Huntington’s 
disease [197], and amyotrophic lateral sclerosis [198, 199] are also affected by protein nitration [33, 200].  
Similarly, elevated levels of nitration are observed in cardiomyopathy, cardiovascular disease, 
atherosclerosis [201-205], arthritis [206], diabetes [207], cancer [208], and aging [209, 210].  It can be 
inferred from the range of disorders affected by this PTM that the immune system is a major target of 
RNS.  Increased NO production by nitric oxide synthases has been suggested to be linked to tissue injury 
[211].  Evidence of oxidative damage has been observed in lymphatic vessels of aged rats [212], CD8+ 
prostatic tumor-infiltrating lymphocytes[213], and T-cell receptors [214] ultimately weakening immune 
system response.  Since protein nitration, specifically 3NT PTMs, are heavily implicated in disease it is 
worthwhile to review the state of current technology available to characterize this PTM in biological 
tissues.  Herein, an overview of 3NT chemical properties and proteomics methods which allow the 
enrichment, characterization, and particularly the quantification of 3NT-modified proteins will be 
discussed.   
The formation of 3NT occurs due to a series of chemical reactions involving ROS and RNS. 
Figure 3.1 outlines the most commonly encountered intracellular mechanism.  A free radical oxidizes 
tyrosine to form a tyrosyl radical.  The structure is stabilized by resonance moving the radical to the ortho 
carbon of the phenol ring [215].  Simultaneously occurring, endogenous nitrogen monoxide radicals 
(NO.) react with superoxide anion (O2.-) to produce peroxynitrite (ONOO-), a conjugate base of the 
peroxynitrous acid, which has a pKa close to physiological pH 7.0 [216].  In the presence of carbon 
dioxide, ONOO- reacts to form nitrocarbonate anions [217].  The nitrocarbonate anion undergoes 
homolytic cleavage to form a highly reactive nitrite radical, which undergoes a combination reaction with 
the tyrosyl radical resulting in 3NT.  Nitration has also been observed in other aromatic residues such as 
tryptophan and phenylalanine [218] through similar reaction mechanisms [219]. 
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Figure 3.1.  Chemical reactions describing the formation of 3-nitrotyrosine. 
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Aside from oxidative stress mechanisms, signaling pathways may rely on 3NT [218, 220].  
Evidence of protein denitration in biological tissues has been observed suggesting that 3NT may be 
initiated and controlled by ROS and RNS leading to redox signaling in cellular processes [221].  Though 
tyrosine nitration is considered to be a stable PTM, and therefore a suitable marker for oxidative damage, 
there has been increasing evidence of a redox signaling pathway involving protein nitration.  3NT has 
been shown to interfere with kinase and phosphatase enzymes, which may have a regulatory effect on 
tyrosine phosphorylation pathways [217].  In addition, Mn superoxide dismutase has reduced function 
due to 3NT formation [222].  It has also been suggested that denitration may be selective to specific 
substrates.  This has been observed in Histone H1.2 and calmodulin as specific targets for protein 
denitration [223].  Further research is currently underway in order to better understand the physiological 
importance of a reversible nitration signaling system [224].   
The addition of the nitro group to the tyrosine ring alters chemical properties of the amino acid. 
The most notable change is the decreased pKa of the phenol group from 10.1 to 7.2 [225] or 6.8 [226].  
This is a result of the nitro group on the phenol ring drawing electron density, which makes the phenol 
proton more labile and tyrosine more acidic.  The lower pKa increases the amount of deprotonated 
nitrotyrosine molecules relative to tyrosine, which in addition to steric effects, can prevent 
phosphorylation events altering cellular signaling processes[218].  Spectroscopic measurements can be 
used to monitor the shift in pKa.  For example, under acidic conditions the phenolic group of 3NT is 
protonated allowing hydrogen bonding with an oxygen atom of the nitro group, which can be observed in 
the 360 nm UV region.  However, basic conditions which lead to deprotonation of the hydroxyl group and 
elimination of this hydrogen bonding shift the absorbance to 430 nm [218].  It should be noted that the 
absorbance changes of 3NT can allow monitoring of sample preparation procedures.      
3.2.  PROTEOMICS 
Better insight to the effects of 3NT can be realized through the analysis of 3NT-modified 
proteins.  Proteomic analysis of 3NT can be classified as redox proteomics, which focus on oxidative 
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modifications.  It is noteworthy that redox proteomic technologies have also been developed for the 
detection of oxidized thiols [227], carbonylation [228], lipid peroxidation [229], and nitration amongst 
others.  Specialized proteomic approaches for the detection of low abundant PTMs have been developed 
[230].  Chapter 1 introduced techniques and strategies used in bottom-up proteomic experiments for 
protein identification and quantitation, which can also be applied to study 3NT presented below.   
3.2.1.  Enrichment 
In vivo nitration of tyrosine residues are such that only five nitrated sites are detected per 10,000 
tyrosine residues in inflammation conditions [217].  Because 3NT is a low abundance PTM, issues with 
ion suppression and false-positive identification arise.  A conservative set of guidelines have been 
proposed to increase confidence in the identification of 3NT-modified proteins as follows: accurate 
peptide charge state and mass, detection of the 3NT immonium ion fragment peak (m/z 181.1), validation 
of 3NT peptide chromatographic retention (in comparison to unmodified peptide), and limitation of 
unassigned fragment peaks [231].  These guidelines can be adopted by any laboratory.  In the context of 
biological tissues it can be challenging to identify 3NT-modified proteins, which has led to the 
development of enrichment strategies [232].  The earliest enrichment approaches included the use of an 
insoluble-antibody column specific to nitrated proteins [233] and immunoprecipitation [234].  Generally, 
enrichment of 3NT-modified proteins can be performed through the use of antibodies (e.g., anti-3NT) or 
alternatives such as chemical tags that target the nitro group.   
Chemical tags rely on increasing the reactivity of 3NT through reduction reactions that generate 
3-aminotyrosine (3AT) at the peptide level.  This can be achieved with reducing reagents such as sodium 
dithionite and dithiothreitol (DTT) in the presence of heme as shown in Figure 3.2.  A chemical tagging 
approach targeting 3AT offers the advantage of being gel-free and antibody-free.  The significant pKa 
difference between the aromatic amine (~4.7) and other primary amines on a peptide chain (~8-10) allow 
for selective addition of chemical tags to 3AT.  A plethora of these tags have been applied targeting 3AT  
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 Figure 3.2.  Reactions demonstrating the reduction of 3-nitrotyrosine to 3-aminotyrosine using sodium 
dithionite or dithiothreitol in the presence of heme. 
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including biotin/avidin interactions [235-237], nickel affinity chromatography [173], sulfhydryl 
enrichment [238], and fluorinated carbon tags [239].  Signature fragment ions that locate the site of 3NT-
modifications can be generated with the use of dansyl chloride tags on the 3AT residue [240].  
Fluorogenic derivatization of 3AT peptides with 1-(4(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-diol 
allows enrichment with boronate affinity chromatography and quantification with fluorescence 
spectroscopy [241].  A summary of enrichment protocols for 3NT enrichment methods is presented [232]. 
An alternative enrichment method for 3NT-modified proteins, which is based on diagonal 
chromatographic separations, was recently reported [242, 243].  Combined fractional diagonal 
chromatography (COFRADIC) is a technique that recognizes the differences in hydrophilicity of 3NT- 
and 3AT-modified peptides in reversed phase chromatography.  Peptide samples are subject to a one-
dimensional reversed phase separation in which several off-line fractions are collected.  Each fraction is 
subsequently reduced so that the 3NT residues are converted to 3AT residues.  Direct LC analysis of the 
3AT-peptide samples results in a shift in retention time due to the hydrophilic nature of the peptides 
relative to the original LC analysis of the 3NT-peptides.  COFRADIC is designed to be a targeted 
analysis of 3NT modifications by focusing only on peptides which shift in retention time.  As this is not a 
direct enrichment method, it does provide a straightforward means of identifying nitrated proteins in 
complex mixtures.  A major observation from the application of COFRADIC to Jurkat cell lines was the 
detection of sulfated 3NT residues which arise due to a side reaction that occurs with the use of sodium 
dithionite during the reduction step.  Thus, database search parameters should include sulfation as an 
additional dynamic modification of nitrated tyrosine residues.      
3.3.  QUANTITATIVE PROTEOMICS  
3.3.1.  Antibodies and Gel Electrophoresis-Based Methods 
Enzyme-linked immunosorbent assay (ELISA) is a traditional method to quantify nitrated 
proteins using anti-3NT antibodies [244].  ELISA assays have been applied to quantitate 3NT in human 
plasma [245, 246], brain of traumatic injury patients [247], plasma from diabetic patients [248], and 
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plasma from smokers with chronic obstructive pulmonary disease [249].  Quantitation of protein bound 
3NT has also been reported using ELISA analysis of human serum plasma [250] and can achieve a 
detection limit of 20 nmol/L [251].  Challenges occur with ELISA quantification due to the limited 
availability of highly specific antibodies [252] potentially resulting in underestimation of nitration levels. 
Additionally, the nature (e.g., monoclonal, polyclonal) and source (e.g., vendor) of the antibody and 
location of the 3NT modification can influence the recognition of 3NT-modified proteins [253].  
Limitations with antibodies are not specific to 3NT or 3NT-based ELISA methods as will be discussed 
below.   
Redox proteomics approaches for high throughput 3NT detection were initiated through gel 
electrophoresis-based measurements [254].  Figure 3.3 gives an overview of the gel-based approach.  
Two-dimensional (2D) gel electrophoresis separates proteins in the first dimension separation according 
to relative mobility (and hence MW) and by protein isoelectric point in the second dimension.  For 
comparative analyses, individual 2D gels are prepared for control and experimental samples.  Detection of 
protein spots can be achieved with fluorescence [7], chemiluminescence [255], or colorimetric assays 
such as Coomassie blue and silver staining [9].  At this stage, only information about the total protein 
abundance is obtained.  
For targeted analysis of 3NT-modified proteins, the proteins in the gel are transferred to a 
nitrocellulose or PVDF membrane such that the 2D blot can be probed with an anti-3NT antibody [256] 
and scanned with an image reader.  In this Western analysis, only protein bands which contain 3NT 
should appear on the blot and be indicative of the relative concentration of the 3NT-modified protein.  
Normalization is used to compare the 3NT signal from the blot to the total protein signal on the 2D gel 
prior to comparisons between the control and experimental samples.  The Western blot image serves to 
locate the nitrated proteins and provide quantification, however does not provide identification of the 
protein spot.  Thus, the Western blot and 2D gel must be aligned, and the protein spots of interest are 
excised, digested, and analyzed with MS.  Examples of the application of this gel-based Western analysis  
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Figure 3.3.  Schematic of general workflows for quantitative proteomic studies of nitrated proteins.  
Note that 3NT sites are identified by triangles. 
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include studies of undernourished rats [257], nitration levels of manganese superoxide dismutase in liver 
[222], and cystic fibrosis in lung [258]. 
Gel-based approaches are very attractive because they are robust, allow detection of thousands of 
protein spots, and can be targeted for specific PTMs such as 3NT.  However, there are some challenges 
with this approach, which require further development.  For example, sample preparation steps which 
incorporate DTT can cause reduction of 3NT-modified proteins (to 3AT) in the presence of heme found 
in many biological samples [259].  This contributes to underestimation of nitrated protein levels.  Site-
specific information about the location of the 3NT modification can only be obtained through MS 
detection of the excised spot [253], however MS analysis of peptides often miss the nitrated peptides.  In 
addition, protein solubility of 3NT-modified proteins in gel-based buffers may not be complete providing 
limited abundance or no abundance information [253, 260].   Finally, antibody specificity as noted above 
and high background signals from antibodies in the blots can mask low level nitrated proteins [261]. 
3.3.2.  Label-Free Methods 
 Label-free methods of quantification in proteomics, as implied, do not use chemical tags.  
Quantification is achieved through protein abundance index [68], MS/MS spectral counts [262] or 
extracted ion intensity (based on peak heights or areas) [65, 263] after LC-MS/MS analyses as shown in 
Figure 3.3.  These methods are advantageous because they are simple, inexpensive, and require minimal 
sample preparation in comparison to chemical tagging approaches.  Additionally, it is possible to analyze 
an unlimited number of samples with label-free methods.  However, with each additional sample the 
overall throughput of the approach is lessened thus making multiplexing approaches attractive.   
The native reference peptide method is capable of quantifying 3NT by comparing the peak area 
of nitrated peptides to a selected peptide present in the mixture [264].  Ideal characteristics concerning the 
choice of the reference peptide have been previously described [265].  Briefly, the peptide must be 
inherent in the digest mixture, contain no potentially modifiable residues, have high digestion efficiency, 
and have similar chromatographic retention times and detector responses to the 3NT peptide of interest. 
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Overall these characteristics result in an internal peptide standard that is inherent in the original digest. 
Native reference peptides selected from in vitro nitrated albumin resulted in a 10% relative standard 
deviation and femtomole detection limit of nitrated peptides [265].   
Stable isotope dilution, which relies on spiking known concentrations of heavy isotope 3NT into 
a hydrolyzed protein sample (i.e., a mixture of free amino acids), can provide absolute quantitative 
information.  Selected ion monitoring (SIM) of heavy isotope peaks using a triple quadrupole MS 
produce detection limits of 3NT as low as five pg in reported nitration studies of human urine [266].  
While this method gives insight to the global levels of 3NT in the mixture it lacks site- and protein-
specific detail, which is important for complete characterization of 3NT-modified proteins.   
 Nitrated peptides upon gas-phase fragmentation result in a peak at m/z 181.1 which is the 
immonium ion of nitrotyrosine [195].  Selected (SRM) or multiple reaction monitoring (MRM) allows 
selective detection of fragments from nitrated peptides by scanning the Q3 of a triple quadrupole MS in a 
collision induced dissociation experiment.  Peak areas from the signature fragments are compared to that 
from reference peptides and are indicative of the relative concentrations of the 3NT-modified peptides 
and hence proteins.  Using MRM, levels of 3NT-modified peptides from α-synuclein have been 
characterized in PD [195].  SRM analyses have also revealed eleven 3NT sites in human hemoglobin 
obtained from cigarette smokers suggesting that in vivo ONOO- levels are higher in smokers [267].   
3.3.3.  Precursor Labeling 
Complementary or alternative MS-based methods to gel-based approaches have been developed 
in the last two decades and are attractive due to multiplexing capabilities [1].  Sample multiplexing with 
bottom-up proteomic methods can be achieved with precursor or isobaric tags at the MS [67] and MS/MS 
spectral levels.  Chapter 1 reviewed precursor quantitation strategies in bottom-up proteomics.  To 
briefly highlight, 3NT-modified proteins can be digested to peptides (e.g., 3NT modified and unmodified) 
using trypsin.  Primary amine groups found in lysine, N-termini, or 3AT residues can be manipulated to 
incorporate chemical groups using acetylation [268] or dimethylation [74] that can contain stable isotopes 
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(e.g., 2H and 13C).  Depending on the nature of the chemical tag and heavy isotope incorporation, a total 
of two to three samples can be pooled and simultaneously measured in the LC-MS/MS experiment.  As 
illustrated in Figure 3.3, the peptide peaks from light and heavy labeled samples elute from the LC 
column simultaneously and are detected in the mass spectrometer.  This assumes that electrospray 
ionization of the peptides is similar and will not influence the final signal measured.  Therefore the peaks 
are shifted in mass by the number of heavy isotopes incorporated into the tag and the intensities or areas 
of the peptide peaks can be used for relative quantification.     
 Due to the reactivity of both primary amine groups in peptides and reduced 3NT to 3AT groups, 
it becomes necessary to block primary amine chemistry on peptides in order to track the location of 
modified residues.  Generally, precursor labeling uses the following major steps to make quantitative 
tagging selective for 3NT sites:  1) digest proteins to peptides, 2) block primary amines with acetyl (or 
other) groups, 3) reduce 3NT to 3AT, and 4) derivatize 3AT with a light or heavy isotope chemical tag.   
Figure 3.4a highlights the incorporation of a light or heavy (e.g., 2H3) 1-(6-methylnicotinoyloxy) 
succinimide reagent  to 3AT residues [269].  The structure of this reagent contains a pyridine ring with a 
methyl group in the para position that has hydrogen atoms which can be exchanged for deuterium.  A 
mass shift of 3 Da would result for every peptide containing a 3NT modification.  Additionally, since 
peptides are capped with either a light or heavy acetyl group at Step 2, a global shift of 3 Da per acetyl 
group is observed for all peptides and an additional 3 Da is observed per 3NT modification.  Interestingly, 
the use of this nicotinoyloxy based reagent results in higher ionization efficiencies for peptides generated 
with matrix assisted laser desorption ionization (MALDI) and prevents photodecomposition with the laser 
[269, 270].  
 Derivatization of 3AT can also be performed using light or heavy (-2H5) phenylisothiocyanate 
depicted in Figure 3.4b [271].  The structure of the tag contains heavy atoms which are incorporated in 
the phenyl ring generating a mass shift of 5 Da and a reactive thiocyanate group to selectively target 3AT.  
The mechanism involves an intermolecular cyclization between the sulfur atom of thiourea and the  
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Figure 3.4. Example precursor quantification tags:  a) 1-(6-methylnicotinoyloxy) succinimide and b) 
phenylisothiocyanate which incorporate mass shifts of 3 and 5 Da, respectively. 
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hydroxyl group of tyrosine, which is the first reported transformation in aqueous media using 
photocatalysis.  Due to the addition of deuterium atoms, the hydrophilic shift which can occur due to 
kinetic isotope effects [272] was evaluated and its effects are negligible.  For quantification purposes, this 
tag demonstrates precursor quantification capabilities and the potential use of signature fragments (m/z 
116 and 121 for light and heavy tags, respectively) in SRM or MRM experiments.  The presence of the 
signature fragment peaks also confirms 3NT-modification sites as the fragments are unique to the 
phenylisothiocyanate tag.     
 
3.3.4.  Isobaric Tags 
A secondary approach to multiplexing techniques is the use of commercially available isobaric 
tags (Figure 3.3).  The most commonly used isobaric tags are tandem mass tags (TMT) [273] and the 
isobaric tag for relative and absolute quantification (iTRAQ) [274], which can multiplex six or eight 
samples, respectively.  To briefly summarize Chapter 1, isobaric tags incorporate heavy isotopes of 13C, 
15N, and 18O such that the overall mass of the tags are similar, however, upon gas-phase fragmentation 
specific low m/z reporter ions (e.g., 126-131 for TMT) are generated.  The reporter ion signals can be 
related to the relative abundances of the peptides from which they were cleaved.  Because relative 
quantification occurs in MS/MS spectra, increased precursor MS complexity is avoided.  Advantages and 
disadvantages of isobaric tagging methods are reviewed [88], as well as improvements to instrumental 
analysis to obtain accurate reporter ion ratios [89, 94].  These methods should be included for future 
quantitation experiments using isobaric tags including the analysis of 3NT-modified proteins.   
Few reports of isobaric tagging applications for 3NT modifications are reported.  Quantification 
of nitrated peptides with isobaric tags was first demonstrated by Chiappetta et. al. using mixtures of 
nitrated bovine serum albumin (BSA) and bovine milk proteins [275].  After acetylation, 3AT BSA 
peptides were tagged with iTRAQ reagents and analyzed with precursor ion scanning using a triple 
quadrupole MS.  The presence of iTRAQ fragment immonium ions at m/z 292.1 proved advantageous for 
confirming modification sites of low abundant nitrated peptides.  Additionally, this approach does not 
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require time consuming sample fractionation steps and provided accurate reporter ion quantification. 
Chapter 4 introduces the novel quantitative approach termed “Combined Precursor Isotopic Labeling and 
Isobaric Tagging (cPILOT)”, which selectively quantifys nitrated peptides and expands the quantification 
capacity of isobaric tags to either 12 or 16 for TMT and iTRAQ, respectively [98].   
3.4.  CONCLUSIONS AND FUTURE OUTLOOK 
Obtaining quantitative information for 3NT allows a better understanding of the role this PTM 
plays in biological systems.  3NT has been linked to neurodegenerative disorders, cancer, and 
cardiovascular disease and has been shown to impact protein function and potentially redox cellular 
signaling pathways.  With the advent of proteomics for PTM investigation, there have been a number of 
reports focusing on qualitative information of 3NT-modified proteins obtained through targeted analyses 
or enrichment methods.  There are fewer reports that address quantification of 3NT-modified proteins in 
complex mixtures.  Perhaps this is partially attributable to the low abundance of this PTM in biological 
samples, which leads to the need for highly selective and sensitive analytical techniques.  As a result, 
enrichment approaches, which rely on antibodies or other chemical tagging strategies, must continue to be 
developed to allow targeted analyses of nitrated proteins in complex biological samples.  A number of 
these methods currently exist, however limitations in antibody selection including nonspecific binding 
have prevented their widespread ability to identify large numbers of nitrated proteins.  Gel-based redox 
proteomics methods offer targeted identification and relative quantification of nitrated proteins using 2D 
Western Analysis, but also have similar issues that arise from antibody use such as high background 
signals and nonspecific binding of non-nitrated proteins.  Furthermore, peptide loss during excision and 
digestion processes often limits the MS detection of nitrated peptides preventing 3NT site-specific 
information.   
Currently, most of the approaches available have yet to provide large-scale identification and 
quantification of nitrated proteins in biological samples since a large percentage of total peptides detected 
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in these experiments contain no site of nitration.  This is notably a result of the challenges associated with 
the low abundance of this modification, sample loss during lengthy derivatization steps using chemical 
tags, and the complexity of samples of interest.  Guidelines that help to strengthen the confidence in 
identification of nitrated peptides and proteins from MS data should also be adapted by many of these 
groups.  Due to the importance of 3NT in numerous diseases, this research area will continue to be of 
great interest such that improved proteomics methods are desirable. 
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4.0  ENHANCED SAMPLE MMULTIPLEXING FOR NITROTYROSINE-MODIFIED 
PROTEINS USING COMBINED PRECURSOR ISOTOPIC LABELING AND ISOBARIC 
TAGGING * 
(*Reprinted with permission from Robinson, R. A. S, Evans, A. R. Analytical Chemistry. 2012. 
84. 4677-4686. Copyright 2014. American Chemical Society.) [98] 
4.1.  INTRODUCTION 
Chapter 3 introduces the biological significance and previous proteomic techniques to quantitate 
3NT.  Briefly, gel electrophoresis with Western blot detection is commonly used to identify and quantify 
3NT proteins, however relies on mass spectrometry (MS) for sequence identification.  Matrix-assisted 
laser desorption ionization (MALDI)-MS [276, 277], electrospray ionization (ESI) tandem mass 
spectrometry (MS/MS) [278, 279], and liquid chromatography (LC) coupled with MS/MS have also been 
employed to identify nitrated residues in tryptic peptides [264, 280, 281].  Precursor [269] [282] and 
isobaric tagging [275] methods have been employed to quantify 3NT.  The isobaric tag for relative and 
absolute quantitation (iTRAQ) was used to tag 3AT peptides after the blocking of N-termini and lysine 
residues with an acetyl group.  In this approach, no enrichment is carried out however, 3NT-modified 
peptides are easily identified by performing precursor ion scanning for specific iTRAQ containing ions.  
Although it was only partially demonstrated, this approach can quantify up to a total of eight samples 
using the iTRAQ 8-plex reagent kit.   
Chapter 4 presents an approach that increases the multiplexing capability of quantitative 
proteomics to assess differences in the relative abundances of 3NT-modified proteins.  Through combined 
precursor isotopic labeling and isobaric tagging (cPILOT), we have developed a novel strategy that uses 
commercially available tandem mass tags (TMT) and iTRAQ reagents in order to increase the number of 
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samples that can be compared in a single analysis to 12 and 16, respectively.  Additionally, the presence 
of reporter ions in the mass spectra can be used to identify nitrated peptides and help to eliminate false 
positive identifications that can arise from shotgun proteomics experiments [283].  cPILOT builds upon 
currently used quantitative proteomics strategies presented in Chapter 1 [73, 275].  Herein, proof-of-
principle cPILOT experiments are presented using simple mixtures of in vitro nitrated bovine serum 
albumin (BSA) and mouse splenic protein digests, which are analyzed using nanoflow LC-MS/MS 
coupled with an LTQ-Orbitrap Velos MS.        
4.2.  EXPERIMENTAL 
4.2.1.  In Vitro Nitration of BSA 
One milligram of BSA (Sigma Aldrich; St. Louis, MO) was dissolved in 500 μL of phosphate 
buffer saline (PBS) and a 50 μL aliquot of ~40 mM ONOO- (Millipore; Billerica, MA) was added to the 
solution.  The sample was incubated at room temperature for 30 minutes under constant stirring (hereafter 
referred to as 3NT-BSA).  The reaction was quenched by flash freezing in liquid nitrogen.  A control BSA 
sample was treated in the same manner with the exception of the addition of ONOO- to the buffer 
solution.  Samples were stored at -80 °C until further use.   
4.2.2.  Spleen Homogenization 
Mouse spleen tissue was homogenized in an ice-cold phosphate buffer saline (PBS) solution 
containing 8 M urea with 100 passes of a Wheaton homogenizer.  Homogenate solution was collected, 
sonicated, and centrifuged at 13000 RPM for 10 minutes (4 °C).  Supernatants were collected and protein 
concentrations determined using the BCA assay according to the manufacturer’s instructions (Pierce 
Thermo; Rockford, IL).  Samples were stored at -80 °C until further use. 
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4.2.3.  Immunochemical Measurement of 3NT-BSA Level 
Control and 3NT-BSA samples (5 µL) were incubated at room temperature for 20 min with 5 µL 
of SDS (12% v/v) and 10 µL of Laemmli buffer [0.125 M Tryzma base, pH 6.8, SDS (4% v/v), and 
glycerol (20% v/v)].  Samples (250 ng) were blotted onto a nitrocellulose membrane and blocked with 
BSA (3% w/v) in a PBS solution containing 0.04% (v/v) Tween-20, and 0.10 M NaCl (hereafter referred 
to as Wash blot).  A 1:2000 dilution of rabbit polyclonal anti-3NT primary antibody (Sigma-Aldrich) was 
added and the blot incubated for 3 hours on a rocker.  The blot was rinsed for 5 min in Wash Blot three 
times and subsequently incubated with a 1:8000 dilution of anti-rabbit IgG alkaline phosphatase 
secondary antibody (Sigma-Aldrich) in Wash blot for 1 h at room temperature on a rocker.  The 
membrane was washed as described above and developed using a solution of 0.2 mM nitrotetrazolium 
blue chloride and 0.4 mM 5-bromo-4-chloro-3-indolyl phosphate dipotassium in an alkaline phosphatase 
buffer (0.1 M Tris, 0.1 M NaCl, 5 mM MgCl2; pH 9.5).  The dried blot was scanned on a Canon scanner 
and saved as a .TIF image.   
4.2.4.  BSA Trypsin Digestion 
Desired amounts of samples were subject to trypsin digestion as follows.  0.25 M DTT (Thermo 
Fisher; Pittsburgh, PA) was added in a 1:40 protein:reagent mole excess and incubated at 37°C for 2 
hours.  0.25 M iodoacetamide (Acros Organics; Morris Plains, NJ) was added in a 1:80 protein:reagent 
mole excess at 0°C for two hours in the dark followed by the addition of 1:40 protein:reagent mole excess 
L-cysteine at room temperature for 30 minutes.  Tris buffer (0.2M tris, 10mM CaCl2, pH 8.0) was added 
to the mixture until final volume was four times the original volume.  TPCK-treated trypsin (Sigma 
Aldrich) was added to each sample at 2% w:w enzyme:protein and incubated at 37°C for 24 hours. 
Samples were flash frozen with liquid nitrogen and stored at -80 °C until further use. 
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4.2.5.  Synthesis of N-acetoxy-H3-succinimide and N-acetoxy-2H3-succinimide 
The procedure for synthesis of N-acetoxy-H3-succinimide and N-acetoxy-2H3-succinimide is 
described elsewhere[73, 146].  Briefly, 1.9478 g of N-hydroxysuccinimide (NHS, Sigma Aldrich) was 
added to 4.8mL of >99% acetic anhydride (Sigma Aldrich) or 1.9451 g of NHS was added to 4.4 mL of 
99% 2H6-acetic anhydride (Sigma Aldrich).  Reactions occurred at room temperature under nitrogen with 
constant stir for 15 hours.  White crystals were collected, washed thoroughly with hexane, and allowed to 
dry under vacuum.  Product yield was 1.9909 g and 1.5085 g for N-acetoxy-H3-succinimide and N-
acetoxy-2H3-succinimide, respectively.  Nuclear magnetic resonance (NMR) analysis confirmed the 
formation of the appropriate succinimide ester (>95% purity). 
4.2.6.  3NT Reduction and Isobaric Tagging of Peptides 
For experiments using the TMT0 reagent, 50 µg of the light and heavy labeled 3AT-BSA peptides 
were pooled into a single mixture. To this sample (100 µg), one vial of TMT0 dissolved in anhydrous 
acetonitrile, was added directly to the sample according to manufacturer’s instructions (Thermo 
Scientific).  Reactions incubated at room temperature under constant stirring for one hour.  Excess 
hydroxylamine hydrochloride (Sigma Aldrich) was used to quench the reaction.  For experiments using 
the TMT 6-plex reagents (hereafter referred to as TMT6), light and heavy labeled 3AT-BSA peptide 
samples were split into six mixtures each.  Samples were reacted with the appropriate TMT6 reagent 
according to manufacturer’s instructions.  Next, portions of the light and heavy labeled TMT6 derivatized 
samples were mixed into a new sample tube to generate the desired mass ratios for reporter ions 
(discussed below).  Overall, the total mass of light and heavy labeled peptides was equal after pooling. 
For experiments using the iTRAQ 8-plex reagents (hereafter referred to as iTRAQ8), light and heavy 
labeled peptide samples (100 µg) were each split into two equal aliquots.  The appropriate iTRAQ8 
reagent was dissolved in 70 µL of ethanol and directly added to the light or heavy labeled peptide 
samples.  Reactions incubated at room temperature under constant stirring for one hour.  Light and heavy 
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labeled peptide samples were then pooled into a single mixture to generate the desired iTRAQ8 reagent 
ratios (discussed below).  Finally, samples were cleaned using Waters Oasis HLB C18 cartridges and dried 
using a speedy-vac. 
4.2.7.  LC-MS/MS 
Samples were reconstituted in a water solution with 0.1% formic acid (1 μg⋅μL-1) and separated 
on a nanoflow Eksigent 2D LC system.  Buffer A was composed of 97:3 H2O:Acetonitrile (ACN) with 
0.1% formic acid.  Buffer B was composed of ACN with 0.1% formic acid.  Samples were injected onto a 
trapping column (100 µm i.d. × 2 cm) packed with 200 Å C18 material (Michrom Bioresources Inc.; 
Auburn, CA) using an autosampler.  After a short wash, samples were eluted to a pulled-tip analytical 
column (75 µm i.d. × 13.2 cm) packed with 100 Å C18 material (Michrom Bioresources Inc.).  Gradient 
elution was performed as follows (% buffer A:% buffer B):  90:10 for 10 minutes, ramp to 70:30 over 90 
minutes,  ramp to 40:60 over 30 minutes, ramp to 20:80 over 5 minutes, hold for 10 minutes, followed by 
column equilibration.  Eluted peptides were ionized using the nanospray source (~1.7 kV) of an LTQ-
Orbitrap Velos MS.  The MS was operated using data-dependent acquisition with the following 
parameters:  full FT parent scans at 60,000 resolution over the m/z range 300-1600, top seven most 
intense ions were selected for CID (isolation width 3 m/z, 35% normalized collision energy) and HCD (10 
ms activation time, isolation width 3 m/z, 45% normalized collision energy).  CID- and HCD-MS/MS 
spectra were recorded in the LTQ and Orbitrap (7500 resolution), respectively. 
4.2.8.  Database Searching and Data Analysis 
RAW data files were searched against the BSA sequence (Swiss Prot Entry: P02769) or mouse 
International Protein Index Database with SEQUEST in Proteome Discoverer 1.2 (Thermo Scientific).  
Database searching parameters include:  precursor mass tolerance of 15 ppm, fragment mass tolerance of 
1.0 Da, static modification of carbamidomethylation to cysteine, dynamic modifications of light and 
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heavy acetyl groups at the N-terminus and lysine residues, methionine oxidation, and special modification 
for TMT or iTRAQ derivatized 3AT residues.  Masses for these modifications were 239.163 Da (TMT0), 
244.174 Da (TMT6), and 319.216 Da (iTRAQ8).  False discovery rates of p<0.05 and p<0.01 were set 
using decoy database searching such that only medium and high confidence peptides, respectively, were 
used for analyses. Intensity and area information for light and heavy labeled peptides were provided in the 
software output (.msf file).  Manual calculation of relative reporter ion peak intensity (or peak area) ratios 
was performed due to limitations in the software output for this cPILOT strategy.     
 
4.3.  RESULTS AND DISCUSSION 
4.3.1.  Combined Precursor Isotopic Labeling and Isobaric Tagging (cPILOT)   
Herein we present the novel approach cPILOT, which combines isotopic labeling with isobaric 
tagging strategies such as TMT and iTRAQ in order to extend the number of 3NT-modified samples that 
can be multiplexed in a single experiment to 12 and 16, respectively.  The strategy consists of three 
primary steps as shown in Figure 4.1:  acetylation of primary amine groups, reduction of 3NT groups to 
3AT, and isobaric tagging (using TMT or iTRAQ) of 3AT groups.  Nitrated tryptic peptides are initially 
reacted with N-acetoxy-H3-succinimide ester or isotopically labeled N-acetoxy-2H3-succinimide ester in 
order to acetylate primary amine groups (i.e., N-termini and lysine residues) with an isotopically light (-
H3) or heavy (-2H3) label, respectively.  The second step involves the use of sodium dithionite to reduce 
3NT to 3AT.  The third major step uses commercially available TMT reagents (Figure 4.1) or the iTRAQ 
reagent to react with 3AT according to manufacturer’s instructions.  Finally, the derivatized samples are 
mixed in a 1:1 light:heavy ratio and analyzed by LC-MS/MS.  We reduce sample loss of low abundance 
3NT-modified peptides by performing a single clean-up step, which occurs after isobaric tagging. 
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  Figure 4.1.  Schematic representation of the chemical derivatization steps performed in the cPILOT strategy. 
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4.3.2.  Validation of In Vitro Nitration and Isotopic Acetylation of BSA   
Immunochemistry and LC-MS/MS experiments were initially performed in order to confirm 
nitration and acetylation of BSA.  BSA 3NT-modification sites have been well-characterized using 
various enrichment methods [173, 242, 275, 284-286].  In total, BSA has 21 Tyr residues (Swiss Prot 
Entry:  P02769) that could potentially be nitrated.  Figure 4.2a shows an immunoblot with a dark band 
corresponding to the 3NT-BSA sample.  Under similar reaction conditions, without the presence of 
ONOO-, BSA control samples showed no immunoreactivity verifying the generation of in vitro nitrated 
BSA.  Validation of the first step of cPILOT was tested by tryptically digesting and acetylating (light 
label) 3NT-BSA followed by LC-MS/MS analysis on an LTQ-Orbitrap Velos MS.  Nitrated peptides 
should be shifted in mass according to the number of added acetyl (42.011 Da) and nitro (44.985) groups.  
Figure 4.2b shows an example MS/MS spectrum obtained upon fragmentation of a peak with a precursor 
m/z 783.897.  Based on the b- and y-type fragment ions detected in the CID MS/MS analysis, the peptide 
has been assigned as [L(Acetyl)GEY(NO2)GFQNALIVR+2H]2+.  The acetylation of the N-terminus was 
observed in this spectrum as well the y9/y10 and b3/b4 singly charged fragment ions locating the position of 
nitration to Tyr424.  The Δm of 208 Da corresponds to the mass shift of a nitrated tyrosine residue.  
Overall in these experiments, we observed nitration of 15 Tyr residues in which MS/MS spectra were 
manually validated.  The location of the 3NT-modification sites are as follows: Tyr54, Tyr108, Tyr161, 
Tyr163, Tyr171, Tyr173, Tyr179, Tyr180, Tyr355, Tyr357, Tyr364, Tyr376, Tyr424, Tyr475, and 
Tyr520.   
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Figure 4.2.  Validation of in vitro nitration.  a) Immunochemical blot of BSA incubated with buffer 
(control) and ONOO- after probing with primary anti-3NT antibody.  b) Example MS/MS spectrum 
obtained for a doubly-charged peak at tr 101.47 min with m/z 783.897 that has been assigned as 
[L(Acetyl)GEY(NO2)GFQNALIVR+2H]2+.  The corresponding CID generated b- and y-type 
fragment ions are labeled in the spectrum. 
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4.3.3.  3AT-BSA Isotopic Labeling & TMT0  
Having validated the presence of nitration and acetylation, 3NT-BSA samples were reduced to 
3AT-BSA, split into two equal aliquots, and isotopically labeled with either a light or heavy acetyl group. 
Acetylated 3AT-BSA samples were derivatized with the TMT0 reagent that generates reporter ion m/z 126 
and pooled in a 1:1 ratio light:heavy mixture.  Figure 4.3a shows an example pair of doubly-charged 
peaks at m/z 913.402 and 916.421 that have a total mass shift of 6 Da.  This mass shift indicates the 
presence of two acetylations to the peptide.  Upon independent CID-MS/MS of the light and heavy 
precursor peaks (Figure 4.3b), this pair has been identified as the peptide [E(Acetyl)Y(NH-
TMT0)EATLEEccAK(Acetyl)+2H]2+.  This tryptic peptide has been modified with both N-terminal and 
Lys acetyl groups, carbamidomethyl groups to Cys, and the addition of the TMT0 reagent to Tyr376.  
Confirmation of the TMT derivatization can be determined by the presence of the reporter ion m/z 126.13 
in the HCD spectra (low m/z range shown) for both the light and heavy labeled precursor ions (Figure 
4.3c). 
It should be noted that fragmentation of acetylated tryptic peptides generates an immonium ion at 
m/z 143.12, which upon loss of NH3 produces a fragment peak at m/z 126.09 [287].  This immonium ion -
NH3 fragment can be detected in the HCD-MS/MS spectrum of the light precursor peak, however at R = 
7500 it is resolved from the TMT0 reporter ion m/z 126.13 in the Orbitrap MS.  For lower resolution MS, 
it will be difficult to discern the contribution of relative peak intensity that is derived from acetylated 
immonium ions -NH3 and TMT reporter ions.  This is not the case for the heavy precursor ions, in which 
the immonium ion -NH3 is shifted by 3 Da.  For example, in the HCD-MS/MS spectrum shown in the 
upper right of Figure 4.3c, the immonium ion -NH3 occurs at m/z 129.11.  For TMT6 reagents, in which 
reporter ions are generated at m/z 126-131, lower resolution MS will not be able to distinguish immonium 
ion vs. reporter ion signal generated at m/z 126 and 129.  Therefore, these reporters would have to be 
avoided in low resolution instruments especially for analysis of more complex mixtures in which the 
relative abundances across samples would not be known a priori.  Another approach is to use iTRAQ 
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Figure 4.3.  Demonstration of chemical derivatization using TMT0 reagents.  a)  Integrated parent mass 
spectrum at tr 54.00-54.45 minutes across the m/z range 912-920 in which a doubly-charged isotopic 
pair is observed at m/z 913.402 and 916.421 for the light and heavy labeled peptide, respectively.  b)  
An overlay of the MS/MS spectra obtained after CID of the light and heavy labeled peaks shown in a).  
It should be noted that each peptide peak was isolated individually.  The MS/MS spectra from the light 
and the heavy labeled peptides have been superimposed in this spectrum.  The b- and y-type fragment 
ions (as labeled in the plot) have led to the peptide assignment of [E(Acetyl)Y(NH-
TMT0)EATLEEccAK(Acetyl)+2H]2+.  The lowercase letter “c” in the peptide sequence corresponds to 
carbamidomethylated cysteine.  c)  Zoomed-in low m/z region of the HCD spectra shown in light (left) 
and heavy (right) labeled peptide peaks, respectively. 
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reagents in which reporter ions occur at lower m/z values (i.e., 113-121); this approach is presented 
below.      
 
4.3.4.  Twelve Sample Multiplexing with TMT6 Reagents   
Isobaric tagging strategies have an inherent cost, which is augmented with the desired sample 
multiplexing capability for an experiment.   This makes analyses expensive for projects involving a large 
N, use of technical and/or biological replicates, and experimental validation (e.g., forward and reverse 
tagging).  Herein, we demonstrate how cPILOT can be employed in order to maximize the cost of 
isobaric tagging strategies for a single experiment that involves the identification of nitrated peptides.  
Figure 4.4a shows a precursor ion MS spectrum obtained for a pair of peaks in 3AT-BSA whereby light 
and heavy acetylated peptides were derivatized with the TMT6 reagents (reporter ions m/z 126-131).  The 
particular peptide pair shown at m/z 488.282 and 489.792 has been assigned to [A(Acetyl)W(NH-
TMT6)SVAR+2H]2+.  The corresponding mass shift of 3 Da confirms the presence of only one acetyl 
group which has been detected on the N-terminus.  Additionally, this peptide contains a Trp residue that 
was nitrated in vitro as validated by the mass shift corresponding to the TMT6 reagent in CID- and HCD-
MS/MS spectra (data not shown).  
In order to assess the ability of this approach to measure quantitative differences across multiple 
samples, we prepared a 3NT-BSA sample and split into twelve equal aliquots whereby six aliquots were 
acetylated with the light label and an additional six aliquots were acetylated with the heavy label.  Each 
sample was then derivatized with a particular TMT6 reagent and samples were pooled to generate the 
following mass ratios.  For aliquots containing 3AT light acetylation and TMT6 tagged peptides, the six 
aliquots were mixed in a 1:50:10:1:2:0.5 ratio corresponding to reporter ions m/z 
126:127:128:129:130:131.  The six aliquots containing 3AT heavy acetylation and TMT6 tagged peptides 
were mixed in a 1:0.5:2:1:10:50 ratio corresponding to reporter ions m/z 126:127:128:129:130:131.  
Overall, the total mass ratios of the derivatized light labeled:heavy labeled tryptic peptides was 1:1.  This 
is reflected in the precursor peaks measured in the parent MS (Figure 4.4a).  Figures 4.4b and 4.4c show  
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Figure 4.4.  Multiplexing of twelve independent samples using TMT6 reagents.  a)  Integrated parent mass 
spectrum at tr 32.65-33.99 minutes of the doubly-charged isotopic pair observed at m/z 488.282 and 489.792 
for the light and heavy labeled peptide, respectively, that has been assigned as [A(Acetyl)W(NH-
TMT6)SVAR+2H]2+.  b)  A zoomed-in low m/z region of the HCD-MS/MS spectra obtained upon isolation 
and fragmentation of the light labeled peak shown in a).  c)  A zoomed-in low m/z region of the HCD-
MS/MS spectra obtained upon isolation and fragmentation of the heavy labeled peak shown in a). 
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the presence of each of the TMT6 reagents for the light and heavy labeled precursor ions, respectively. 
The observed relative abundance ratios for the light precursor peak (Figure 4.4b) according to peak areas 
are 1.0:38:8.5:1.2:2.9:1.2 and the ratios for the heavy precursor peak (Figure 4.4c) are 
1.0:5.6:3.6:1.7:4.0:11.  The correlation in measured versus expected reporter ion ratios is linear for both 
the light (R2=0.9991) and heavy (R2=0.7956) precursor ions.  However, the measured reporter ion ratios 
are compressed in some cases and overestimated in others deviating from expected reporter ion ratios 
from sample preparation.  While some error in quantitation can be related to errors during sample 
preparation, upon closer inspection of the precursor and CID-MS/MS and HCD-MS/MS spectra, we 
attribute the inaccuracy in measured reporter ion ratios to overlap of the isotopically labeled precursor 
ions that occurs during isolation in the LTQ.  The [A(Acetyl)W(NH-TMT6)SVAR+2H]2+ peptide shown 
in Figure 4.4 is doubly charged and contains a single label; thus precursor ions are shifted in mass by 1.5 
m/z.  The isolation window used in these studies was 3.0 m/z (±1.5 m/z).  Therefore, it is highly possible 
that ions from the heavy labeled precursor m/z were isolated with the light labeled precursor m/z and vice 
versa.  Isolation of both precursor ions in one MS scan event would cause an overlap in the ion signal for 
each of the reporter ions and hence inaccuracies in the measured relative abundances.  This is consistent 
with the compressed and overestimated reporter ion ratios that were detected in the [A(Acetyl)W(NH-
TMT6)SVAR+2H]2+ and other peptides detected in this dataset.  Similar issues with underestimation of 
reporter ion abundance ratios have been previously discussed [288, 289].  Solutions to reduce quantitation 
errors might involve the use of proton transfer reactions to charge reduce precursor ions [89, 290] or the 
use of different isotopically labeled reagents (e.g., dimethylation) that will increase the mass shift 
between light and heavy labeled precursors in the parent mass scan [94]. Overall, this is the first 
demonstration of a quantitative proteomics approach that couples precursor isotopic labeling with isobaric 
tagging to enhance sample multiplexing capabilities for 3NT-modified peptides.  Roughly speaking, the 
relative abundances for the cPILOT 12-plex study presented above are reflective of the expected 
abundances based on sample pooling for most of the reporter ions.  The ability to distinguish immonium 
ions is indicated in these spectra (Figures 4.4b and 4.4c) by the two resolved peaks at m/z 126.09 and 
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129.10 in both HCD-MS/MS spectra.  Based on experimental design, cPILOT offers inter- and intra- 
sample quantification.  For example, cPILOT could be employed to control (light) vs. diseased (heavy) 
samples whereby information regarding the relative change in abundance across multiple N could be 
assessed at the level of precursor ion signal (i.e., average of all control or disease biological replicates) 
and intra-sample variation can be assessed at the level of reporter ion signal. 
4.3.5.  3AT-BSA Isotopic Labeling & iTRAQ  
Figure 4.5 shows the extension of cPILOT to iTRAQ multiplex reagents.  The doubly charged 
peptide pair at m/z 949.380 and 952.399 shifted in mass by 6 Da (Figure 4.5a) has been assigned to 
[E(Acetyl)TY(NH-iTRAQ8)GDmADccEK(Acetyl)+2H]2+.  The number of observed acetyl groups agrees 
with labeling of the N-terminus and a Lys residue, carbamidomethylation of Cys, and tagging of Tyr108 
with the iTRAQ8 reagent that produces reporter ion m/z 113.  Addition of the iTRAQ8 reagent to the 
Tyr108 is also confirmed by the presence of the reporter ion m/z 113 in the HCD-MS/MS spectra of both 
the light and heavy labeled precursor ions (Figures 4.5b and 4.5c, respectively).  This peptide also 
contains an oxidized Met residue in which oxidation could have occurred during the in vitro nitration 
reaction.  Due to the lower m/z range (i.e., 113-121) of iTRAQ reporter ions there is no overlap with the 
acetylated immonium ion-NH3 that occurs at m/z 126.    
4.3.6.  Multiplexing with iTRAQ Reagents  
We designed another proof-of-principle experiment to assess whether or not overlap in reporter 
ion abundances occurs during precursor ion isolation.  Non-overlapping reporter ion m/z values for 
isotopically labeled peptides were purposefully selected for this experiment.  Briefly, two aliquots of light 
labeled 3AT-BSA were derivatized with iTRAQ8 reagents that produce reporter ions m/z 113 and 115 and 
mixed in a 1:1 ratio.  Two equal aliquots of heavy labeled 3AT-BSA were derivatized with iTRAQ8 
reagents that produce reporter ions m/z 117 and 118 and mixed in a 1:4 ratio.  Light and heavy labeled 
samples (1:1 ratio) were combined into a single mixture for analysis.  Figure 4.6 shows the low m/z  
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Figure 4.5.  Demonstration of chemical derivatization using a single iTRAQ8 reagent (i.e., reporter ion m/z 
113).  a)  Integrated parent mass spectrum at tr 44.93-47.83 minutes in which a doubly-charged isotopic pair 
is observed at m/z 949.380 and 952.399 for the light and heavy labeled peptide, respectively, that has been 
assigned as [E(Acetyl)TY(NH-iTRAQ8)GDmADccEK(Acetyl)+2H]2+. The lowercase “m” and “c” 
correspond to methionine oxidation and cysteine carbamidomethylation, respectively.  b) and c) Zoomed-in 
low m/z region of the HCD-MS/MS spectra obtained for the light and heavy labeled peptide peaks shown in 
a), respectively. 
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Figure 4.6.  Quantitative demonstration of four multiplexed samples using iTRAQ8 reagents.  A 
zoomed-in low m/z region of the HCD MS/MS spectra obtained upon isolation and fragmentation of 
the light labeled peak at tr 67.48 minutes and m/z 548.983 that has been assigned as 
[H(Acetyl)PEY(NH-iTRAQ8)AVSVLLR+3H]3+.  The observed reporter ion peak intensities and 
peak areas are displayed in the tables (top). 
76 
 
region of the HCD-MS/MS spectra generated upon isolation and fragmentation of the light labeled 
precursor peak at m/z 548.983.  Based on CID- and HCD-MS/MS spectra (data not shown) this peak has 
been assigned as [H(Acetyl)PEY(NH-iTRAQ8)AVSVLLR+3H]3+.  The issue of overlapping precursor 
ion isolation for the isotopically labeled pairs is better demonstrated in this data than could be delineated 
with the data presented in Figure 4.4.  Theoretically, the HCD-MS/MS spectrum (Figure 4.6) should only 
contain the reporter ions at m/z 113 and 115 since it was generated upon isolation and fragmentation of 
the light labeled precursor peak.  However, there is signal observed from the heavy labeled precursor ion 
peak as the reporter ions at m/z 117 and 118 are also present in the spectrum.  Detection of the heavy 
labeled reporter ion peaks confirms that overlap in precursor ion isolation is occurring in the LTQ and is 
consistent with the inaccurate abundances measured in the 12-plex experiments (Figures 4.4b and 4.4c).         
Figure 4.6 only displays the HCD-MS/MS spectrum obtained for the light labeled precursor peak, 
however accurate reporter ion abundances for both isotopically labeled peaks are observed.  The expected 
reporter ion ratios for the light labeled peak are 1:1 for m/z 113:115 and for the heavy labeled peak are 1:4 
for m/z 117:118.  For the light labeled precursor peak, the measured reporter ion abundances based on 
peak intensity are 1:1.1 for m/z 113:115.  The heavy labeled precursor peak measured reporter ion 
abundances are 1:4.0 for m/z 117:118.  Similar ratio values are obtained using peak areas as opposed to 
peak intensities for abundance calculations (see table in Figure 4.6).  These data provide evidence to 
support that cPILOT allows differences in relative protein abundances to be measured across multiple 
samples.  Furthermore, cPILOT can increase the multiplexing capability of iTRAQ8 (m/z 113-121) to the 
analysis of 16 samples in a single experiment.  We also note that the presence of reporter ion tags in the 
HCD spectra can be used as a selection criterion to filter for 3NT-modified peptides during data analysis.       
In order to demonstrate the potential capability of this approach to detect nitrated peptides in complex 
mixtures, the cPILOT workflow was carried out on tryptic peptides from mouse splenic proteins.  Based 
on the aforementioned issues, only a four-plex experiment was designed which allowed us to track the 
occurrence of precursor ion overlap and evaluate the reporter ion quantitation.  The peptide mixture was 
split into four individual aliquots, acetylated with either light or heavy labels, derivatized with iTRAQ8 
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reagents, and mixed in a 1:1 ratio for m/z 113, 114 and 1:1 ratio for m/z 115 and 116, respectively.  Figure 
4.7a shows a precursor mass spectrum for a doubly-charged precursor peak pair at m/z 810.972 (light) and 
812.481 (heavy) that is shifted by 3 Da.  This pair has been assigned as the [A(Acetyl)PGISY(NH-
iTRAQ8)QRLVR+2H]2+ peptide belonging to phosphoinositide 3-kinase regulatory subunit 5 protein 
(IPI00400180.1).  From the HCD-MS/MS spectra obtained from the light and heavy labeled precursors, it 
is evident that this peptide was nitrated as indicated by the presence of the four reporter ions. 
Additionally, the observed peak intensity ratios for reporter ions are similar to the expected values.  It is 
still apparent from the MS/MS spectra that there is overlap in the precursor isolation indicated by the 
presence of the reporter ions at m/z 115 and 116 in the HCD spectra (Figure 4.7b) taken upon isolation of 
the light precursor peak and the presence of m/z 113 and 114 in the HCD spectra taken upon isolation of 
the heavy precursor peak (Figure 4.7b).  Under ideal conditions, only reporter ions at 113 and 114 m/z 
should be present in HCD spectra from the light labeled precursor (similarly 115 and 116 m/z should be 
observed for the heavy precursor).   Overall, we identified 371 peptides, which correspond to 96 mouse 
splenic proteins.  Five proteins (five peptides and twelve spectral counts) were identified with nitrated 
residues:  phosphoinositide 3-kinase regulatory subunit 5 protein [A(Acetyl)PGISY(NH-
iTRAQ8)QRLVR], nebulin [D(Acetyl)Y(NH-iTRAQ8)DLREDAISIK(Acetyl)], Ep300 protein 
[K(Acetyl)VEGDM(Ox)Y(NH-iTRAQ8)ESANNR], Isoform 1 of Bullous pemphigoid antigen 1 
[S(Acetyl)IDELNSAWDSLNK(Acetyl)AW(NH-iTRAQ8)K(Acetyl)], and Npas3 protein 
[V(Acetyl)ERY(NH-iTRAQ8)VESEADLR].  We note that a low percentage (i.e., 1.6%) of nitrated 
peptides was identified with modifications on Tyr or Trp residues.  Additional enrichment steps (i.e., 
immunoprecipitation of 3NT-modified peptides prior to cPILOT) will be necessary in order to identify 
large numbers of nitrated peptides in complex mixtures.     
Caveats to obtaining accurate quantitative information with cPILOT relies on minimal to no 
overlap in the precursor ion isolation for isotopically labeled peaks, efficient chemical reactions, and 
minimal errors during sample preparation.  The N-acetoxy-2H3-succinimide reagent used to isotopically 
label tryptic peptides in these studies can be substituted with other reagents that will increase the mass 
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Figure 4.7.  Application of cPILOT to mouse spleen tissue using iTRAQ8 reagents in a four-plex experiment.  
a) Parent mass spectrum at tr 105.03 minutes of the doubly-charged isotopic pair observed at m/z 810.972
and 812.481 for the light and heavy labeled peptide, respectively, [A(Acetyl)PGISY(NH-
iTRAQ8)QRLVR+2H]2+ of the phosphoinositide 3-kinase regulatory subunit 5 protein (IPI00400180.1) 
protein from spleen tissue.  b)  A zoomed-in low m/z region of the HCD-MS/MS spectra obtained upon 
isolation and fragmentation of the light (left) and heavy (right) labeled peaks shown in a).   
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shift between light and heavy labeled peptides, thus eliminating compression and overestimation of 
reporter ion abundance ratios.  Section 4.3.7 and Chapters 5 and 6 explore alternative precursor isotopic 
labeling reagents to improve these issues.  Errors associated with sample loss were minimized during 
these experiments by performing “one-pot” reactions and using a single sample clean-up step prior to LC-
MS/MS analysis.  Finally, for application of cPILOT to complex peptide mixtures in which protein 
abundances are not known a priori it is necessary to have efficient chemical reactions in order to reduce 
complexity in data analysis and interpretation.  The isotopic labeling and commercial TMT and iTRAQ 
reactions have efficiencies reported to be greater than 98% [74, 218, 291, 292].  Our results are consistent 
with these reported efficiencies.     
4.3.7.  Improved cPILOT Quantitative Accuracy using 13C2, 2H3-Acetylation* 
(*De Gruyter Proteomics Quantification of Protein Nitration, Walter De Gruyter GmbH Berlin 
Boston, 2013.  Copyright and all rights reserved.  Material from this publication has been used 
with the permission of Walter De Gruyter GmbH.) [99] 
To directly address the issue of precursor ion overlap, acetylation reagents which generate higher 
mass shifts in the precursor MS spectra have been employed as shown in Figure 4.8.  The cPILOT 
workflow was modified by exchanging the GIST reagent with direct addition of light (C4H6O3) and heavy 
(13C42H6O3) acetic anhydride for acetylation of protein digests.  Nitrated BSA peptides after acetylation 
exhibit a mass shift of 5 Da between light and heavy (13C2,2H3-acetyl) precursor peaks.  Due to the 
enhanced m/z shift, there should be no overlap in MS ion selection between light and heavy precursors. 
Improvements in quantification are observed using this approach.  For example, the light and heavy 
MS/MS spectra generated for the doubly-charged peptide (Acetyl)NY(NH-TMT6)QEAK(Acetyl), show a 
1.0:4.5 and 3.7:1.0 reporter ion ratio for m/z 130:131, respectively.  Due to the accuracy of the ratios 
(which should be 1:4 and 4:1 for light and heavy, respectively), this demonstrates the applicability of 
increasing precursor mass shifts for reducing ion overlap while yet improving quantification.  Also, the  
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Figure 4.8. Chemical reaction of peptide primary amines with acetic anhydride (top).  Example HCD 
MS/MS spectra (zoom-in of lower m/z region) of BSA peptide whereby light (-COCH3, bottom left) 
and heavy (-13CO13C2H3, bottom right) peptide mixtures were tagged with TMT reagents that generate 
reporter ions at m/z 130 and 131.  Theoretical ratios should be 1:4 and 4:1 (m/z 130:131) for light and 
heavy peptides, respectively.   
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use of Lys C protease as opposed to trypsin results in all Lysine terminated peptides ensuring at least two 
sites of acetylation (and thus a mass shift of 10 Da).    
4.4.  CONCLUSIONS 
This work reports on the first quantitative proteomics approach that combines precursor ion 
isolation with isobaric tagging strategies such as TMT and iTRAQ for the analysis of 3NT-modified 
proteins.  cPILOT extends sample multiplexing capabilities to 12 and 16 samples with commercial TMT6 
and iTRAQ8 reagents, respectively, and provides the identification of nitrated peptides through detection 
of reporter ions in HCD MS/MS spectra.  Despite the observed limitations with the reagents used for this 
cPILOT strategy, accurate quantitative information could be obtained with appropriate precursor tagging 
reagents and/or improvements to experimental design.  The incorporation of a 5 Da acetylation mass shift 
and the use of LysC protease are an important steps to achieve accurate quantitation using cPILOT.  Since 
3NT modifications are low-abundance, we also note that this approach can be combined with prior 
enrichment procedures for nitrated peptides such as immunoprecipitation or with selected ion monitoring 
experiments to search for reporter ions.  Primary advantages with cPILOT include the ability to use 
reporter ion tags to identify nitrated peptides, reduction of cost associated with purchasing commercial 
isobaric tag kits, and increasing the number of samples analyzed in a single experiment.  The ability to 
increase multiplexing of proteomics experiments is an attractive area for many researchers that are 
examining expression differences in a large number of biological samples.  Chapters 5 and 6 extend 
cPILOT to a global quantitative proteomic approach to enhance multiplexing, which can be applied to 
protein samples of any origin. 
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5.0.  GLOBAL COMBINED PRECURSOR ISOTOPIC LABELING AND ISOBARIC TAGGING 
(cPILOT) APPROACH WITH SELECTIVE MS3 ACQUISITION* 
(*Global Combined Precursor Isotopic Labeling and Isobaric Tagging (cPILOT) Approach with 
Selective MS3 Acquisition. Evans, A. R.; Robinson, R. A. S. Proteomics. 13. Copyright © 2013. 
Permission granted by John Wiley and Sons. 2014.) 
5.1.  INTRODUCTION 
Enhanced multiplexing techniques were presented in Chapter 1, which include SILAC combined 
with TMT [102], Neucode tags [105], and the synthesis of novel TMT reagents [103].  However, these 
approaches are limited to cell cultures, ultra-high resolution mass analyzers (R > 480k), or require tags 
not commercially available.  Chapter 4 reported a strategy for combining precursor isotopic labeling and 
isobaric tagging, termed “cPILOT”, which increases the multiplexing of isobaric tagging to 12 and 16 
samples for TMT and iTRAQ, respectively [98].  This approach however, is exclusive to the detection of 
nitrated peptides.  Herein, Chapter 5 presents a novel global cPILOT method, which can be applied to 
protein samples from any origin (e.g., cell cultures, tissues, biological fluids, etc.) using common 
commercially available reagents. This new approach relies on the use of low pH dimethylation to 
chemically tag peptide N-termini [293], leaving lysine residues accessible for TMT tagging.  The key to 
this workflow for future multiplexing experiments is the use of light [-(CH3)2] and heavy [-(13C2H3)2] 
dimethyl tags for precursor labeling of up to 12 or 16 samples that will be subsequently tagged with TMT 
six-plex or iTRAQ eight-plex reagents, respectively.  Global cPILOT is a technique, which can be applied 
to any laboratory interested in enhanced multiplexing. 
 The second aspect of global cPILOT includes a novel strategy which increases detection of 
reporter ions at the MS3 level.  Several methods have been presented, which clean up precursor 
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interferences [86, 87] and thus improve reporter ion quantitation, such as gas-phase purification with 
electron transfer dissociation [89], HCD-MS3 [94], and the analysis of fragment ions other than the 
traditional reporter ions (i.e., TMT clusters) [90].  It has been previously suggested that HCD-MS3 data 
collection using gas phase fractionation significantly increases the number of MS3 reporter ion spectra 
from trypsin digests [294].  This method is limited because it generates MS3 spectra that do not contain 
reporter ions due to the selection of y-ions from arginine-terminated peptides, which lack a TMT tag.  To 
overcome this limitation and increase the number of HCD-MS3 spectra with reporter ions accessible for 
quantitation, we developed a selective MS3 data acquisition method that uses y1 (m/z 371.2) collisional 
induced dissociation (CID) fragments arising from C-terminal lysine-TMT peptides.   
5.2.  EXPERIMENTAL 
In order to demonstrate the global nature of this new cPILOT workflow, peptide mixtures from 
wild-type mice (14 months old, C57BL/6J) brain homogenates were prepared.  Mice were purchased from 
Jackson Laboratory and housed in the Division of Laboratory Animal Resources at the University of 
Pittsburgh. All animal protocols were approved by the Institutional Animal Care and Use Committee at 
the University of Pittsburgh.  Brains were homogenized in phosphate buffer saline (PBS) with 8M urea, 
centrifuged at 13000 rpm, and the protein concentration of the supernatant was determined by BCA assay 
(Pierce Thermo Scientific).  Proteins (100 µg)  were reduced with dithiothreitol DTT, alkylated with 
iodoacetamide [98], and digested with either trypsin or LysC at a 1:50 protein:enzyme for 24 hours at 
37°C or 18 hours at 30°C, respectively.  LysC and trypsin digests were split into equal portions for low 
pH dimethylation [293] resulting in light [-(CH3)2] or heavy [-(13C2H3)2] labeled peptides that were 
individually subject to TMT0 tagging according to manufacturer’s protocol (Thermo Fisher).  Pooled 
mixtures of light and heavy TMT0 tagged peptides were separated using nanoflow reverse phase liquid 
chromatography (nRPLC) as previously described [98] with the following gradient (%A:%B):  90:10 for 
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5 minutes, 87:13 over 40 minutes, 80:20 over 50 minutes, 70:30 over 25 minutes, 40:60 over 15 minutes, 
20:80 over 5 minutes, hold for 10 minutes, and re-equilibrate column for 30 minutes.  Eluting peptides 
were nanosprayed into an LTQ Orbitrap Velos MS that was operated with data-dependent acquisition as 
follows: parent scan m/z range 300-1800, 60,000 resolution, top 7 ions were selected for CID-MS/MS 
(35% normalized collision energy, 2.0 isolation window, rejection of +4 or higher charge states) with 
HCD-MS3 scans following each CID-MS/MS.   MS3 spectra were acquired either from selection of the 
most intense ion in CID-MS/MS spectra [94] across the m/z range 300-800 or selection of the y1 (m/z 
371.2 ± 0.5 Da, within the top 50 most intense in MS/MS) fragment ion in CID-MS/MS spectra.  RAW 
files were searched against the International Protein Index (IPI) for mouse proteome database (v3.87, 
59534 sequences, 08/16/2012) using SEQUEST (Thermo Proteome Discoverer v1.3) with the following 
parameters:  trypsin or lysC protease, two miscleavages, 15 ppm parent mass tolerance, 1 Da fragment 
mass tolerance, static modifications of light (28.031 Da) or heavy (36.076 Da) dimethylation on N-
termini and carbamidomethyl (57.021 Da) on cysteine, dynamic modifications of oxidation (15.995 Da) 
on methionine and the TMT0 tag (224.152 Da) on lysine.  Raw data was searched against the database 
separately for static light and heavy dimethylation modifications (adding twice the search time).  Both 
search results were manually combined for further data analysis processing.  Decoy database searching 
was performed using a reverse protein database with FDRs set at 0.01 and 0.05 for high and medium 
confidence peptides, respectively.  Two technical replicates for each pooled sample were acquired. 
5.3.  RESULTS AND DISCUSSION 
For the presented global cPILOT workflow (Figure 5.1), different peptide samples (e.g., control 
and experimental, longitudinal, etc.) that arise from any source can be independently subject to low pH 
(~2.5) dimethylation, which selectively targets N-termini [293] in order to generate light or heavy labeled 
peptides.  The mechanism for dimethylation involves the formation of an imine resulting from  
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Figure 5.1.  Schematic of the workflow for a global cPILOT approach applied to two samples that use 
TMT0 reagents. 
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nucleophilic attack of primary amines to formaldehyde.  The reaction is pH dependent to the reaction 
system pH and the amine pKa.  Due to the pKa differences between amines of the lysine side chain 
(~10.5) and the peptide N-terminus (~7.5), the low pH (~2.5) conditions of 1% acetic acid solution are 
able to fully protonate lysines, while retaining reactivity of the N-terminus.  Following dimethylation, 
samples can be further tagged with TMT reagents at high pH (~8.0), which will target lysine residues.  
After pooling, precursor spectra will show peak pairs separated in mass by 8 Da.  Each peak is subject to 
CID and fragment ions are selected for HCD to generate MS3 spectra based on two approaches described 
as top ion [94] and selective y1 (Figure 5.1).    
 Figures 5.2a-c demonstrate the global cPILOT approach for tryptic mouse brain peptides.  An 
example spectrum (Figure 5.2a) for the doubly-charged peptide D(dimethyl)SYVGDEAQSK(TMT0) with 
precursor m/z values of 725.851 and 729.873 for the light and heavy peptides, respectively, shows a pair 
separated by an m/z shift of 4 (i.e., 8 Da).  Figure 5.2b shows the CID fragmentation spectra for the light 
peptide (heavy not shown) and supports the sequence identified.  The top ion-MS3 method corresponds to 
selection of the y2 fragment for both the light and heavy labeled peptides, resulting in detection of TMT0 
reporter ions (Figure 5.2c right panel).  Using our selective y1-MS3 method (Figure 5.2c left panel), only 
the TMT0 peaks are observed for the light and heavy labeled peptide peaks also demonstrating that this 
selection method gives similarly clean MS3 spectra in the reporter ion region as the top ion method.  
Labeling efficiencies at both the low pH dimethylation and high pH TMT tagging steps were determined 
to be >98% and there was minimal cross labeling of reagents (data not shown).  Overall, the combination 
of precursor low pH dimethylation with high pH TMT isobaric tagging provides a proteomics method that 
can be used for global quantitation of all peptides in a mixture, assuming the peptides contain free N-
termini and C-terminal lysine residues.  While the example shown in 5.2 represents the simplest case of 
two samples, through the use of additional TMT multiplex reagents an enhanced multiplexing experiment 
could be designed [98].   
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Selection of the top most intense ion for HCD-MS3 data acquisition is limited by selection of 
CID-MS/MS fragments that do not contain a TMT tag.  Examples include selection of a b-ion, 
Figure 5.2.  a) Precursor MS spectra for the peptide D(dimethyl)SYVGDEAQSK(TMT0) with b) 
corresponding CID-MS/MS for the light peptide.  The shaded region corresponds to the m/z window for 
selection of the most intense ion for MS3, indicated by the (**).  The (*) indicates the y1 fragment selected.   
c) HCD-MS3 is shown for the top ion method (right) and the selective y1 method (left) for light and heavy
precursor peaks.   
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Selection of the top most intense ion for HCD-MS3 data acquisition is limited by selection of 
CID-MS/MS fragments that do not contain a TMT tag.  Examples include selection of a b-ion, 
miscleavage from enzymatic digestion, or selection of an unidentified background ion due to coisolation 
of another peak at the MS/MS level.  Top ion-MS3 selection is limited to the likelihood that a y-ion will 
be the most intense ion in the noted m/z range.  One of the most frequent limitations occurs when a b-type 
ion is the most intense across the m/z range as opposed to a y-type ion (this occurs in ~20% of MS3 
spectra in these data).  In this situation, the top ion-MS3 method will fail to generate a reporter ion 
because the fragment will not contain any TMT-labeled amino acid.  In order to increase the probability 
of selection of a TMT containing MS/MS fragment for HCD-MS3, selective fragmentation of the y1 ion 
corresponding to the C-terminal lysine-TMT fragment (m/z 371.2) can be applied.  Figures 5.3a-c 
highlight an example for the doubly-charged D(dimethyl)FTPAAQAAFQK(TMT0) light and heavy 
labeled peptides (Figure 5.3a) in which it is apparent that the b3 fragment ion is the most intense in the 
shaded region of Figure 5.3b.  Selection of this fragment ion with the top ion-MS3 method does not 
generate reporter ion fragments (Figure 5.3c right panel).  However, through use of the selective y1 HCD-
MS3 method, reporter ions for the TMT0 reagent are observed (Figure 5.3c left panel) demonstrating an 
advantage to this approach.   
There are cases when both the top ion HCD-MS3 and selective y1 HCD-MS3 methods will fail to 
generate reporter ions due to limitations of signal for low abundance ions and the need for high sensitivity 
to detect these ions at the MS3 level.  Despite these limitations, significantly more reporter ion spectra are 
observed with the selective y1 MS3 method (Table 5.1).  For example, the total number of spectral counts 
(SC) for these methods is 4833 and 4960 for the top ion and selective y1, respectively, when trypsin is 
used as the protease (Table 5.1).  In addition, the number of SC containing reporter ions increased from 
3023 to 3678 when the selective y1 method was used instead of the top ion MS3 method.  In order to 
assess the reporter ion detection efficiency of each MS3 method, we determined the total number of SC 
that should lead to generation of reporter ions based on sequence (from database search results).  This  
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Figure 5.3.  a) MS spectrum for the peptide D(dimethyl)FTPAAQAAFQK(TMT0) with b) CID-
MS/MS for the light peptide.  c) HCD-MS3 is shown for the top ion method (right) and the 
selective y1 method (left) for light and heavy precursor peaks.  The shaded region corresponds to 
the m/z window for selection of the most intense ion for MS3, indicated by the (**).  The (*) 
indicates the y1 fragment selected.    
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corresponds to 3844 and 3970 possible MS3 reporter ion spectra using our cPILOT workflow with the top 
ion and selective y1 HCD-MS3 methods, respectively (Table 5.1).  Based on the number of MS3 spectra 
that contained reporter ions (minimum S/N ≥3), ~78% vs. ~93% efficiency was observed with the top ion 
vs. selective y1 MS3 methods, respectively.  
In order to demonstrate the accuracy and reproducibility of the presented method, we prepared a 
12-plex sample whereby a fixed amount (50 µg) of complex mouse liver digest was treated similarly for 
all reporter ion channels in light and heavy dimethylated steps. Triplicate MS analyses were performed 
using the selective y1 HCD-MS3 (m/z 376.3 Da) method.  As shown in Figure 5.4a, reporter ion signal 
intensities are similar for m/z 126-131 for light and heavy dimethylated peaks of the example peptide 
Q(dimethyl)TALAELVK(TMT6).  Figure 5.4b shows the frequency distribution of protein ratios for each 
replicate considering all possible TMT reporter ions as the fixed channel.  The average measured TMT 
ratios across all replicates were 1.02 (19% CV, N = 3254) and 1.00 (17% CV, N = 2723) for light and 
heavy modified proteins, respectively, providing support for suitable accuracy and reproducibility of this 
approach.  Typical quantitative proteomic experiments using isobaric tags have a quantitative dynamic 
range of approximately two orders of magnitude [63, 67].  Although not assessed directly herein, we 
anticipate some limitations with dynamic range using our selective y1-MS3 approach.  This is due to 
signal loss that occurs with each fragmentation step as is also a caveat to other methods that rely on MS3 
reporter ion signal for quantitation [94]. 
Finally, the use of LysC ensures that all MS3 spectra contain a reporter ion regardless of b- or y-
ion selection in MS/MS [94].  This advantage is lost during global cPILOT experiments because N-
termini are modified with the dimethyl group.  Additionally, trypsin digests have been shown to generate 
more quantifiable spectra with reporter ions when performing MS3 data collection [294].  Our results are 
consistent with this as a lower number of SCs are observed when LysC is used (regardless of MS3 
method, Table 5.1).  This could be attributed to the fact that LysC generates longer peptides, which 
typically contain higher charge state distributions that may decrease identifications [294, 295].  Higher  
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Table 5.1.  Peptide and Spectra Evaluation
Enzyme Method SC Predicted Observed Efficiency (%)
Trypsin Top Ion 4833 3844 3023 78
LysC Top Ion 2807 2751 2200 80
Trypsin y1 selection 4960 3970 3678 93
LysC y1 selection 2889 2853 2509 88
cPILOT Reporter Ion Spectral Counts (SC)
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Figure 5.4. a) HCD-MS3 fragmentation spectra (low m/z shown) for light (left) and heavy 
(right) petide Q(dimethyl)TALAELVK(TMT-6plex) showing equimolar twelve plex spectra.  
b) Log2 plot of protein TMT ratios from three replicate experiments.
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charge states (≥4) are rejected in our workflow to minimize overlap between light and heavy precursor 
pairs.   
 
5.4.  CONCLUSIONS 
 Chapter 5 presents a novel global cPILOT method, which includes a selective y1-MS3 method 
for increased coverage of reporter ion spectra.  Global cPILOT can be applied peptide mixtures (trypsin 
or LysC) from various sources (e.g., cell cultures, tissue, etc) and can be expanded to multiplex 12 and 16 
samples for TMT and iTRAQ tags, respectively.  Accurate and reproducible quantitation was 
demonstrated with < 20 % CV.  Chapter 6 expands global cPILOT to assess the dynamic range and 
applies the technique to biological tissues in a large scale discovery-based proteomics experiment. 
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6.0. GLOBAL cPILOT ANALYSIS OF THE APP/PS-1 MOUSE LIVER PROTEOME* 
(*Information in this chapter is written based on a submitted manuscript, Evans, A.R.; Gu, L.; Guerrero 
Jr. R.; Robinson, R.A.S.  Proteomics Clinical Applications.) 
6.1.  INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder accounting for 60-80% of total 
dementia cases [296].  Symptoms include memory loss, confusion, decreased language skills and reduced 
motor function [297].  Senile plaques (SP), consisting of amyloid β (Aβ) peptides, are a major hallmark of 
AD, and are formed from the cleavage of amyloid precursor protein (APP) by α, β, and γ secretases [298, 
299].  Presenilin-1 (PS-1) is a part of the γ-secretase complex and several mouse models of AD have been 
created which have APP and PS-1 mutations [300, 301].  Aβ peptides can be cleared from the brain by 
forming a complex with high density lipoprotein, which is facilitated by Apolipoprotein E (ApoE) [302].  
Overexpression of ApoEε4 is a genetic risk factor for AD [303].  Disruption of cholesterol metabolism 
and homeostasis is linked to APP processing, β and γ-secretase activity, and Aβ peptide production [304, 
305].  Other AD hallmarks include synapse loss, dystrophic neuritis, oxidative stress, mitochondrial 
dysfunction and neurofibrillary tangles composed of hyperphosphorylated tau protein [297].  AD is also a 
metabolic disorder as evidenced by alterations in glucose [306] and lipid metabolism [304], and insulin 
resistance [307].  Lower glucose metabolism in brains of AD subjects contributes to cognitive decline 
[308] and mitochondrial dysfunction [309].    
Aside from the noted characteristics of AD present in the central nervous system there are also 
changes that take place in peripheral tissues, such as liver. Presenilin-2 (PS-2) is heritable in R1.40 human 
APP transgenic mouse liver [310].  Glucose intolerance and insulin resistance are observed in APP/PS-1 
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mouse liver and results in Aβ overproduction [311].  Docosahexaenoic acid (DHA), a neuroprotective 
fatty acid synthesized in the liver, decreases Aβ toxicity [312].  Impaired DHA biosynthesis correlates 
with cognitive impairment [313], while DHA administration decreases Aβ deposition [314].  The liver 
also plays a role in the clearance and degradation of Aβ peptides through liver low-density lipoprotein 
receptor-related protein (LRP) [315-317].  Higher LRP expression in liver increases Aβ peptide clearance 
and improves behavioral changes in APP/PS-1 and APPwIndJ20 mouse models of AD [318].  However, 
LRP is oxidized in AD which prevents Aβ peptide clearance ultimately contributing to elevated Aβ 
concentrations in the circulatory system [319].  It is clear that the liver plays a major role in AD however, 
the specific mechanisms and their relation to characteristic hallmarks in the central nervous system are 
not fully understood.  The liver is responsible for system wide metabolic regulation, protein synthesis, 
and detoxification [320]. We believe that dyshomeostasis in the liver could contribute to AD 
pathogenesis.  Here, we sought to measure changes in the liver proteome of an APP/PS-1 mouse model at 
advanced stages of disease [321] in comparison to heterozygous wild-type (WT) controls. Proteomic 
studies using this mouse model have been performed on the brain [322, 323], immune cells [324], 
astrocytes [325].  
Enhanced multiplexing increases sample throughput and minimizes experimental variations, 
which result from multiple sample preparations and separate LC-MS injections.  Chapters 4 and 5 
present cPILOT [98, 100], which increases sample multiplexing capabilities through multiple labeling 
steps.  Global cPILOT enhances sample multiplexing and can be applied to protein digests from any 
sample origin (e.g., tissues, cell cultures, cell types, etc.) [100].  Here, we apply global cPILOT to the 
liver proteome of 14-month old APP/PS-1 and WT control mice.  In a single proteomics workflow, six 
biological replicates are analyzed simultaneously.  Independent verification of the changes in the liver 
proteome was performed using precursor dimethylation experiments of the six biological replicates 
independently.  Merits of the cPILOT approach, results from the liver proteome analysis, and implications 
for AD are presented.  
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6.2.  EXPERIMENTAL 
6.2.1.  Animal Housing and Tissue Harvesting 
APP/PS-1 male mice [B6.Cg-Tg(APPswe, PSEN1dE9) 85Dbo/Mmjax, stock no. 005864, genetic 
background:  C57BL/6J] and heterozygous controls were purchased from Jackson Laboratory and housed 
in the Division of Laboratory Animal Resources at the University of Pittsburgh.  All animal protocols 
were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh.  Mice 
were fed standard Purina rodent laboratory chow ad libitum and kept in a 12 hour light/dark cycle.  Liver 
tissues were harvested from 14-month old APP/PS-1 (N=6) and WT (N=6) mice and stored at -80°C. 
6.2.2.  Protein Extraction and Digestion 
Livers were individually homogenized in phosphate buffer saline (PBS) with 8 M urea using a 
Wheaton homogenizer.  Homogenates were sonicated, centrifuged (13000 RPM, 4°C, 15 minutes), and 
supernatant collected.  Protein concentrations were determined using BCA assay according to the 
manufacturer’s protocol (Thermo Pierce, Rockford IL).  Proteins (100 µg) were diluted to a concentration 
of 1.0 µg/µL in PBS with 8 M urea and spiked with bovine alpha-casein (Sigma, 1.0 µg) to serve as an 
internal quality control.  Samples were digested with trypsin as previously described [98, 100].  Briefly, 
protein mixtures were treated with dithiothreitol (1:40 protein:reagent mol ratio, 2 hours, 37°C), 
iodoacetamide (1:80 protein:reagent mol ratio, 2 hours, 0°C, dark), and cysteine (1:40 protein:reagent mol 
ratio, 30 minutes, 25°C).  Protein solutions were diluted using Tris buffer (0.2 M Tris, pH 8.0, 10 mM 
CaCl2) and TPCK-treated trypsin was added (2.5% w/w enzyme/protein, 37°C, 24 hours).  Digestions 
were quenched by flash freezing in liquid nitrogen, desalted using HLB C18 cartridges, and dried by 
speed-vac.   
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6.2.3.  cPILOT Chemical Tagging 
The global cPILOT [100] study design allows the simultaneous analysis of twelve biological 
samples in a single experiment (Figure 6.1).  WT and APP/PS-1 mouse liver digests were paired using a 
random number generator and low pH (~2.5) dimethylation was performed to selectively modifies 
peptides with light [-(CH3)2] or heavy [-(13C2H3)2] dimethyl groups at the N-termini [100, 293].  Peptide 
digests were reconstituted in 1% acetic acid (0.25 µg/µL, pH = 2.5) and treated with either formaldehyde 
(60 mM)/sodium cyanoborohydride (24 mM) or 13C,2H2-formaldehyde (60 mM)/sodium 
cyanoborodeuteride (24 mM) for light and heavy dimethylation, respectively.  All samples were 
incubated (10 min, 25°C), quenched with 1% NH3 (5 min, 25°C), acidified with 5% formic acid, and 
desalted using HLB C18 cartridges.  After sample cleanup, TMT6 reagents are used to modify lysine 
residues at high pH (~8.5).  Peptide solutions were reconstituted in 100 mM triethylammonium 
bicarbonate (TEAB) buffer (1 µg/µL) for TMT tagging (Thermo Scientific).  Dimethylated WT and 
APP/PS-1 liver peptides were individually tagged with TMT reagents 126, 128, or 130 and TMT reagents 
127, 129, or 131, respectively, according to the manufacturer’s protocol.  Samples were pooled to a single 
mixture, dried, and reconstituted in 25% acetonitrile (5 mM KH2PO4, pH 2.98). 
6.2.4.  Strong Cation Exchange 
The pooled peptide sample (600 µg) was separated by offline strong cation exchange (SCX) on a 
Polysulfoethyl A column (Nest Group Inc., 2.1 mm i.d., 10.0 cm, 5U, 100Å) using a Waters 2695 LC 
with a Waters 996 PDA detector (210 nm – 400 nm).  Buffer A was composed of 25% acetonitrile and 5 
mM KH2PO4 (pH 3.0).  Buffer B was composed of 25% acetonitrile, 5 mM KH2PO4, and 350 mM KCl 
(pH 3.0).  Gradient elution was performed at 0.20 mL/min as follow (%A/%B):  100/0 for 5 minutes, 
60/40 over 55 minutes, 40/60 over 25 minutes, 20/80 over 5 minutes, 0/100 over 10 minutes, hold 0/100 
for 10 minutes, followed by column re-equilibration.  Fractions were collected in a 96 well plate and 
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divided equally to create 13 equimolar fractions.  Each fraction was cleaned using HLB C18 cartridges and 
dried by speed-vac. 
 
6.2.5.  RPLC-MS3 Data Acquisition 
 SCX fractions were reconstituted in 0.1% formic acid solution and separated using nanoflow 
reversed phase liquid chromatography (nRPLC).  Buffer A was composed of 3% acetonitrile (ACN) with 
0.1% formic acid (FA) and buffer B was composed of 100% ACN with 0.1% FA.  Samples were loaded 
onto a trap column (C18, 200 Å, 2.0 cm, 5U, 3 µL/min), washed with buffer A for 3 minutes, and 
transferred onto an analytical column (C18, 100 Å, 5U, 13.2 cm).  Separation occurred at 300 nL/min with 
the following gradient:  (%A/%B) 90/10 for 5 minutes, 85/15 over 20 minutes, 80/20 over 75 minutes, 
70/30 in 20 minutes, 40/60 in 10 minutes, 20/80 in 5 minutes, hold 20/80 for 10 minutes, followed by 
column re-equilibration.  Eluted peptides underwent nanospray ionization and were detected using an 
LTQ-Orbitrap Velos MS instrument.  Parent MS scans (60,000 resolution, 400-1600 m/z, AGC 1x106 
ions, maximum injection time 500 ms) were performed followed by data-dependent acquisition (DDA).  
The top seven most intense ions were selected for CID MS/MS (500 minimum signal, 3 m/z isolation 
width, 35% NCE, 0.25 activation q, 10 ms activation time, 3x104 AGC, 50 ms max injection time) 
followed by selection and fragmentation of the most intense ion from CID-MS/MS for HCD-MS3 
(Orbitrap detection, 200 minimum signal, 4 m/z isolation width, 60% NCE, 0.1 activation time, 3x105 
AGC, 250 ms IT, 300-1300 m/z MS/MS selection range, exclude unfragmented parent ion).  Charge state 
screening was disabled, +4 or higher precursor mass charge states were rejected, and dynamic exclusion 
was disabled.  To increase proteome coverage and the number of 12-plex peptides, second-tier 
experiments were performed for all samples using the same DDA conditions with the exception that the 
top 8 through 14th most intense ions were selected for CID-MS/MS.  Triplicate injections were performed 
for all samples. 
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6.2.6.  Database Searching and Processing 
 RAW files were searched with SEQUEST HT against the Uniprot mouse database (51178 
sequences, 11/13/2013, bovine alpha-S1-casein P02662 added manually) and processed using Proteome 
Discoverer v1.4 (Thermo Scientific).  Search parameters included:  trypsin with two missed cleavages, 
peptide mass range 300-6000 Da, 15 ppm parent mass tolerance, 1 Da fragmentation tolerance, dynamic 
modifications of TMT-6plex (+229.163) on lysine residues, oxidation (+15.995) on methionine, static 
modifications of light (+28.031) or heavy (+36.076) dimethylation on the N-terminus, and 
carbamidomethyl (+57.021) on cysteine.  Decoy database searching was performed using a reverse 
protein database with FDR settings at 0.01 and 0.05 for high and medium confidence peptides, 
respectively.  Peptide reporter ion intensities were extracted using Proteome Discoverer v1.4 software (20 
ppm mass tolerance, most confident peak, MS3 scan event).  The median value across an individual 
reporter ion channel was calculated from all peptides quantified. Next, the median of the medians for the 
twelve reporter ion channels was used to normalize reporter ion signals. Light or heavy peptide spectra 
containing at least one TMT tagged lysine and six reporter ions in HCD-MS3 were used for 
quantification.  Protein TMT ratios were calculated as the average of the summed reporter ion intensity 
ratio corresponding to assigned APP/PS-1 and WT pairs for each peptide (referred to hereafter as 
AD/WT).  The following criteria were used to derive differentially-expressed proteins:  one-way ANOVA 
(p < 0.05) with Bonferroni correction, protein score ≥ 10.0, spectral counts (SCs) ≥ 4, and biological 
replicate count ≥ 3.  AD/WT ratios were considered differentially expressed if AD/WT values < 0.7 and > 
1.4.  Appropriate fold-change cutoff values were chosen based on the 95% confidence interval of average 
protein AD/WT ratios and previously described methods [100, 326, 327].  IPA pathway analysis, Panther 
[328], and Uniprot functional analysis was used to categorize differentially-expressed proteins by 
biological function. 
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6.2.7.  Precursor Dimethyl Labeling 
Liver tissues were also subject to precursor dimethylation in six independent experiments [75].  
WT (N=6) and APP/PS-1 (N=6) mouse homogenates (100 µg) were digested as described above, cleaned 
using HLB C18 cartridges, dried, and reconstituted in 100 mM TEAB buffer (0.25 µg/µL, pH = 8.5).  WT 
and APP/PS-1 samples were treated with formaldehyde (60 mM)/sodium cyanoborohydride (24 mM) and 
13C,2H2-formaldehyde (60 mM)/sodium cyanoborodeuteride (24 mM), respectively and incubated for 1 
hour at 25°C.  Samples were quenched with aqueous ammonia (0.1% final concentration), acidified with 
FA, and pooled pairwise to match the cPILOT experiment design (Supplemental Figure S3).  Samples 
were cleaned using HLB C18 cartridges, dried, and reconstituted in 0.1% FA.  Each sample was analyzed 
using nano-RPLC-MS/MS as described above with the following exceptions:  350-1700 m/z range for MS 
scans, selection of the top 15 most intense ions for CID-MS/MS, charge state screening enabled with 
rejection of +1 ions, and dynamic exclusion enabled (repeat count 2, 60 s duration).  Database search 
parameters were performed with dynamic modifications of oxidation (+15.995) on methionine, light 
(+28.031) or heavy (+36.076) dimethylation on the N-terminus and lysine residues, and static 
modifications of carbamidomethyl (+57.021) on cysteine.  Precursor signals were extracted using 
Proteome Discoverer v1.4 and peptide ratios (heavy/light for AD/WT) were calculated. Median peptide 
ratios across biological replicates were used for normalization.  
6.3.  RESULTS 
6.3.1.  Global cPILOT Approach 
  Global cPILOT [100] performed simultaneous analysis of twelve biological samples (Figure 
6.1).  To increase the number of peptide pairs resulting in 12-plex quantitation, we employed a two-tiered 
DDA method (Figure 6.2), which increased 12-plex peptides by approximately 50%.  Tradeoffs to the 
multi-tier approach are additional instrument and data analysis times.  We chose the top-ion-HCD- 
101 
Figure 6.1.  Schematic diagram of global cPILOT workflow.  Details are described in text. 
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 Figure 6.2.  Data-dependent acquisition (DDA) method employed for AD mouse liver experiments. 
Offline SCX fractions were injected in triplicate and DDA parameters set to scan the top 1 through 7 most 
intense ions across 150 minutes of analysis time.  Samples were re-injected three additional times and the 
top 8-14 most intense ions were selected and fragmented. 
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MS3 [94] method since a 4-fold reduction in reporter ion signal was observed using the previously 
described selective y1-MS3 approach [100].  Reduced signal with selective y1-MS3 data acquisition can be 
attributed to the relatively lower signal (i.e., the y1 fragment is ~35% of the base peak) of the selected 
MS/MS fragments and signal spread across six reporter ion channels and other MS3 fragments. 
6.3.2.  Global cPILOT Accuracy and Dynamic Range 
We assessed the accuracy of cPILOT across two orders of magnitude based on samples prepared 
as follows:  0.01:0.02:0.10:0.20:1.0:1.0 using TMT reagents that generate reporter ions at m/z = 
126:127:128:129:130:131.  Ratios were calculated with reporter ions at m/z = 130 or 131 as the 
numerator to measure fold-change values as follows: 1:1, 1:5, 1:10, 1:50, and 1:100.  Box plots of 
experimental log2 (TMT ratios) are shown in Figure 6.3.  TMT ratios for light dimethylated precursors 
were 1.0:1.0 ± 0.1 (average ± standard deviation) (N=416 proteins), 1.0:6.0 ± 1.0 (N=784), 1.0:10.5 ± 2.1 
(N=682), 1.0:46.4 ± 15.9 (N=316), and 1.0:72.4 ± 27.4 (N=132) while TMT ratios from heavy precursors 
were 1.0:1.0 ± 0.1 (N=218), 1.0:5.8 ± 0.8 (N=424), 1.0:10.7 ± 1.8 (N=390), 1.0:53.3 ± 11.5 (N=214), and 
1.0:81.8 ± 20.5 (N=158) (average ± standard deviation).  Linearity is observed across a 50-fold change 
range between reporter ion channels for light (r2 = 0.9988) and heavy (r2 = 0.9999) protein TMT ratios 
and across a 100-fold change range with r2 = 0.9823 and 0.9791 for light and heavy protein TMT ratios, 
respectively.  Based on these findings, cPILOT is accurate over a 50-fold change range. 
6.3.3.  cPILOT Analysis of the APP/PS-1 Liver Proteome 
Global cPILOT was applied to the liver proteome of 14-month old male APP/PS-1 mice, 
mimicking advanced stages of AD.  In total, 1734 unique proteins were identified from 5084 unique 
peptides (324517 SCs) and 545 proteins were quantified, which contain twelve reporter ion signals.  In  
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Figure 6.3.  Box and whisker plot of experimental log2(TMT ratios) for light (black) and heavy (grey) 
precursor labeled proteins.  Protein ratios (1:1) were calculated from reporter ions at m/z = 130:131, 
5:1 from reporter ions at m/z = 130:129 and 131:129, 10:1 from reporter ions at m/z = 130:128 and 
131:128, 50:1 from reporter ions at m/z = 130:127 and 131:127 and 100:1 from reporter ions at m/z = 
130:126 and 131:126.  Similar calculations were performed for light and heavy dimethylated protein 
ratios.  Theoretical protein ratios are indicated by the dashed lines. Only LC-MS/MS was used to 
analyze this set of samples. 
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some cases, only a single dimethylated peak (i.e. light or heavy) was selected for MS/MS thus 
yielding results for less than six biological replicates.  Figure 6.4a shows a sample 12-plex spectrum for 
the peptide [T(dimethyl)ITVSQDEGVRPSTTMQGLAK(TMT6)+3H]3+ which identifies to the protein 3-
ketoacyl-CoA thiolase B, peroxisomal.  HCD-MS3 of light and heavy dimethylated peptides 
results in 12-plex quantitation (Figure 6.4b).  Higher expression of this peptide is observed in AD 
tissue compared to WT (AD/WT = 1.4 ± 0.4, average ± standard deviation).  Sixty-four proteins are 
differentially-expressed in AD liver (Figure 6.5) and have total reporter ion signals that span five orders 
of magnitude.  
6.3.4.  Precursor Dimethyl Labeling 
Precursor isotopic dimethylation [75] was used as an independent means to verify cPILOT 
fold-change values (Figure 6.6).  This approach included six duplex dimethylation experiments 
compared to the single 12-plex cPILOT analysis described above.  Figure 6.4c displays the peptide 
[T(dimethyl)ITVSQDEGVRPSTTMQGLAK(dimethyl)+3H]3+ observed in Figure 6.4a with light and 
heavy peaks. Similar to the cPILOT data, this peptide his higher abundance in the AD liver (1.4 ± 
0.6). The six duplex dimethylation experiments resulted in 1415 proteins identified in which 712 
proteins overlapped with the single 12-plex cPILOT experiment. Both approaches identified novel 
proteins that were not present in the other dataset. Overall, we have identified 2437 total liver proteins in 
these studies. Of the 64 differentially-expressed proteins from the cPILOT analysis, 22 protein ratios 
were verified using precursor dimethylation (Figure 6.7).  Thirteen additional differentially-
expressed proteins were detected using precursor dimethylation.  Precursor dimethylation verified many 
of the cPILOT ratios. 
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Figure 6.4. a) Precursor spectra for the peptide [T( dimethyl)ITVSQDEGVRPSTTMQGLAK(TMT
6)+3H]3+ 
which belongs to 3-Ketoacyl-CoA Thiolase B (Uniprot Acc. No. Q8VCH0) with b) left, HCD-MS3 
reporter ion spectra from light (m/z = 831.442) and right, heavy (m/z = 834.123) peptide peaks.  Only 
the low m/z region is shown.  c) Precursor specrum from the precursor dimethylation experiment of the 
same peptide from a).  The light (m/z = 759.068) and heavy (m/z = 764.430) peptide peaks correspond to 
WT and AD samples, respectively.   
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Figure 6.5.  AD/WT protein ratios (log2 scale) as a function of reporter ion signal (log scale).  The 
highlighted area corresponds to a 95% confidence interval.  Ratios for differentially-expressed proteins (   ) 
with error bars (coefficient of variation) are shown in the plot.  The following proteins are labeled in the 
figure:  3-keto-CoA thiolase, peroxisomal (ACAA1), Dihydropteridine reductase (DHPR), U3 small 
nucleolar ribonucleoprotein (MPP10), Ferric-chelate reductase (FRRS1), Zinc finger CCCH domain-
containing protein 6 (C3H6), ATP-binding cassette, sub-family F (ABCF1), Dystrophin (DMD), 
cytochrome c oxidase, subunit 2 (MT-CO2), Fanconi anemia group D2 (FANCD2), Ras-related protein 
Rab-5C (Rab5C), PHD finger protein 21A (PHF2A), TATA-box binding protein (TBP), Coiled-coil 
domain-containing protein 86 (CCDC86), Alpha-1,3-mannosyl-glycoprotein 4-beta-N-
acetylglucosaminyltransferase A (MGT4A), tetratricopeptide repeat domain 6 (TCC), interferon-induced 
protein 44 (IFI44), cytoplasmic dynein 1 heavy chain 1 (DYNC1H1), Acyl-CoA thioesterase 10, 
mitochondrial (ACO10), Glycogen [starch] synthase, liver (GYS2), serine-pyruvate aminotransferase 
(AGXT). 
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Figure 6.6.  Schematic diagram of workflows used for cPILOT and precursor dimethylation experiments. 
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Figure 6.7.  a) Bar graph comparing the AD/WT ratios (average ± standard deviation) 
calculated from cPILOT (light grey) and precursor dimethylation (dark grey) experiments.  b) 
Bar graph comparing WT/AD ratios (average ± standard deviation) calculated from cPILOT 
(light grey) and precursor dimethylation (dark grey) experiments. 
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6.4.  DISCUSSION 
6.4.1.  Global cPILOT Methodology  
Previously, we presented global cPILOT, which performs precursor dimethylation at the N-
termini followed by isobaric tagging of lysine residues [100].  Traditional analysis of twelve samples 
using stable isotopic labeling techniques requires six or two experiments using precursor dimethylation 
[75] or TMT tags [329], respectively.  cPILOT provides the ability to perform simultaneous quantitation 
of twelve samples in a single experiment, which saves analysis time and isobaric tagging reagent.  
Fragmentation of both light and heavy dimethylated peptides is necessary to achieve 12-plex quantitation.  
This occurred for 59.3% of our quantified peptides, which is consistent with similar experiments 
previously presented [102].  Our two-tiered approach also resulted in detection of additional peptide pairs 
and increased overall peptide identification.   
Significant overlap was observed between cPILOT and precursor dimethylation results in protein 
identifications, differentially expressed proteins, and similar protein fold change ratios (Figure 6.7), 
highlighting the complementary nature of these techniques.  Interestingly, precursor dimethylation 
resulted in 703 additional unique proteins not detected using cPILOT, which we attribute to differences in 
data collection.  cPILOT experiments required the selection of the top CID-MS/MS ion for MS3 
fragmentation to obtain maximum sensitivity due to enhanced reporter ion signal compared to selective 
y1-HCD-MS3 [100]. We recommend disabling the dynamic exclusion parameter in cPILOT MS3 
experiments in order to maximize the number of peptides that contain full 12-plex information.  We 
recognize that this impacts protein identification rates and compensated for the decrease by incorporating 
SCX fractionation and a two-tiered data collection method.  These add-ons resulted in a total 
experimental time of ten days, compared to 2.5 days for the six duplex dimethylation experiments that 
lacked any fractionation.  Similar fractionation experiments performed on six duplex dimethylation would 
have resulted in an experimental time of almost 30 days.   New instrumentation, such as the Orbitrap 
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Fusion, performs multinotched MS3 scan events [330], which may allow the dynamic exclusion setting 
with the enhanced MS3 sensitivity, thus eliminating the need for a two-tiered data method.  The faster 
scan rates of the Fusion significantly enhance proteome coverage coupled with highly sensitive MS3 
scans.   
In future cPILOT experiments, it could be helpful to perform one analysis that focuses on 
identification of many features in the data similar to an accurate mass tag approach [331].  After this 
initial experiment, then inclusion or reject lists could be used to setup faster and more focused scanning 
methods based on HCD-MS3 without CID-MS/MS. This would minimize the amount of time associated 
with these experiments. Compared to label-free analyses of the twelve samples, precursor labeling or 
multiple TMT samples that would incorporate multidimensional separations, we still believe that cPILOT 
drastically reduces experimental time and costs. Overall, cPILOT successfully performed high throughput 
protein identification and quantitation of relatively high abundant liver metabolism related proteins and is 
discussed below. 
 
6.4.2.  Differentially-Expressed Proteins in APP/PS-1 Liver 
Decreased glucose metabolism, disruption of energy homeostasis, insulin resistance, and 
dysregulation of lipid metabolism are manifested in AD subjects and can greatly help our understanding 
of AD pathogenesis [308, 332].  Since the liver is responsible for metabolic regulation and detoxification 
of Aβ peptides, we sought to characterize the liver proteome in an AD mouse model (i.e., APP/PS-1) and 
assess if metabolic dysfunction is systemic in AD.  It is noteworthy to highlight that there exists no mouse 
model which contains all characteristics and behaviors of AD.  Sporadic AD accounts for a majority of 
cases, however autosomal dominant AD caused by genetic mutations contains similar characteristics and 
pathologies [333].  We refer the reader to extensive reviews on genetically modified AD mouse models as 
well as potential limitations of their use [300, 334].  The APP/PS-1 develops amyloid senile plaques at 6 
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months of age [335] and exhibits cognitive impairment by 12 months of age.  The mice used in this study 
are 14 months of age, which is appropriate to study the effects of late stage AD on the liver proteome.  
Below is a brief discussion of major pathways identified across differentially-expressed proteins in AD 
liver.  
 
6.4.3.  Fatty Acid Metabolism 
 β-oxidation is the principle pathway for fatty acid metabolism that ends in the production of 
acetyl-CoA.  β-oxidation can occur in mitochondria [336] or peroxisomes [337] that are present in the 
liver.  Long chain specific acyl CoA dehydrogenase (1.4 ± 0.4), 3-keto-CoA thiolase (1.4 ± 0.4), and 
acyl–CoA thioesterase 10 (0.2 ± 0.1) are differentially-expressed in AD liver (Figure 6.8a), which 
suggests elevated fatty acid β-oxidation and increased acetyl-CoA production.  This is consistent with 
acyl-CoA dehydrogenase in APP/PS-1 cerebral cortices [325] and enoyl-CoA hydratase in 3xTG-AD 
(APP/PS-1/Tau-p) cortices [338].  Our laboratory has simultaneously detected differential-expression of 
acyl-CoA oxidase in APP/PS-1 liver using a cysteine selective cPILOT approach [326].  Ketogenesis 
produces ketone bodies such as β-hydroxybutyrate, acetone, and acetoacetate from acetyl-CoA in liver, 
which supplies energy to other organs during starvation [339].  Increased ketone body-producing enzymes 
have been previously observed in AD mouse models [326, 338].  Ketogenic diets improve motor 
functions in APP/PS-1 mice and may be a potential therapeutic approach for neurological disorders [340, 
341].  Since glucose metabolism is dysfunctional in AD brain [332], increased fatty acid metabolism in 
the AD mouse liver may increase ketone body formation. This would provide a compensatory energy 
source for AD brain (Figure 6.8b).  We hypothesize there may be elevated ketone body synthesis in liver, 
transport of these ketone bodies to the brain, and ketone body metabolism in AD brain.  However, further 
experiments are necessary in order to test this hypothesis.  
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Figure 6.8.  a) Metabolic pathways of selected differentially-expressed proteins in AD liver from 
cPILOT studies.  Grey arrows represent elevated protein abundances and black arrows represent reduced 
protein abundances in AD liver.  b) Proposed model of how metabolism changes in the AD liver are 
connected to AD brain. 
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6.4.4.  Pyruvate Metabolism 
 Serine hydroxymethyltransferase (1.4 ± 0.4) and NADP-dependent malic enzyme (1.4 ± 0.4) are 
higher in AD liver, while serine-pyruvate aminotransferase (0.7 ± 0.1) was lower suggesting elevated 
pyruvate concentrations.  Pyruvate is an essential metabolite that fuels the tricarboxylic acid cycle (TCA) 
and drives other biosynthetic pathways [342].  Alanine aminotransferase 1 (1.5 ± 0.8) and glutamic 
pyruvate transaminase 2 (1.4 ± 0.3) are enzymes involved in the alanine cycle that produce pyruvate in 
liver.  The alanine cycle coupled with glutamate dehydrogenase creates α-ketogluterate and ammonia, 
which must be detoxified through the urea cycle [342].  The α-ketoglutarate dehydrogenase complex has 
decreased activity in AD brain [306] and is inhibited by elevated ammonia concentrations [343].  Our 
laboratory has measured differential expression in aspartate aminotransferase and glutamate synthetase in 
the APP/PS-1 mouse tissue elsewhere.  Hyperammonemia can lead to hepatic encephalopathy, a 
neurological complication resulting from liver damage [344].  Clinically, elevated alanine 
aminotransferase activity is indicative of liver damage [345].  Impairment of ammonia detoxification may 
contribute to AD pathology and neurodegeneration [346].   
 
6.4.5.  Other Metabolic Processes 
Gluconeogenesis is a process related to the alanine cycle in which glucose is synthesized from 
pyruvate and alanine.  Phosphoenolpyruvate carboxykinase (3.9 ± 2.1) is involved in glucose synthesis.  
Differential-expression of glycogen synthase (0.7 ± 0.2) and glycogen break-down proteins [326] in AD 
liver suggests reduced glucose storage.  The liver regulates glucose levels by balancing the synthesis and 
breakdown of glycogen.  Diabetes, hyperglycemia, and insulin resistance may be metabolic mediators of 
AD [332].  Observed proteomic changes from cPILOT analysis point to dysregulation of blood-glucose 
levels in APP/PS-1 mouse liver.  It is possible that this systemic dysregulation may correlate with altered 
glucose metabolism in AD brain. 
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Propionyl CoA carboxylase (0.7 ± 0.3) and methylmalonyl-CoA mutase (1.6 ± 1.3) are enzymes 
involved in catabolism of succinyl-CoA, an intermediate of the TCA cycle.  Succinyl-CoA is a precursor 
for heme synthesis [347].  Ferrochelatase (0.6 ± 0.2) forms protoheme in heme biosynthesis and 
hemopexin (0.7 ± 0.1) is a heme scavenger [348].  Lower levels of these proteins in AD liver would result 
in low circulating heme levels.  Mitochondrial dysfunction in AD can decrease TCA cycle activity, which 
depletes succinyl-CoA concentrations and reduces the cells’ ability to synthesize heme [349].  
Dihydropteridine reductase (1.5 ± 0.5) is involved in the formation of tetrahydrobiopterin, an important 
cofactor required in the biosynthesis of tyrosine in liver [350].  Higher dihydropteridine reductase levels 
in AD liver can cause more liver resident tyrosine. Tyrosine can be metabolized into fumarate for use in 
the TCA cycle or be converted into ketone bodies.  Alterations in TCA cycle intermediates are likely due 
to mitochondrial dysfunction in AD liver.  
6.4.6.  Redox Signaling 
  Enzymes involved in the electron transport chain can generate reactive oxygen species by 
forming the superoxide anion from molecular oxygen [351].  We detected elevated levels of cytochrome 
C oxidase subunit 2 (2.5 ± 1.6) and sulfite oxidase (1.5 ± 0.7) in AD liver and hence potential elevation of 
oxidative phosphorylation.  Changes in oxidative phosphorylation have been reported in triple transgenic 
AD mouse models [352].  Differentially-expressed redox enzymes which use NADPH as a cofactor are 
dihydropteridine reductase, NADP-dependent malic enzyme (1.4 ± 0.4), carbonyl reductase 1 (0.7 ± 0.1), 
ferric-chelate reductase 1 (2.1 ± 1.4), 25-hydroxycholesterol 7 alpha hydroxylase (0.6 ± 0.1), and protein-
methionine sulfoxide oxidase (0.6 ± 0.3).  Antioxidant regeneration relies on a continuous supply of 
NADH and NADPH, which may be altered in AD liver [353].  Oxidative stress is a key contributor to AD 
pathology [27]  and may impact redox signaling activity of protein-methionine sulfoxide oxidase (0.6 ± 
0.3) [354] and cytochrome p450 (0.7 ± 0.1) [27].  Ferric-chelate reductase 1 (2.1 ± 1.4) may also induce 
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metal-catalyzed oxidative damage.  Imbalance of redox signaling enzymes and oxidative stress in liver 
tissue can result in cellular dysfunction and damage. 
 
6.4.7.  Transcription and Translation 
 We detected a number of differentially-expressed proteins involved in transcription and 
translation processes.  60S ribosomal protein L5 (1.5 ± 0.8), 39 ribosomal protein L22 (1.4 ± 0.2), 40S 
ribosomal protein S27 (1.4 ± 0.3), and zinc finger CCCH domain-containing protein 10 (2.3 ± 1.7), 
histone H2A (1.5 ± 0.5), and fanconi anemia group D2 (2.2 ± 1.4) are enzymes which play a role in RNA 
binding, protein synthesis or DNA transcription.  RNA oxidation is increased in AD including 60S 
ribosomal fractions and can lead to dysregulation of protein synthesis [355].  Phosphorylated histone 
family proteins are indicative of DNA damage and lead to apoptosis [356].  Fanconi anemia group D2 
actively eliminates damaged DNA during the cell replication [357] and higher levels in AD liver is likely 
in response to elevated damaged DNA.  Alterations in transcription and protein synthesis in AD liver can 
be a result of damaged DNA and RNA, although additional studies are necessary to confirm this 
hypothesis. 
 
6.5.  CONCLUSIONS  
 We performed an enhanced multiplexed proteomic study of the APP/PS-1 liver proteome using 
the global cPILOT approach developed in our laboratory.  Global cPILOT analysis allowed six biological 
replicates (twelve samples) of APP/PS-1 and WT mouse liver to be measured in a single proteomics 
experiment.  Advantages of enhanced multiplexing include higher sample throughput, reduced variation 
across multiple samples, and lower cost of isobaric tagging reagents in comparison to the cost associated 
with repeated isobaric tagging experiments.  However, we note that samples are not pooled in our 
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approach until after precursor labeling and isobaric tagging steps are complete.  Precursor dimethylation 
was performed in parallel and verified differentially-expressed proteins from cPILOT.  Necessary 
improvements to the approach are focused on increasing the duty cycle of the acquisition to increase 
selection of dimethylated pairs. For example, in some cases only the light or heavy dimethylated 
precursor ions were selected for MS/MS, which resulted in only half of the reporter ion channels being 
detected (although the other precursor in the pair was detected in parent scans). Also, we increased 
experimental time by incorporation of the two-tiered DDA approach to improve the likelihood of 
selecting dimethylated pairs. This could be reduced significantly by improvements to data acquisition or 
by using faster and more sensitive MS instruments such as the Orbitrap Fusion. In comparison to label-
free or other isotopic labeling approaches, the overall experimental time was still significantly shorter. 
cPILOT provides the ability to perform high-throughput quantitative analysis of clinical laboratory 
samples using readily available chemical reagents.  Multiplexing can be further increased by using 
iTRAQ 8-plex or TMT 10-plex reagents. 
The cPILOT approach was used to successfully identify changes in the liver proteome of 
APP/PS-1 mice.  Differentially-expressed proteins in the AD liver proteome are involved in fatty acid 
metabolism, pyruvate metabolism, redox signaling, transcription and translation processes, and 
gluconeogenesis.  The changes observed in AD liver have considerable overlap with already reported 
metabolic changes in AD brain.  Novel findings from this work highlight the potential use of ketone 
bodies produced in the liver as an alternative energy source for AD brain. Furthermore, hyperammonia 
production from the alanine cycle could lead to hepatic encephalopathy, which is linked with 
neurodegeneration. The changes observed in the liver proteome of APP/PS-1 mice provide further 
evidence that AD is a metabolic disorder and redox signaling and oxidative stress may be manifested in 
the periphery of AD subjects.   Future studies that shed insight on the global or systemic changes that 
occur in AD are warranted.  This work represents a promising step in that direction, which will lead to a 
more thorough and better understanding of AD. 
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 7.0.  EXPANDING VERSITILITY OF cPILOT USING N-N-DIMETHYL LEUCINE ISOBARIC 
TAGS 
 
7.1. INTRODUCTION 
 Stable isotopic labeling in proteomics achieves relative quantitation of two or more samples in a 
single experiment using mass spectrometry (MS) [358].  Sample throughput and multiplexing is limited 
by the chemical tagging approach and the data collection method.  Chapter 1 highlights common 
techniques used in proteomics to perform relative quantitation.  Precursor isotopic labeling employs a 
chemical tag, which creates a mass shift in MS and can multiplex up to five samples in an experiment 
using dimethylation [359].  Isobaric tags, such as tandem mass tags (TMT), achieves relative quantitation 
by comparing the signals from signature reporter ions, which are detected using tandem mass 
spectrometry (MS/MS) [88].  These tags offer multiplexing up to ten samples in a single shotgun 
proteomics experiment. 
Enhanced multiplexing beyond the sample limitations mentioned above is achieved using 
combined precursor isotopic labeling and isobaric tagging (cPILOT) [100, 101].  The work presented in 
Chapter 6 demonstrates protein quantitation of twelve samples in a single experiment by combining light 
and heavy dimethylation with TMT 6-plex reagents [101].  Multiplexing of 20 samples per experiment is 
possible using TMT 10-plex reagents with an Orbitrap resolution of R > 35,000 (m/z = 200) in higher 
energy collisional dissociation (HCD) MS/MS [85].  One disadvantage in current cPILOT methodology is 
the cost of the TMT reagents.  Despite the sample throughput capabilities of isobaric tags, the cost to 
perform full multiplexed experiments is $516 and $933 per experiment for TMT 6-plex and 10-plex 
reagents, respectively (Thermo Scientific).  cPILOT approaches can reduce the costs by half since TMT 
reagent vials can be split among light and heavy dimethylated peptides, however routine analysis is still 
approximately $250 per 12-plex experiment (Chapter 6).  Deuterium isobaric amine reactive tags 
119 
 
(DiART) [82] and N-N-dimethyl leucine reagents (DiLeu) are alternative isobaric tagging reagents in 
quantitative proteomics.  Specifically, DiLeu tags are chemically synthesized by performing 
dimethylation on the amine of L-leucine [83].  Additional heavy atoms are incorporated by performing 
18O exchange on the carbonyl group.  Similar to other isobaric tags, DiLeu tags contain a reporter ion 
region (m/z 114-117), a mass balance region, and a peptide reactive group.  Currently, these isobaric tags 
enhance reporter ion stability and are developed as 4-plex [83], 8-plex [360], and 12-plex reagents [361].  
Herein, Chapter 7 demonstrates the incorporation of DiLeu tags into the cPILOT method using bovine 
serum albumin.  cPILOT using the DiLeu approach is benchmarked against the TMT0 tag and a cost 
analysis is presented for multiplexed experiments.  The implementation of DiLeu into the cPILOT 
approach demonstrates the versatility and accessibility of this high throughput quantitative proteomics 
method. 
 
7.2.  EXPERIMENTAL 
7.2.1.  BSA Digestion 
 Bovine serum albumin (BSA, Sigma) solution was prepared in PBS with 8M urea (1.0 µg/µL) 
and digested as previously described [107].  Briefly, 200 µg of BSA was treated with DTT (0.600 mM 
final concentration, 37°C, 2 hours), iodoacetamide (1.20 mM final concentration, 0°C, 2 hours), and L-
cysteine (0.600 mM, 25 °C, 30 minutes).  Tris buffer (0.2 M tris, 10 mM CaCl2, pH 8.0) was added to the 
mixture resulting in a four time volume dilution.  TPCK-treated trypsin (Sigma Aldrich) was added to 
each sample at 2% w:w enzyme:protein and incubated at 37°C for 24 hours.  Samples were quenched by 
flash freezing in liquid nitrogen, cleaned using a Waters HLB C18 cartridge, and dried by speed vac.  
   
7.2.2.  Activation of Dimethyl Leucine Tag 118  
 N,N-dimethyl leucine tag 118 (DiLeu118) was synthesized as previously described [83].  To 
activate the tag, 11.1 mg of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate 
(DMTMM, Sigma) was dissolved in 350 µL 1% N-methylmorpholine in anhydrous dimethylformamide 
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and added (50 µL) to 1.0 mg of DiLeu118.  The resulting mixture was stirred, incubated for 30 minutes 
(25 °C), and centrifuged (1000x g) to collect supernatant, which contains activated DiLeu118 reagent. 
 
7.2.3.  BSA Peptide Labeling 
 BSA digests were reconstituted in 1% acetic acid solution (0.25 µg/µL) for light and heavy 
dimethylation as previously described [100, 101].  Briefly, BSA digests were treated with either 
formaldehyde (60 mM)/sodium cyanoborohydride (24 mM) or 13C,2H2-formaldehyde (60 mM)/sodium 
cyanoborodeuteride (24 mM) for light and heavy dimethylation, respectively.  All samples were 
incubated (10 min, 25°C), quenched with 1% NH3 (5 min, 25°C), acidified with 5% formic acid, and 
desalted using HLB C18 cartridges.  For DiLeu118 tagging, dimethylated peptides were reconstituted in 
500 mM triethylammonium bicarbonate (TEAB) buffer (2.0 µg/µL).  Anhydrous acetonitrile (1.6x 
volume) was added to the peptide solution followed by the activated DiLeu118 mixture (1:15 peptide:tag 
mol ratio).  Peptides were incubated at 25°C for 3 hours followed by addition of hydroxylamine (50 mM) 
to quench the reaction.  Samples were diluted two-fold with water, cleaned using SCX spin tips (Protea 
Biosciences) and desalted using C18 HLB solid phase extraction cartridges.  For TMT0 tagging, 
dimethylated BSA peptides were reconstituted in 100 mM TEAB buffer and modified with TMT0 reagent 
according to manufacturer instructions (Thermo Scientific).  Sample was desalted using C18 HLB solid 
phase extraction cartridges.   
 
7.2.4.  LC-MS/MS 
 Peptide samples were reconstituted in 0.1% formic acid solution and separated using nRPLC on a 
C18 column (1.7U, 130Å, 300nL/min) [98].  Buffer A was 5% DMSA and 0.1% formic acid (FA) in water 
and buffer B was 5% DMSO and 0.1% FA in acetonitrile.  Gradient elution was performed as follow 
(%A/%B):  95/5 for 5 minutes, ramp to 65/35 over 55 minutes, ramp to 5/95 over 10 minutes followed by 
15 minute column re-equilibration for a total run time of 85 minutes.  DiLeu cPILOT peptides were 
detected using an LTQ-Orbitrap Elite mass spectrometer [49].  Parent MS scans were performed (1E6 
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AGC, 380-1600 m/z, R = 120,000) followed by data dependent acquisition selection of the top 10 most 
intense ions for HCD-MS/MS (2.0 Th isolation window, 29% NCE, 0.1 activation time, 5E4 AGC, R = 
15,000) and detection using the Orbitrap (scans start at 110 m/z).  Charge state screening was enabled and 
singly charged peptides were rejected for HCD-MS/MS scan events.  The dynamic exclusion was enabled 
with a repeat count of one (five seconds, 500 max exclusion list).  TMT0 cPILOT BSA peptides were 
detected using an LTQ-Orbitrap Velos.  Parent MS scans were performed (1E6 AGC, 300-1600 m/z) 
followed by data dependent acquisition selection of the top 10 most intense ions for HCD-MS/MS (2.0 Th 
isolation window, 29% NCE, 0.1 activation time, 3E5 AGC) and detection using the Orbitrap (scans start 
at 110 m/z).  Charge state screening was enabled in which singly charged peptides were rejected for 
MS/MS scan events.  The dynamic exclusion was enabled with a repeat count of one for a duration time 
of five seconds (500 max exclusion list).  The small duration time for all dynamic exclusion parameters 
allows for the collection of more MS/MS events across a peptide extracted ion chromatogram.  Since the 
samples are single protein digests, a more quantitative data collection method can be employed without 
the need for in-depth proteome coverage. 
 
7.2.5.  Database Searching 
 RAW files were searched using SEQUEST HT against the BSA sequence (Uniprot P02769) and 
processed using Proteome Discoverer v1.4 (Thermo Scientific).  Search parameters included:  trypsin 
with two missed cleavages, peptide mass range 300-5000 Da, 15 ppm parent mass tolerance, 1 Da 
fragmentation tolerance, dynamic modifications of DiLeu118 (+145.132) or TMT0 (+224.152) on lysine 
residues, oxidation (+15.995) on methionine, static modifications of light (+28.031) or heavy (+36.076) 
dimethylation on the N-terminus, and carbamidomethyl (+57.021) on cysteine.  Decoy database searching 
was performed using a reverse protein database with FDR settings at 0.01 and 0.05 for high and medium 
confidence peptides, respectively.  Reporter ion intensities were extracted using Proteome Discoverer 
122 
 
software (30 ppm mass tolerance, most confident centroid) at m/z = 118.153 and 126.128 for DiLeu118 
and TMT0, respectively.   
 
7.3.  RESULTS AND DISCUSSION 
7.3.1.  cPILOT and N,N-Dimethyl Leucine Isobaric Tags 
DiLeu tags are chemically synthesized isobaric tags, which can be employed in MS/MS 
quantitative proteomic experiments [83].  Figure 7.1a illustrates the chemical structure of the DiLeu118 
reagent.  Similar to other isobaric tags (i.e. iTRAQ, TMT), DiLeu118 contains a reporter ion region, a 
mass balance region, and a peptide reactive group.  Four deuterium atoms are incorporated within the 
reporter ion region from dimethylation of L-leucine with 2H-formaldehyde during tag synthesis.  In order 
to modify peptides, the DiLeu tags must be activated with DMTMM to create a triazide-based reactive 
group towards peptide amines [83].  Global cPILOT was previously presented in Chapters 5 and 6 using 
TMT0 [100] or 6-plex tags [101].  Figure 7.1b illustrates the cPILOT method with incorporation of the 
DiLeu isobaric tags.  BSA protein digests are modified with either light or heavy dimethyl groups at low 
pH to selectively modify peptide N-termini.  After sample clean-up and a buffer exchange, activated 
DiLeu118 modifies the lysine residues.  The method demonstrates the versatility of cPILOT by the 
incorporation of isobaric tagging reagents other than TMT. 
 
7.3.2.  BSA with DiLeu cPILOT 
 To benchmark the incorporation of the DiLeu118 isobaric tag into cPILOT, BSA samples were 
prepared using the TMT0 reagent as previously described [100].  Figure 7.2a shows the sample peptide 
D(dimethyl)LGEEHFK(TMT0) with light and heavy peaks at m/z 613.823 and 617.844, respectively.  
Isolation and HCD fragmentation of light and heavy peptides results in the MS/MS spectra shown in 
Figure 7.2b (only low m/z range shown).  The presence of the reporter ion corresponding to the TMT0 tag 
at m/z 126.13 is detected in the light (left) and heavy (right) HCD-MS/MS spectra similar to previously 
presented TMT cPILOT experiments [100].  DiLeu118 based cPILOT samples were prepared using BSA 
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Figure 7.1. a) Chemical structure of the DiLeu118 isobaric tag.  b) Incorporation of DiLeu tags into 
the cPILOT method. 
124 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. a) MS spectra for the peptide D(dimethyl)LGEEHFK(TMT0) resulting in light (m/z = 613.823) and 
heavy peptide (m/z = 617.844) peaks.  Isolation and fragmentation of b) light (left) and heavy (right) peptides 
results in the detection of the TMT0 reporter ion at m/z = 126.13. 
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following the cPILOT procedure shown in Figure 7.1b.  The MS spectra for the peptide 
D(dimethyl)LGEEHFK(DiLeu118) is shown in  Figure 7.3a.  Light and heavy dimethylated peptides are 
located at m/z 574.319 and 578.340, respectively, which corresponds to the mass shift of 8 Da per 
dimethyl modification [100].  DiLeu cPILOT peptides differ in m/z values compared to TMT0 cPILOT 
peptides due to the mass differences between the isobaric tags, which are +145.132 Da and +224.152 Da 
for DiLeu118 and TMT0, respectively.  Figure 7.3b (left) shows the low m/z region of the HCD-MS/MS 
spectra resulting from fragmentation of the light peptide at m/z = 574.32, which results in the detection of 
the DiLeu118 reporter ion at m/z = 118.15.  Isolation and fragmentation of the heavy peptide at m/z = 
578.34 also results in the detection of the m/z 118.15 reporter ion peak.  These spectra show that the 
DiLeu118 reporter ion is detected similarly for the same peptide sequences detected in TMT0 cPILOT 
experiments. 
We compared BSA proteome coverage and labeling efficiency between TMT-based cPILOT and 
DiLeu based cPILOT experiments.  Overall, 62 unique peptides were detected in BSA samples tagged 
with DiLeu118, which corresponds to 81.6% protein sequence coverage  Comparatively, TMT0 cPILOT 
peptides produced an 88.3% protein sequence coverage resulting from the identification of 85 unique 
peptide sequences.  Results show high protein sequence coverage from a large pool of peptides detected 
in both methods.  To determine labeling efficiency in both methods, RAW files were searched with each 
isobaric tag as a dynamic modification, which allows mislabeled lysine residues to be reported in 
SEQUEST search results.  Spectral count (SC) comparisons were performed between labeled and 
unlabeled lysine ending peptides only.  Due to the cPILOT design, all Arg-ending peptides (from 
digestion with trypsin) will not be modified with an isobaric tag and are not considered in cPILOT data 
analysis.  Labeling efficiency was 91% and 99% using DiLeu118 and TMT0, respectively.  DMTMM 
condensation reactions have been reported with 80-100% efficiency [362].  DiLeu activation and peptide 
labeling is highly sensitive to hydrolysis in aqueous solutions and can impact labeling efficiency 
compared to NHS reactions employed by TMT [83].  Drying agents such as MgSO4 or adjusting the 
DMTMM/NMM ratio during DiLeu tag activation may improve labeling efficiency in future experiments.   
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Figure 7.3. a) MS spectra for the peptide D(dimethyl)LGEEHFK(DiLeu118) resulting in light (m/z = 574.319) 
and heavy peptide (m/z = 578.340) peaks.  Isolation and fragmentation of b) light (left) and heavy (right) 
peptides results in the detection of the DiLeu reporter ion at m/z = 118.15. 
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The experiments performed in Chapter 7 employed data dependent acquisition selecting the top 
10 most intense ions for HCD-MS/MS in order to collect more spectra containing the targeted reporter 
ion.  HCD-MS/MS is more efficient at detecting reporter ion signal in MS/MS spectra compared to MS3 
spectra and was employed to verify successful DiLeu chemical labeling by the detection of the 118 
reporter ion [294].  Peptides detected with both dimethyl and DiLeu tag modifications indicate a properly 
labeled peptide for cPILOT and should produce reporter ions at m/z 118.15 and 126.13 in the HCD-
MS/MS spectra for DiLeu118 and TMT0, respectively.  Overall, 32 detected DiLeu cPILOT peptides 
overlapped with TMT0 cPILOT peptides.  These sample spectra and data demonstrate that DiLeu 
chemistry can be successfully incorporated into the cPILOT workflow after low pH dimethylation to 
modify lysine amines.  Additionally 100% of cPILOT labeled peptides produced the reporter ion in HCD-
MS/MS fragmentation spectra (S/N > 3) for both DiLeu118 and TMT0.  These results are consistent with 
previous reports of DiLeu tags, whereby a stable reporter ion is produced [83].  We note that in MS3 
quantitative multiplexed experiments, there is an expected increase in the number of spectra which 
contain missing reporter ions due to sensitivity limitations [100, 294].  Ongoing experiments include MS3 
data collection using DiLeu based cPILOT samples with multinotch data collection [330] and 
incorporation of DiLeu 12-plex reagents [361]. 
   
 
7.3.3.  Cost Analysis 
 Substituting DiLeu tags in place of TMT tags for cPILOT provides a more cost-effective 
multiplexing approach.  Table 7.1 compares the cost of TMT 6-plex tags, a 12-plex cPILOT or 20-plex 
cPILOT experiment, and a cPILOT experiment using the DiLeu 4-plex tags.  Isobaric tags are 
approximately 100x the cost of precursor dimethylation reagents per experiment (Table 7.1) making these 
reagents the biggest contributor to experimental cost.  Implementing less expensive isobaric tags in 
cPILOT is imperative to create a more cost-effective method.  cPILOT experiments using commercially 
available isobaric tags were determined to be over $500 per experiment.  Table 7.1 shows that DiLeu tags  
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offer multiplexing at roughly $15 per experiment which is significant savings compared to TMT reagents.  
This is attributed to the number of samples that can be labeled using DiLeu tags.  Dimethyl leucine tags 
are synthesized in quantities that can label approximately 100 reactions per isobaric tag (estimated based 
on average product yields), compared to 30 total reactions using TMT tags (6-plex and 10-plex).  cPILOT 
doubles the amount of samples analyzed per experiment resulting in a cost of $43.13 per 12-plex 
experiment.  Substitution of the DiLeu 4-plex tags into cPILOT results in approximately a 25-fold 
reduction in cost per experiment.  Cost can be reduced further using DiLeu 8-plex reagents [360] and 12-
plex reagents [361].  It is also noteworthy that the cost of graduate student hours and synthesis tools were 
not factored into the calculation, however long term savings are expected due to the significantly higher 
sample throughput offered by DiLeu tags. 
 
7.4.  CONCLUSIONS 
 N,N-dimethyl leucine (DiLeu) isobaric tagging reagents can be synthesized in house and perform 
multiplexed experiments at a lower cost compared to TMT tags.  DiLeu tags were implemented into the 
cPILOT workflow by substitution with TMT isobaric tags at high pH buffer conditions.  DiLeu tags 
successfully bind to the lysine amines of light or heavy dimethylated peptides with labeling efficiencies > 
90% as demonstrated using BSA.  Fragmentation of DiLeu cPILOT peptide pairs results in the detection 
of the reporter ion at m/z 118.15 and is comparable to the TMT0 reporter ion generated at m/z 126.13.  
Future work includes the optimization of tag activation, peptide labeling efficiency, multiplexing cPILOT 
with DiLeu tags, and implementation to study biological tissues.  Overall, the incorporation of DiLeu tags 
into the cPILOT workflow enhances multiplexing, significantly reduces cost, and demonstrates the 
versatility and accessibility of this method. 
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8.0.  CONCLUDING REMARKS AND FUTURE DIRECTIONS 
8.1.  SUMMARY 
This dissertation presents novel multiplexing techniques in quantitative proteomics that increase 
sample throughput in a single experiment.  Chapter 2 presents a precursor quantitative technique called 
global internal standard technology (GIST), which adds light (-CH3) or heavy (-C2H3) acetyl groups to 
peptide amines from two different samples.  Relative quantitation is achieved by comparing the peak 
areas of light and heavy acetylated peptides.  GIST was applied to study the spleen proteome of mice 
treated with Adriamycin, which revealed alterations to cell structural integrity and calcium binding 
proteins potentially leading to a weakened immune system in response to anti-cancer treatment.  Chapter 
3 reviews the biological significance and proteomic techniques used to study 3-nitrotyrosine (3NT).  
Protein nitration is mediated by the presence of reactive oxygen species when cellular conditions are 
under oxidative stress.  Neurodegenerative diseases, arthritis, and cardiovascular disease are associated 
with 3NT.  Identification and quantitation of 3NT is analytically challenging due to the need for selective 
and sensitive approaches to isolate 3NT peptides.  Chapter 4 presents a novel approach termed 
“combined precursor isotopic labeling and isobaric tagging” (cPILOT), which selectively quantifies 3NT-
modified peptides and enhances multiplexing in quantitative proteomics using TMT and iTRAQ tags.  
Acetylation (Chapter 2) blocks primary amines on 3NT peptides with light or heavy labels.  Afterwards, 
3NT is reduced to 3-aminotyrosine, which allows for selective addition of an isobaric tag directly on 3NT 
sites.  Reporter ion detection in HCD-MS/MS confirms the location of 3NT modifications.  In addition, 
relative quantitation of 12 and 16 nitrated samples is performed in a single experiment for TMT and 
iTRAQ tags, respectively.  Due to the overlap of precursor acetylated peak pairs, it was determined that a 
mass shift of at least 5 Da is required to generate accurate and reproducible reporter ion quantitation in 
MS/MS using cPILOT. 
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 Chapter 5 transforms cPILOT from a post-translation modification technique to a global 
approach (global cPILOT), which can be applied to protein samples of any origin.  This is made possible 
by performing light (-2CH3) or heavy (-213C2H3) dimethylation at low pH (~2.5) to selectively modify 
peptide N-termini.  After sample cleanup and a buffer exchange, high pH conditions (~8.0) allow the 
modification of lysine residues with isobaric tags.  Peptides exhibit a mass shift of 8 Da per precursor 
modification.  Isolation and fragmentation of light and heavy dimethylated peaks results in the appearance 
of two sets of reporter ions for enhanced multiplexing and relative quantitation.  Selective y1-HCD-MS3 
targets TMT modified peptides for HCD fragmentation, which increases the number of MS3 spectra 
containing reporter ions.  Global cPILOT is accurate over a dynamic range of two orders of magnitude 
and is reproducible with < 25% CV.   
Global cPILOT is applied to the liver proteome of APP/PS-1 mice to study the effects of 
metabolism in Alzheimer’s disease (AD) liver in Chapter 6.  Strong cation exchange and a multi-tiered 
data collection method resulted in 1734 proteins identified in AD liver.  Six duplex precursor 
dimethylation experiments showed comparable results with 12-plex cPILOT analysis.  Differentially-
expressed proteins in AD liver were involved in fatty acid β-oxidation and pyruvate metabolic enzymes, 
which have significant overlap with the changes observed in AD brain.  For example, increased fatty acid 
metabolism can result in the formation of ketone bodies in the liver, which can be a compensatory energy 
source in AD brain.  While cPILOT successfully expands sample throughput in protein quantitation, the 
overall cost for routine cPILOT experiments is high (although less expensive compared to multiple 
isobaric tagging experiments).  Chapter 7 demonstrates the versatility of cPILOT by incorporating N,N-
dimethyl leucine (DiLeu) isobaric tags into the method.  The reporter ion corresponding to the DiLeu118 
tags (m/z = 118.15) was detected in HCD-MS/MS spectra resulting from fragmentation of light and heavy 
dimethyated peptides.  DiLeu tags have potential to provide a more cost-effective cPILOT workflow and 
multiplexing of 24 samples in a single experiment. 
 In summary, novel methods for increasing sample multiplexing in quantitative proteomics have 
been developed using stable isotopic labeling.  The combination of precursor isotopic labeling with 
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isobaric tags enhances sample throughput.  Currently, cPILOT can be adapted in any laboratory to 
simultaneously quantify 20 proteomic samples in a single experiment using TMT 10-plex reagents.  
cPILOT can be either selective to the PTM 3-nitrotyrosine or be used as a global approach to study 
disease conditions.  cPILOT saves instrument time, reduces overall experimental cost, and is comparable 
to precursor techniques such as dimethylation in large scale experiments.   
8.2.  FUTURE DIRECTIONS 
8.2.1.  Improving cPILOT Sample Preparation Techniques 
Currently cPILOT requires sample preparation using multiple reaction steps across twelve 
samples (using TMT 6-plex reagents) in approximately 3-4 days.  While data normalization can account 
for errors associated with multiple pipetting steps and separate chemical reactions, emphasis should be 
placed on creating a lean workflow.  Optimized sample preparation should focus on reduced clean-up 
steps and implementation of stable isotopes earlier in the procedure.  One solution would be to perform all 
chemical reactions in a one pot system.  Current cPILOT protocol employs dimethylation in a 1% acetic 
acid solution to obtain a reaction pH of 2.5.  After dimethylation, the solution pH can be adjusted to 8.0 
without sample clean up using base.  This is only possible by ensuring a completely quenched 
dimethylation reaction prior to pH adjustment so the lysine amines are not modified with excess reagent.  
Additionally, the reagent that quenches the reaction should not be reactive with succinimide chemistry 
employed by most isobaric tags.  This presents a chemical challenge as amines are the best quenching 
reagents for dimethylation, however secondary or tertiary amines may be possible since 
triethylammonium bicarbonate (TEAB) buffer currently used in TMT protocol does not interfere with the 
reaction.  Another option is to perform peptide capture and chemical reactions on a resin.  Thiol selective 
[363] and amine selective [364] peptide immobilization has been previously presented and may provide a 
starting point for resin-assisted cPILOT.  Hydrophobic interaction-based capture methods may also be 
explored such as a high pore size C18 resin.  This will provide the ability to perform multiple chemical 
reactions without the need for clean-up steps and provide optimal peptide recovery. 
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cPILOT requires manual preparation of twelve samples simultaneously, which introduces 
variation prior to instrumental analysis.  Additionally as cPILOT continues to develop, it is possible that 
more samples will need to be prepared as multiplexing expands, which creates a need for high throughput 
sample preparation.  This can be accomplished by using a 96 well plate with a liquid handling robotic arm 
as shown in Figure 8.1.  Automation in sample preparation procedures reduces pipetting mixing errors 
and streamlines a continuous workflow for large scale studies.  The use of a 96 well plate can also 
simultaneously perform multiple reactions (Figure 8.1).  For example, the chemistries of multiple 
precursor labeling techniques (acetylation, dimethylation) and isobaric tags (TMT, iTRAQ, DiLeu) can be 
performed in one experiment.  This could allow for cPILOT expansion, incorporation of more channels, 
and analysis of more samples prepared with minimal variation.   
Reduced cPILOT variation can be achieved using alternative chemical labeling techniques.  
Metabolic labeling offers the lowest variation using stable isotopic chemical tags which incorporates 
heavy atoms at the earliest point in sample preparation.  Metabolic labeling using SILAM (Chapter 1) 
adds stable isotopes in animal mouse models with sufficient labeling efficiency [365].  SILAM 
experiments are gradually increasing in popularity [365], which includes the newest generation of 
NeuCode tags [366].  While ideal, this technique is challenging to implement to new labs due to the high 
cost and need for multiple animal generations to obtain optimal labeling efficiency.  Alternatively, protein 
chemical labeling techniques can provide reduced variation since the reactions occur before digestion.  
Samples can be labeled, digested, and chemically modified at the N-terminus with isobaric tags, which 
eliminates a post-digestion sample cleanup step.  Protein labeling has been experimented in our laboratory 
and is shown in Figure 8.2.  Here, dimethylation was performed on intact proteins to modify lysine 
residues.  After digestion with chymotrypsin or Arg-C [367] proteases, the N-terminal is accessible for 
isobaric tagging.  Figure 8.2a shows the sample peptide A(TMT6)LK(Dimethyl)AWSVAR (Bovine 
serum albumin) showing light and heavy dimethylated peptides at m/z 629.897 and 633.919, respectively.  
Isolation and fragmentation spectra for both precursor peaks are shown in Figure 8.2b.  Target reporter  
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Figure 8.1.  Sketch of cPILOT implementation on a 96-well plate with robotic arm attachment for 
high throughput sample preparation. 
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Figure 8.2. a) Precursor spectra for the protein labeled cPILOT peptide 
A(TMT6)LK(Dimethyl)AWSVAR showing light (m/z = 629.897) and heavy (m/z = 633.919) 
precursor peaks.  b) HCD-spectra showing isolation and fragmentation light (left) and heavy 
(right) peptides.  c) Alternative protein tagging using isotope coded protein labels.  “X” 
indicates the atoms 12C and 13C for light and heavy ICPL tags, respectively. 
ICPL 
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ion ratios are 1:1:4 (TMT 126:127:128) and 4:1:1 (TMT 126:127:128) for light and heavy dimethylated 
proteins, respectively.  As seen in Figure 8.2b, accurate reporter ion ratios were detected.  These 
preliminary results are promising, however optimization is required since labeling efficiency was 
determined to be approximately 85%.  Precursor labeling using isotope coded protein labels (ICPL, 
Figure 8.2c) provides labeling efficiency greater than 95% and modifies peptide lysine residues prior to 
digestion creating accurate and reproducible quantitation [368, 369].  Future protein labeling based 
cPILOT experiments should explore ICPL reagents. 
8.2.2.  Enhanced Multiplexing 
cPILOT expansion can occur by creating additional precursor and isobaric channels to further 
enhance the multiplexing shown in Figure 8.3.  Currently, cPILOT employs two precursor dimethylated 
channels, which can easily be expanded to add a third “middle” channel resulting in a +4 Da mass shift 
(Figure 8.3a).  Challenges with this approach are ensuring precursor peaks do not overlap so that clean 
MS/MS spectra are obtained.  To accomplish this, the isolation window during data collection should be 
narrowed to 1.5-2.0 Th.  It is also likely that peptides with charge states of three or higher may not be 
used for analysis due to closely spaced precursors.  A different approach to enhanced multiplexing 
combines TMT and iTRAQ tags in a single experiment [106].  Peptides modified with different isobaric 
tags will not co-elute, which prevents quantitation across different isobaric tags, however enhanced 
multiplexing and sample throughput is still achieved.  TMT tags produce reporter ions at m/z 126-131, 
while iTRAQ tags produce reporter ions at m/z 113-121 (exclude m/z 120).  Methods which employ both 
sets of tags will perform quantitation of 14 samples in a single MS/MS spectrum (m/z range 113-131) as 
illustrated in Figure 8.3b.  Multiple precursor labeling techniques could also be applied to one cPILOT 
sample, such as acetylation and dimethylation seen in Figure 8.1.  These approaches rely on the ability to 
perform selective N-terminal modification using succinimide based chemical tags, which should work 
since the reaction mechanism begins with nucleophilic attack of the primary amine rather than the  
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Figure 8.3.  Increases in sample throughput using cPILOT can be done by a) the 
addition of more precursor channels or b) combining iTRAQ and TMT isobaric 
tags in a single experiment. 
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chemical nature of the electrophile.  However, increasing multiplexing in quantitative proteomics creates 
a paradox.  Large scale proteomic experiments typically perform protein identification simultaneously 
with relative quantitation.  To identify as many unique proteins as possible in a single experiment, data 
collection methods employ as many fragmentation scan events as possible, which requires efficient 
separations, fast scanning mass spectrometers, careful exclusion parameters, and a high scan count per 
instrument cycle.  Quantitation requires the collection of multiple points across a single peptide extracted 
ion chromatogram.  As a result, there is a tradeoff between qualitative and quantitative based experiments.  
Increasing multiplexing channels in quantitative proteomics using cPILOT also has a similar tradeoff.  As 
more precursor channels are added, unique peptide identifications will decrease because MS/MS scan 
events are performed on the same peptide sequence to obtain complete quantitative information.  cPILOT 
can be developed to further enhance multiplexing beyond the current maximum of 20 samples, however a 
sample limit will eventually be reached due to the impact in unique protein identification rates.  Figure 
8.4a shows the scan cycle for a typical cPILOT experiment performed in Chapters 5 and 6.  After 
precursor MS scans in the Orbitrap, the top seven most intense ions are selected for CID-MS/MS and 
HCD-MS3 for each instrument cycle.  The LTQ Orbitrap Velos instrument performs approximately 
48,000 total scans, which includes 22,400 CID-MS/MS scans during cPILOT experiments (Table 8.1).  
As more precursor peaks are added to increase cPILOT multiplexing, MS/MS and MS3 scan events must 
be performed on the same peptide sequence in order to obtain complete reporter ion coverage under all 
peaks.  As seen in Table 8.1, the number of predicted MS/MS scan events on unique precursor ions 
decreases proportionally by the number of precursor channels added, which will impact identification.  
This can be circumvented by implementing multi-dimensional separations or longer LC gradients (i.e. 7+ 
hours) because more MS/MS spectra will be acquired.  Additionally, this calculation is assuming uniform 
selection of all precursor channels (i.e. light, middle, heavy, etc) across the entire experiment, which does 
not happen under data dependent acquisition (DDA) conditions since precursor 1:1 ratios have 
approximately 20% CV.  This leads to the most important future direction in cPILOT method 
development, which is changing data collection strategies discussed below. 
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Figure 8.4. a) Scan event process and timing for cPILOT experiments presented in Chapters 5 
and 6.  b) cPILOT data collection would be improved by performing DDA acquisition 
according to the most intense precursor pairs as opposed to most intense ions. 
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Table 8.1.  Predicted Number of MS/MS Scans with Increasing Precursor peaks for cPILOT Expansion.
TMT only Current cPILOT Triplex cPILOT Four Precursors
Number of precursor peaks per peptidea 1 2 3 4
Number of samples (TMT 6-plex reagent) 6 12 18 24
Total MS/MS scans availableb 22400 22400 22400 22400
MS/MS scans required to cover all precursorc 1 2 3 4
MS/MS scans of unique peptides 22400 11200 7467 5600
aNumber of precursors for added multiplex in cPILOT.
bEstimated based on 3 hour LC gradient and top 7 CID-MS/MS and HCD-MS3.
cAdded Precursor channels requires a separate fragmentation scan for each peak.
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8.2.3. cPILOT Data Collection and Processing 
DDA determines which fragmentation events to perform in real time based on the previous MS 
scan.  The Orbitrap scans with high resolution and high mass accuracy, which can be exploited to search 
for dimethylated peak pairs in real time.  After MS scans, isolation and fragmentation should occur on 
peaks which are separated by the mass corresponding to dimethylated peptides (Figure 8.4b).  This would 
create a targeted data collection method specific to cPILOT peptide pairs and eliminate the random nature 
of DDA.  Selection for MS/MS by peak pairing would also result in additional 12-plex peptide pairs in 
current cPILOT experiments since MS/MS events for each peptide pair would be back-to-back scans in 
the instrument cycle.   
cPILOT presented in Chapters 5 and 6 utilized MS3 to obtain accurate reporter ion quantitation.  
While this is powerful in quantitative proteomics, the tradeoff is the need to perform slow HCD-MS3 scan 
events (300-400 ms) using the Orbitrap Velos, which reduces the number of proteins identified.  
Additionally, reporter ion sensitivity decreases in MS3 scan events compared to MS/MS, which increases 
the likelihood of missing reporter ions.  The most recent hybrid mass spectrometer, the Orbitrap Fusion 
(Thermo Scientific, 2013), can circumvent these limitations by performing ~20 fragmentation 
scans/second and synchronous MS3 to enhance sensitivity [52, 330].  The Orbitrap Fusion is an ideal 
instrument for MS3 experiments, and increases reporter ion signal in MS3 scan events by 10-fold [330].  
Additionally, the enhanced Fourier Transform algorithm recently reported doubles the resolving power of 
the Orbitrap under the similar transient lengths currently used [52, 370].  Performing faster high 
resolution scan events, synchronous MS3 scans, and collection of more total MS/MS spectra provide the 
ability to enhance protein identification in cPILOT experiments.  
Ion mobility in quantitative proteomics would also add an additional dimension of separation for 
enhanced protein identification, while simultaneously cleaning precursor windows for accurate 
quantitation.  Global cPILOT currently employs multiple SCX fractions and a two tiered experiment in 
cPILOT.  Ion mobility has the advantage of both enhancing proteome coverage and reducing co-
fragmentation of neighboring peptides, which eliminates the need to perform MS3 scan events [91, 92].  
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Ion mobility appears to be growing in popularity in proteomic experiments [35, 36] and would provide an 
additional separation technique. 
Finally, new data processing strategies are required for any enhanced multiplexing.  Currently, 
commercially available software, such as Proteome Discoverer, cannot process cPILOT data or other 
multiplexed strategies properly.  For example, Proteome Discoverer combines reporter ion signals 
collected by fragmentation of light and heavy peptide ions, which much remain separate to perform 
accurate quantitation across all channels.  New software technology and processing tools should be 
developed to streamline data analysis of cPILOT experiments.  Variables to control in cPILOT data 
processing include normalization, determination of fold-change cutoffs, statistical analysis and protein 
filtering criteria.   
  
8.2.4.  Alzheimer’s Disease and the Liver 
 Chapter 6 revealed alteration in enzymes involved in fatty acid and pyruvate metabolic proteins 
in APP/PS-1 mouse liver.  To summarize, elevated fatty acid oxidation can lead to the production of 
ketone bodies, which travel to other organs as an alternative energy source when glucose metabolism is 
low.  Reduced glucose metabolism and mitochondrial dysfunction is observed in Alzheimer’s disease 
(AD) brain [306].  When glucose levels are low, the brain relies on ketone body and glucose production 
through gluconeogenesis as fuel sources, which are processes that occur in the liver [371].  Proteomic 
data from Chapter 6 reveals elevations in the alanine cycle, which suggests elevated pyruvate, the 
precursor required for gluconeogenesis [101].  The alanine cycle also results in ammonia as a downstream 
byproduct, which must be detoxified [342, 372].  Ammonia is elevated in both the blood and brain of AD 
patients, which suggest a correlation between ammonia concentrations and cognitive impairment [346].  
In order to metabolize and detoxify ammonia from cells, it must be converted to urea and eliminated by 
the kidneys.  Therefore, a proteomic study on the kidneys of APP/PS-1 mice may reveal alterations in 
nitrogen metabolism and the urea cycle.  Additionally, alanine aminotransferase (ALT) was elevated in 
APP/PS-1 mouse liver and is clinically measured in serum to determine liver failure.  Acute liver failure 
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results in altered cognitive function and often results in acute kidney injury [373].  Due to the reported 
elevated levels of ammonia coupled with an altered pyruvate/alanine cycle, the kidney is the next logical 
peripheral organ to study in APP/PS-1 mice due to its involvement in the urea cycle and ammonia 
detoxification.  Combining studies of multiple peripheral organs provides the ability to fully trace 
metabolism changes throughout AD and would present an in-depth understanding of AD metabolism.  
 Ketone bodies are an alternative energy source to the brain in states of glucose shortage.  These 
small molecules are formed when fatty acid metabolism (β-oxidation) is elevated [374].  Experiments 
should be performed to evaluate key metabolites in β-oxidation.  During fatty acid metabolism, long chain 
fatty acids are esterfied with coenzyme A (CoA), then modified with L-carnitine to form acylcarnitines, 
which shuttle into the mitochondria matrix for metabolism [375].  Measurements of acylcarnitine 
concentrations using mass spectrometry can verify altered fatty acid metabolism in AD liver (Chapter 6).  
Derivatization using butanol and HCl adds a butyl group to the carboxylic acid group of acylcarnitines for 
MS analysis (Figure 8.5a).  It is noteworthy to point out that Figure 8.5 depicts L-carnitine, however the 
derivatization is similar for acylcarntines [376, 377].  Butyl derivatization creates hydrophobic 
metabolites that allows for optimal reversed phase separation conditions [376].  Additionally, stable 
isotopic labeling is performed for differential analysis between WT and AD samples by using 2H10-
butanol.  Preliminary targeted experiments are shown in Figure 8.5b.  Butyl carnitine exhibits a mass of 
218.1726 (singly charged, experiments at R = 100,000), which is detected in MS (Figure 8.5a).  Isolation 
and fragmentation of this ion results in a signature buytl-acylcarnitine ion at m/z 159.04 in MS/MS 
(Figure 8.5b).  By selectively scanning for this MS/MS fragment, targeted quantitation of fatty acid 
metabolites can be achieved within a complex mixture.  Heavy 2H9-acylcarnitine would present a total 
mass of approximately 227.2 Da with a signature fragment nine Da higher in mass at m/z 168.2.  While 
the data shown is collected using the ion trap, the Orbitrap is capable of performing parallel reaction 
monitoring (PRM) at high resolution if multiple peaks co-elute during targeted MS/MS analysis [378].  
Additionally, the benchtop Q-Exactive would be the optimal instrument of choice due to the quadrupole 
filtering prior to Orbitrap analysis for multiplexed selected ion monitoring and PRM data collection [50].    
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Figure 8.5.  a) Chemical derivatization of l-carnitine using light or heavy isotopic butanol in 
HCl.  Targeted MS/MS data collection is shown in b) by scanning for the signature butyl 
carnitine peak at m/z 159.04.  The peak at m/z 85.07 is present in both derivatized and 
underivatized carnitines and can be used to verify the presence of the analyte. 
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Future work should focus on development and optimization of the assay in order to quantify 
acylcarnitines in liver and serum from APP/PS-1 mice. 
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Identification Category DDA Top 1 to 7 DDA Top 8 to 14 Combined
Total PSMs 211453 113064 324517
6-plex PSMsᵃ 144357 72895 217252
Unique Peptides 3258 4289 5084
Quantified Peptidesᵇ 2090 2606 3068
12-plex Peptide Pairsᵈ 1206 1246 1821
ᵃ Identified Peptide Spectra with 6 TMT channels
ᵇ Peptides used for protein quantification
ᵈ Peptides identified with both precursor dimethyl labels
Appendix C Table 6.1.  Peptide Identification Using Multi-Tier Data Dependent Acquisition.
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Appendix C Figure 6.9.  Box plot of reporter ion signal (log scale) for top-ion-HCD-
MS3 (black) and selective-y1-HCD-MS3 (red) using an equim olar 12-plex liver digest.  
Reporter ion signals for each TMT channel correspond to a) light and b) heavy 
dimethylated peptides. The number of peptides, N, shown in a) are as f ollows [top-ion-
HCD-MS3 (selective-y1-HCD-MS3)]:  1637 (510), 1622 (522), 1667 (600), 1597 
(524), 1618 (533), 1522 (519), for reporter ions at m/z = 126, 127, 128, 12 9, 130, 
and 131, respectively. The number of peptides, N, shown in b) are as follows [top-
ion-HCD-MS3 (selective-y1-HCD-MS3)]: 1612 (776), 1604 (775), 1637 (827), 1586 
( 763), 1586 (793), 1574 (763), for reporter ions at m/z = 126, 127, 128, 129, 130, and 
131, respectively.  Only LC-MS/MS was applied to this set of samples. 
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Appendix C Figure 6.10.  Venn Diagrams illustrating overl ap between cPILOT and precursor 
dimethylation experiments regarding the number of uniquely identified a) peptides and b) 
proteins and c) the number of quantified proteins. 
152 
REFERENCES 
[1] Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207. 
[2] Yates, J. R., 3rd, The revolution and evolution of shotgun proteomics for large-scale proteome 
analysis. J Am Chem Soc 2013, 135, 1629-1640. 
[3] Hernandez-Fernaud, J. R., Reid, S. E., Neilson, L. J., Zanivan, S., Quantitative mass spectrometry-
based proteomics in angiogenesis. Proteomics Clin Appl 2013, 7, 464-476. 
[4] Cox, J., Mann, M., Quantitative, high-resolution proteomics for data-driven systems biology. Annu 
Rev Biochem 2011, 80, 273-299. 
[5] Lehmann, S., Hoofnagle, A., Hochstrasser, D., Brede, C., et al., Quantitative Clinical Chemistry 
Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med 
2013, 51, 919-935. 
[6] Rabilloud, T., Chevallet, M., Luche, S., Lelong, C., Two-dimensional gel electrophoresis in 
proteomics: Past, present and future. J Proteomics 2010, 73, 2064-2077. 
[7] Van den Bergh, G., Arckens, L., Fluorescent two-dimensional difference gel electrophoresis unveils 
the potential of gel-based proteomics. Curr Opin Biotechnol 2004, 15, 38-43. 
[8] Tao, Q., Wang, Z., Zhao, H., Baeyens, W. R., et al., Direct chemiluminescent imaging detection of 
human serum proteins in two-dimensional polyacrylamide gel electrophoresis. Proteomics 2007, 7, 3481-
3490. 
[9] Patton, W. F., Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed 
Life Sci 2002, 771, 3-31. 
[10] Han, X., Aslanian, A., Yates, J. R., 3rd, Mass spectrometry for proteomics. Curr Opin Chem Biol 
2008, 12, 483-490. 
[11] Lopez, J. L., Two-dimensional electrophoresis in proteome expression analysis. J Chromatogr B 
Analyt Technol Biomed Life Sci 2007, 849, 190-202. 
153 
[12] Zhang, Y., Fonslow, B. R., Shan, B., Baek, M. C., Yates, J. R., 3rd, Protein analysis by 
shotgun/bottom-up proteomics. Chem Rev 2013, 113, 2343-2394. 
[13] Preisler, J., Hu, P., Rejtar, T., Karger, B. L., Capillary electrophoresis--matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry using a vacuum deposition interface. Anal Chem 
2000, 72, 4785-4795. 
[14] Faserl, K., Sarg, B., Kremser, L., Lindner, H., Optimization and evaluation of a sheathless capillary 
electrophoresis-electrospray ionization mass spectrometry platform for peptide analysis: comparison to 
liquid chromatography-electrospray ionization mass spectrometry. Anal Chem 2011, 83, 7297-7305. 
[15] Hebert, A. S., Richards, A. L., Bailey, D. J., Ulbrich, A., et al., The one hour yeast proteome. Mol 
Cell Proteomics 2014, 13, 339-347. 
[16] Schrimpf, S. P., Weiss, M., Reiter, L., Ahrens, C. H., et al., Comparative functional analysis of the 
Caenorhabditis elegans and Drosophila melanogaster proteomes. PLoS Biol 2009, 7, e48. 
[17] Witze, E. S., Old, W. M., Resing, K. A., Ahn, N. G., Mapping protein post-translational 
modifications with mass spectrometry. Nat Methods 2007, 4, 798-806. 
[18] Junger, M. A., Aebersold, R., Mass spectrometry-driven phosphoproteomics: patterning the systems 
biology mosaic. Wiley Interdiscip Rev Dev Biol 2014, 3, 83-112. 
[19] Paulsen, C. E., Carroll, K. S., Cysteine-mediated redox signaling: chemistry, biology, and tools for 
discovery. Chem Rev 2013, 113, 4633-4679. 
[20] Gould, N., Doulias, P. T., Tenopoulou, M., Raju, K., Ischiropoulos, H., Regulation of protein 
function and signaling by reversible cysteine S-nitrosylation. J Biol Chem 2013, 288, 26473-26479. 
[21] Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., Mann, M., The growing landscape of lysine 
acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol 2014, 15, 536-550. 
[22] Ma, J., Hart, G. W., O-GlcNAc profiling: from proteins to proteomes. Clin Proteomics 2014, 11, 8. 
[23] Finley, D., Ciechanover, A., Varshavsky, A., Ubiquitin as a central cellular regulator. Cell 2004, 116, 
S29-32, 22 p following S32. 
154 
 
[24] Maes, E., Tirez, K., Baggerman, G., Valkenborg, D., et al., The use of elemental mass spectrometry 
in phosphoproteomic applications. Mass Spectrom Rev 2014. 
[25] Gault, J., Malosse, C., Machata, S., Millien, C., et al., Complete posttranslational modification 
mapping of pathogenic Neisseria meningitidis pilins requires top-down mass spectrometry. Proteomics 
2014, 14, 1141-1151. 
[26] Butterfield, D. A., Dalle-Donne, I., Redox proteomics. Antioxid Redox Signal 2012, 17, 1487-1489. 
[27] Butterfield, D. A., Dalle-Donne, I., Redox proteomics: from protein modifications to cellular 
dysfunction and disease. Mass Spectrom Rev 2014, 33, 1-6. 
[28] Butterfield, D. A., Gu, L., Di Domenico, F., Robinson, R. A., Mass spectrometry and redox 
proteomics: applications in disease. Mass Spectrom Rev 2014, 33, 277-301. 
[29] Sultana, R., Perluigi, M., Newman, S. F., Pierce, W. M., et al., Redox proteomic analysis of 
carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox 
Signal 2010, 12, 327-336. 
[30] Baraibar, M. A., Ladouce, R., Friguet, B., Proteomic quantification and identification of 
carbonylated proteins upon oxidative stress and during cellular aging. J Proteomics 2013, 92, 63-70. 
[31] Yeo, W. S., Kim, Y. J., Kabir, M. H., Kang, J. W., Kim, K. P., Mass spectrometric analysis of 
protein tyrosine nitration in aging and neurodegenerative diseases. Mass Spectrom Rev 2014. 
[32] Feeney, M. B., Schoneich, C., Proteomic approaches to analyze protein tyrosine nitration. Antioxid 
Redox Signal 2013, 19, 1247-1256. 
[33] Butterfield, D. A., Perluigi, M., Reed, T., Muharib, T., et al., Redox proteomics in selected 
neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal 2012, 17, 
1610-1655. 
[34] Zhou, H., Ning, Z., Starr, A. E., Abu-Farha, M., Figeys, D., Advancements in top-down proteomics. 
Anal Chem 2012, 84, 720-734. 
[35] Helm, D. V., J.; Hughes, C. J.; Hahne, H.; Ruprecht, B.; Pachl, F.; Grzyb, A.; Richardson, K.; 
Wildgoose, J.; Maier, S. K.; Marx, H.; Wilhelm, M.; Becher, I.; Lemeer, S.; Bantscheff, M.; Langridge, J. 
155 
 
I.; Kuster, B., Ion Mobility Tandem Mass Spectrometry Enhances Performance of Bottom-up Proteomics. 
mol Cell Proteomics 2014, Article in Press. 
[36] Brown, L. M., in: Woods, A. G. D., C. C. (Ed.), Advancements of Mass Spectrometry in Biomedical 
Research, Springer International Puiblishing, Springer International Publishing Switzerland 2014, pp. 79-
91. 
[37] Simpson, D. C., Smith, R. D., Combining capillary electrophoresis with mass spectrometry for 
applications in proteomics. Electrophoresis 2005, 26, 1291-1305. 
[38] Righetti, P. G., Sebastiano, R., Citterio, A., Capillary electrophoresis and isoelectric focusing in 
peptide and protein analysis. Proteomics 2013, 13, 325-340. 
[39] Eng, J. K., McCormack, A. L., Yates, J. R., An approach to correlate tandem mass spectral data of 
peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994, 5, 976-989. 
[40] Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., Whitehouse, C. M., Electrospray ionization for 
mass spectrometry of large biomolecules. Science 1989, 246, 64-71. 
[41] Karas, M., Hillenkamp, F., Laser desorption ionization of proteins with molecular masses exceeding 
10,000 daltons. Anal Chem 1988, 60, 2299-2301. 
[42] Takats, Z., Wiseman, J. M., Ifa, D. R., Cooks, R. G., Desorption Electrospray Ionization (DESI) 
Analysis of Tryptic Digests/Peptides. CSH Protoc 2008, 2008, pdb prot4993. 
[43] Trimpin, S., Inutan, E. D., Herath, T. N., McEwen, C. N., Laserspray ionization, a new atmospheric 
pressure MALDI method for producing highly charged gas-phase ions of peptides and proteins directly 
from solid solutions. Mol Cell Proteomics 2010, 9, 362-367. 
[44] Pagnotti, V. S., Chubatyi, N. D., McEwen, C. N., Solvent assisted inlet ionization: an ultrasensitive 
new liquid introduction ionization method for mass spectrometry. Anal Chem 2011, 83, 3981-3985. 
[45] Xian, F., Hendrickson, C. L., Marshall, A. G., High resolution mass spectrometry. Anal Chem 2012, 
84, 708-719. 
[46] Perry, R. H., Cooks, R. G., Noll, R. J., Orbitrap mass spectrometry: instrumentation, ion motion and 
applications. Mass Spectrom Rev 2008, 27, 661-699. 
156 
 
[47] Page, J. S., Masselon, C. D., Smith, R. D., FTICR mass spectrometry for qualitative and quantitative 
bioanalyses. Curr Opin Biotechnol 2004, 15, 3-11. 
[48] Olsen, J. V., Schwartz, J. C., Griep-Raming, J., Nielsen, M. L., et al., A dual pressure linear ion trap 
Orbitrap instrument with very high sequencing speed. Mol Cell Proteomics 2009, 8, 2759-2769. 
[49] Michalski, A., Damoc, E., Lange, O., Denisov, E., et al., Ultra high resolution linear ion trap 
Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide 
fragmentation modes. Mol Cell Proteomics 2012, 11, O111 013698. 
[50] Michalski, A., Damoc, E., Hauschild, J. P., Lange, O., et al., Mass spectrometry-based proteomics 
using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer. Mol Cell 
Proteomics 2011, 10, M111 011015. 
[51] Denisov, E. D., E.; Lange, O.; Makarov, A., Orbitrap Mass Spectrometry with Resolving Powers 
above 1,000,000. International Journal of Mass Spectrometry 2012, 325-327, 80-85. 
[52] Senko, M. W., Remes, P. M., Canterbury, J. D., Mathur, R., et al., Novel parallelized 
quadrupole/linear ion trap/Orbitrap tribrid mass spectrometer improving proteome coverage and peptide 
identification rates. Anal Chem 2013, 85, 11710-11714. 
[53] Michalski, A., Cox, J., Mann, M., More than 100,000 detectable peptide species elute in single 
shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. J Proteome Res 
2011, 10, 1785-1793. 
[54] Shen, Y., Tolic, N., Xie, F., Zhao, R., et al., Effectiveness of CID, HCD, and ETD with FT MS/MS 
for degradomic-peptidomic analysis: comparison of peptide identification methods. J Proteome Res 2011, 
10, 3929-3943. 
[55] Kocher, T., Pichler, P., Schutzbier, M., Stingl, C., et al., High precision quantitative proteomics 
using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method combining the benefits of all. J 
Proteome Res 2009, 8, 4743-4752. 
[56] Olsen, J. V., Macek, B., Lange, O., Makarov, A., et al., Higher-energy C-trap dissociation for 
peptide modification analysis. Nat Methods 2007, 4, 709-712. 
157 
 
[57] Dayon, L., Pasquarello, C., Hoogland, C., Sanchez, J. C., Scherl, A., Combining low- and high-
energy tandem mass spectra for optimized peptide quantification with isobaric tags. J Proteomics 2010, 
73, 769-777. 
[58] MacCoss, M. J., Wu, C. C., Yates, J. R., 3rd, Probability-based validation of protein identifications 
using a modified SEQUEST algorithm. Anal Chem 2002, 74, 5593-5599. 
[59] Bairoch, A., Apweiler, R., Wu, C. H., Barker, W. C., et al., The Universal Protein Resource 
(UniProt). Nucleic Acids Res 2005, 33, D154-159. 
[60] Qian, W. J., Liu, T., Monroe, M. E., Strittmatter, E. F., et al., Probability-based evaluation of peptide 
and protein identifications from tandem mass spectrometry and SEQUEST analysis: the human proteome. 
J Proteome Res 2005, 4, 53-62. 
[61] Eng, J. K., Fischer, B., Grossmann, J., Maccoss, M. J., A fast SEQUEST cross correlation algorithm. 
J Proteome Res 2008, 7, 4598-4602. 
[62] Kall, L., Storey, J. D., MacCoss, M. J., Noble, W. S., Assigning significance to peptides identified by 
tandem mass spectrometry using decoy databases. J Proteome Res 2008, 7, 29-34. 
[63] Bantscheff, M., Lemeer, S., Savitski, M. M., Kuster, B., Quantitative mass spectrometry in 
proteomics: critical review update from 2007 to the present. Anal Bioanal Chem 2012, 404, 939-965. 
[64] Wasinger, V. C., Zeng, M., Yau, Y., Current status and advances in quantitative proteomic mass 
spectrometry. Int J Proteomics 2013, 2013, 180605. 
[65] Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., Kuster, B., Quantitative mass spectrometry in 
proteomics: a critical review. Anal Bioanal Chem 2007, 389, 1017-1031. 
[66] Schulze, W. X., Usadel, B., Quantitation in mass-spectrometry-based proteomics. Annu Rev Plant 
Biol 2010, 61, 491-516. 
[67] Xie, F., Liu, T., Qian, W. J., Petyuk, V. A., Smith, R. D., Liquid chromatography-mass 
spectrometry-based quantitative proteomics. J Biol Chem 2011, 286, 25443-25449. 
[68] Zhu, W., Smith, J. W., Huang, C. M., Mass spectrometry-based label-free quantitative proteomics. J 
Biomed Biotechnol 2010, 2010, 840518. 
158 
 
[69] Wang, M., You, J., Bemis, K. G., Tegeler, T. J., Brown, D. P., Label-free mass spectrometry-based 
protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomic 2008, 7, 329-
339. 
[70] Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., et al., Stable isotope labeling by amino 
acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell 
Proteomics 2002, 1, 376-386. 
[71] Rauniyar, N., McClatchy, D. B., Yates, J. R., 3rd, Stable isotope labeling of mammals (SILAM) for 
in vivo quantitative proteomic analysis. Methods 2013, 61, 260-268. 
[72] Wu, C. C., MacCoss, M. J., Howell, K. E., Matthews, D. E., Yates, J. R., 3rd, Metabolic labeling of 
mammalian organisms with stable isotopes for quantitative proteomic analysis. Anal Chem 2004, 76, 
4951-4959. 
[73] Chakraborty, A., Regnier, F. E., Global internal standard technology for comparative proteomics. J 
Chromatogr A 2002, 949, 173-184. 
[74] Boersema, P. J., Aye, T. T., van Veen, T. A., Heck, A. J., Mohammed, S., Triplex protein 
quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. 
Proteomics 2008, 8, 4624-4632. 
[75] Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S., Heck, A. J., Multiplex peptide stable 
isotope dimethyl labeling for quantitative proteomics. Nat Protoc 2009, 4, 484-494. 
[76] Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., et al., Quantitative analysis of complex protein 
mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17, 994-999. 
[77] Schmidt, A., Kellermann, J., Lottspeich, F., A novel strategy for quantitative proteomics using 
isotope-coded protein labels. Proteomics 2005, 5, 4-15. 
[78] Patton, G. C., Sanci, L. A., Sawyer, S. M., Adolescent medicine. Med J Aust 2002, 176, 3. 
[79] Bantscheff, M., Kuster, B., Quantitative mass spectrometry in proteomics. Anal Bioanal Chem 2012, 
404, 937-938. 
159 
 
[80] Becker, G. W., Stable isotopic labeling of proteins for quantitative proteomic applications. Brief 
Funct Genomic Proteomic 2008, 7, 371-382. 
[81] Nasef, A., Fouillard, L., El-Taguri, A., Lopez, M., Human bone marrow-derived mesenchymal stem 
cells. Libyan J Med 2007, 2, 190-201. 
[82] Zhang, J., Wang, Y., Li, S., Deuterium isobaric amine-reactive tags for quantitative proteomics. Anal 
Chem 2010, 82, 7588-7595. 
[83] Xiang, F., Ye, H., Chen, R., Fu, Q., Li, L., N,N-dimethyl leucines as novel isobaric tandem mass tags 
for quantitative proteomics and peptidomics. Anal Chem 2010, 82, 2817-2825. 
[84] McAlister, G. C., Huttlin, E. L., Haas, W., Ting, L., et al., Increasing the multiplexing capacity of 
TMTs using reporter ion isotopologues with isobaric masses. Anal Chem 2012, 84, 7469-7478. 
[85] Viner, R. B., R.; Blank, M.; Rogers, J., Increasing the Multiplexing of Protein Quantitation from 6- 
to 10-plex with Reporter Ion Isotopologues. Thermo Fisher Scientific Technical Note 2013. 
[86] Bantscheff, M., Boesche, M., Eberhard, D., Matthieson, T., et al., Robust and sensitive iTRAQ 
quantification on an LTQ Orbitrap mass spectrometer. Mol Cell Proteomics 2008, 7, 1702-1713. 
[87] Karp, N. A., Huber, W., Sadowski, P. G., Charles, P. D., et al., Addressing accuracy and precision 
issues in iTRAQ quantitation. Mol Cell Proteomics 2010, 9, 1885-1897. 
[88] Christoforou, A. L., Lilley, K. S., Isobaric tagging approaches in quantitative proteomics: the ups and 
downs. Anal Bioanal Chem 2012, 404, 1029-1037. 
[89] Wenger, C. D., Lee, M. V., Hebert, A. S., McAlister, G. C., et al., Gas-phase purification enables 
accurate, multiplexed proteome quantification with isobaric tagging. Nat Methods 2011, 8, 933-935. 
[90] Wuhr, M., Haas, W., McAlister, G. C., Peshkin, L., et al., Accurate multiplexed proteomics at the 
MS2 level using the complement reporter ion cluster. Anal Chem 2012, 84, 9214-9221. 
[91] Shliaha, P. V., Jukes-Jones, R., Christoforou, A., Fox, J., et al., Additional precursor purification in 
isobaric mass tagging experiments by traveling wave ion mobility separation (TWIMS). J Proteome Res 
2014, 13, 3360-3369. 
160 
 
[92] Sturm, R. M., Lietz, C. B., Li, L., Improved isobaric tandem mass tag quantification by ion mobility 
mass spectrometry. Rapid Commun Mass Spectrom 2014, 28, 1051-1060. 
[93] Savitski, M. M., Sweetman, G., Askenazi, M., Marto, J. A., et al., Delayed fragmentation and 
optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass 
tag quantification on Orbitrap-type mass spectrometers. Anal Chem 2011, 83, 8959-8967. 
[94] Ting, L., Rad, R., Gygi, S. P., Haas, W., MS3 eliminates ratio distortion in isobaric multiplexed 
quantitative proteomics. Nat Methods 2011, 8, 937-940. 
[95] Cihoric, N., Tapia, C., Kruger, K., Aebersold, D. M., et al., IMRT with (1)(8)FDG-PET\CT based 
simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol 2014, 9, 83. 
[96] Qu, J., Young, R., Page, B. J., Shen, X., et al., Reproducible ion-current-based approach for 24-plex 
comparison of the tissue proteomes of hibernating versus normal myocardium in swine models. J 
Proteome Res 2014, 13, 2571-2584. 
[97] Nouri-Nigjeh, E., Sukumaran, S., Tu, C., Li, J., et al., Highly multiplexed and reproducible ion-
current-based strategy for large-scale quantitative proteomics and the application to protein expression 
dynamics induced by methylprednisolone in 60 rats. Anal Chem 2014, 86, 8149-8157. 
[98] Robinson, R. A., Evans, A. R., Enhanced sample multiplexing for nitrotyrosine-modified proteins 
using combined precursor isotopic labeling and isobaric tagging. Anal Chem 2012, 84, 4677-4686. 
[99] Evans, A. R. R., R. A. S., Proteomics Quantification of Protein Nitration. Reviews in Analytical 
Chemistry 2013, 32, 173-187. 
[100] Evans, A. R., Robinson, R. A., Global combined precursor isotopic labeling and isobaric tagging 
(cPILOT) approach with selective MS(3) acquisition. Proteomics 2013, 13, 3267-3272. 
[101] Evans, A. R. G., L.; Guerrero Jr., R.; Robinson, R. A. S., Global cPILOT Analysis of the APP/PS-1 
Liver Proteome. Manuscript Submitted 2014. 
[102] Dephoure, N., Gygi, S. P., Hyperplexing: a method for higher-order multiplexed quantitative 
proteomics provides a map of the dynamic response to rapamycin in yeast. Sci Signal 2012, 5, rs2. 
161 
 
[103] Everley, R. A., Kunz, R. C., McAllister, F. E., Gygi, S. P., Increasing Throughput in Targeted 
Proteomics Assays: 54-plex Quantitation in a Single Mass Spectrometry Run. Anal Chem 2013. 
[104] Werner, T., Becher, I., Sweetman, G., Doce, C., et al., High-resolution enabled TMT 8-plexing. 
Anal Chem 2012, 84, 7188-7194. 
[105] Merrill, A. E., Hebert, A. S., MacGilvray, M. E., Rose, C. M., et al., NeuCode Labels for Relative 
Protein Quantification. Mol Cell Proteomics 2014, 13, 2503-2512. 
[106] Parker, J. B., K.; Zhu, F.; Zhu, N.; Chen, S., cysTMTRAQ - An Integrative Method for Unbiased 
Thiol-based Redox Proteomics. Mol Cell Proteomics 2014, Article in Press. 
[107] Evans, A. R., Miriyala, S., St Clair, D. K., Butterfield, D. A., Robinson, R. A., Global effects of 
adriamycin treatment on mouse splenic protein levels. J Proteome Res 2012, 11, 1054-1064. 
[108] Bonadonna, G., Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 
1992, 52, 2127-2137. 
[109] Di Marco, A., Gaetani, M., Scarpinato, B., Adriamycin (NSC-123,127): a new antibiotic with 
antitumor activity. Cancer Chemother Rep 1969, 53, 33-37. 
[110] Chuang, R. Y., Chuang, L. F., Inhibition of chicken myeloblastosis RNA polymerase II activity by 
adriamycin. Biochemistry 1979, 18, 2069-2073. 
[111] Cummings, J., Anderson, L., Willmott, N., Smyth, J. F., The molecular pharmacology of 
doxorubicin in vivo. Eur J Cancer 1991, 27, 532-535. 
[112] Buzdar, A. U., Marcus, C., Smith, T. L., Blumenschein, G. R., Early and delayed clinical 
cardiotoxicity of doxorubicin. Cancer 1985, 55, 2761-2765. 
[113] Aluise, C. D., Sultana, R., Tangpong, J., Vore, M., et al., Chemo brain (chemo fog) as a potential 
side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in 
cognitive dysfunction. Adv Exp Med Biol 2010, 678, 147-156. 
[114] Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W., van Dam, F. S., Neurophysiological 
evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001, 
51, 159-165. 
162 
 
[115] Multani, P., White, C. A., Grillo-Lopez, A., Non-Hodgkin's lymphoma: review of conventional 
treatments. Curr Pharm Biotechnol 2001, 2, 279-291. 
[116] Handa, K., Sato, S., Generation of free radicals of quinone group-containing anti-cancer chemicals 
in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gan 1975, 66, 43-47. 
[117] Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., St Clair, D. K., Collateral damage in 
cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007, 7, 147-156. 
[118] Aluise, C. D., St Clair, D., Vore, M., Butterfield, D. A., In vivo amelioration of adriamycin induced 
oxidative stress in plasma by gamma-glutamylcysteine ethyl ester (GCEE). Cancer Lett 2009, 282, 25-29. 
[119] Joshi, G., Sultana, R., Tangpong, J., Cole, M. P., et al., Free radical mediated oxidative stress and 
toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free 
Radic Res 2005, 39, 1147-1154. 
[120] Llesuy, S. F., Milei, J., Gonzalez Flecha, B. S., Boveris, A., Myocardial damage induced by 
doxorubicins: hydroperoxide-initiated chemiluminescence and morphology. Free Radic Biol Med 1990, 
8, 259-264. 
[121] DeAtley, S. M., Aksenov, M. Y., Aksenova, M. V., Carney, J. M., Butterfield, D. A., Adriamycin 
induces protein oxidation in erythrocyte membranes. Pharmacol Toxicol 1998, 83, 62-68. 
[122] Qin, X. J., He, W., Hai, C. X., Liang, X., Liu, R., Protection of multiple antioxidants Chinese herbal 
medicine on the oxidative stress induced by adriamycin chemotherapy. J Appl Toxicol 2008, 28, 271-282. 
[123] Prahalathan, C., Selvakumar, E., Varalakshmi, P., Remedial effect of DL-alpha-lipoic acid against 
adriamycin induced testicular lipid peroxidation. Mol Cell Biochem 2004, 267, 209-214. 
[124] Kalaiselvi, P., Pragasam, V., Chinnikrishnan, S., Veena, C. K., et al., Counteracting adriamycin-
induced oxidative stress by administration of N-acetyl cysteine and vitamin E. Clin Chem Lab Med 2005, 
43, 834-840. 
[125] Siegfried, J. A., Kennedy, K. A., Sartorelli, A. C., Tritton, T. R., The role of membranes in the 
mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically 
hypoxic and drug-resistant tumor cells. J Biol Chem 1983, 258, 339-343. 
163 
 
[126] Kusuoka, H., Futaki, S., Koretsune, Y., Kitabatake, A., et al., Alterations of intracellular calcium 
homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc 
Pharmacol 1991, 18, 437-444. 
[127] Singh, V., Singh, S. M., Effect of high cell density on the growth properties of tumor cells: a role in 
tumor cytotoxicity of chemotherapeutic drugs. Anticancer Drugs 2007, 18, 1123-1132. 
[128] Joshi, G., Aluise, C. D., Cole, M. P., Sultana, R., et al., Alterations in brain antioxidant enzymes 
and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: 
implications for oxidative stress-mediated chemobrain. Neuroscience 2010, 166, 796-807. 
[129] Joshi, G., Hardas, S., Sultana, R., St Clair, D. K., et al., Glutathione elevation by gamma-glutamyl 
cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by 
in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 2007, 85, 497-503. 
[130] Aluise, C. D., Miriyala, S., Noel, T., Sultana, R., et al., 2-Mercaptoethane sulfonate prevents 
doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive 
oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 2011, 50, 1630-1638. 
[131] Chen, Y., Daosukho, C., Opii, W. O., Turner, D. M., et al., Redox proteomic identification of 
oxidized cardiac proteins in adriamycin-treated mice. Free Radic Biol Med 2006, 41, 1470-1477. 
[132] Chen, S. T., Pan, T. L., Tsai, Y. C., Huang, C. M., Proteomics reveals protein profile changes in 
doxorubicin--treated MCF-7 human breast cancer cells. Cancer Lett 2002, 181, 95-107. 
[133] Hammer, E., Bien, S., Salazar, M. G., Steil, L., et al., Proteomic analysis of doxorubicin-induced 
changes in the proteome of HepG2cells combining 2-D DIGE and LC-MS/MS approaches. Proteomics 
2010, 10, 99-114. 
[134] Dong, X., Xiong, L., Jiang, X., Wang, Y., Quantitative proteomic analysis reveals the perturbation 
of multiple cellular pathways in jurkat-T cells induced by doxorubicin. J Proteome Res 2010, 9, 5943-
5951. 
[135] Jiang, Y. J., Sun, Q., Fang, X. S., Wang, X., Comparative mitochondrial proteomic analysis of Rji 
cells exposed to adriamycin. Mol Med 2009, 15, 173-182. 
164 
 
[136] Sultana, R., Di Domenico, F., Tseng, M., Cai, J., et al., Doxorubicin-induced thymus senescence. J 
Proteome Res 2010, 9, 6232-6241. 
[137] Zhang, J. T., Liu, Y., Use of comparative proteomics to identify potential resistance mechanisms in 
cancer treatment. Cancer Treat Rev 2007, 33, 741-756. 
[138] Peng, X., Gong, F., Xie, G., Zhao, Y., et al., A proteomic investigation into adriamycin chemo-
resistance of human leukemia K562 cells. Mol Cell Biochem 2011, 351, 233-241. 
[139] Shen, S. H., Gu, L. J., Liu, P. Q., Ye, X., et al., Comparative proteomic analysis of differentially 
expressed proteins between K562 and K562/ADM cells. Chin Med J (Engl) 2008, 121, 463-468. 
[140] Zhu, F., Wang, Y., Zeng, S., Fu, X., et al., Involvement of annexin A1 in multidrug resistance of 
K562/ADR cells identified by the proteomic study. OMICS 2009, 13, 467-476. 
[141] Keenan, J., Murphy, L., Henry, M., Meleady, P., Clynes, M., Proteomic analysis of multidrug-
resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. 
Proteomics 2009, 9, 1556-1566. 
[142] Brown, K. J., Fenselau, C., Investigation of doxorubicin resistance in MCF-7 breast cancer cells 
using shot-gun comparative proteomics with proteolytic 18O labeling. J Proteome Res 2004, 3, 455-462. 
[143] Gehrmann, M. L., Fenselau, C., Hathout, Y., Highly altered protein expression profile in the 
adriamycin resistant MCF-7 cell line. J Proteome Res 2004, 3, 403-409. 
[144] Strong, R., Nakanishi, T., Ross, D., Fenselau, C., Alterations in the mitochondrial proteome of 
adriamycin resistant MCF-7 breast cancer cells. J Proteome Res 2006, 5, 2389-2395. 
[145] Orsini, F., Pavelic, Z., Mihich, E., Increased primary cell-mediated immunity in culture subsequent 
to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 1977, 37, 1719-1726. 
[146] Ji, J., Chakraborty, A., Geng, M., Zhang, X., et al., Strategy for qualitative and quantitative analysis 
in proteomics based on signature peptides. J Chromatogr B Biomed Sci Appl 2000, 745, 197-210. 
[147] Mebius, R. E., Kraal, G., Structure and function of the spleen. Nat Rev Immunol 2005, 5, 606-616. 
[148] Lee, J. W., Sung, N. Y., Kim, J. K., Kim, J. H., et al., Effect of gamma irradiation on spleen cell 
function and cytotoxicity of doxorubicin. Chem Biol Interact 2008, 173, 205-214. 
165 
 
[149] Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., et al., Hfe deficiency increases susceptibility 
to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 2003, 102, 
2574-2580. 
[150] Wu, W. R., Zheng, J. W., Li, N., Bai, H. Q., et al., Immunosuppressive effects of dihydroetorphine, 
a potent narcotic analgesic, in dihydroetorphine-dependent mice. Eur J Pharmacol 1999, 366, 261-269. 
[151] Zhang, X. Y., Li, W. G., Wu, Y. J., Zheng, T. Z., et al., Proanthocyanidin from grape seeds 
potentiates anti-tumor activity of doxorubicin via immunomodulatory mechanism. Int Immunopharmacol 
2005, 5, 1247-1257. 
[152] Cesta, M. F., Normal structure, function, and histology of the spleen. Toxicol Pathol 2006, 34, 455-
465. 
[153] Gerke, V., Moss, S. E., Annexins: from structure to function. Physiol Rev 2002, 82, 331-371. 
[154] Zhang, F., Zhang, L., Zhang, B., Wei, X., et al., Anxa2 plays a critical role in enhanced 
invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009, 8, 5041-5047. 
[155] Munoz, L. E., Frey, B., Pausch, F., Baum, W., et al., The role of annexin A5 in the modulation of 
the immune response against dying and dead cells. Curr Med Chem 2007, 14, 271-277. 
[156] Gehrmann, M. L., Hathout, Y., Fenselau, C., Evaluation of metabolic labeling for comparative 
proteomics in breast cancer cells. J Proteome Res 2004, 3, 1063-1068. 
[157] Gelebart, P., Opas, M., Michalak, M., Calreticulin, a Ca2+-binding chaperone of the endoplasmic 
reticulum. Int J Biochem Cell Biol 2005, 37, 260-266. 
[158] Gold, L. I., Eggleton, P., Sweetwyne, M. T., Van Duyn, L. B., et al., Calreticulin: non-endoplasmic 
reticulum functions in physiology and disease. FASEB J 2010, 24, 665-683. 
[159] Tufi, R., Panaretakis, T., Bianchi, K., Criollo, A., et al., Reduction of endoplasmic reticulum Ca2+ 
levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 2008, 15, 274-282. 
[160] Mayur, Y. C., Jagadeesh, S., Thimmaiah, K. N., Targeting calmodulin in reversing multi drug 
resistance in cancer cells. Mini Rev Med Chem 2006, 6, 1383-1389. 
166 
 
[161] Nicotera, P., Bellomo, G., Orrenius, S., Calcium-mediated mechanisms in chemically induced cell 
death. Annu Rev Pharmacol Toxicol 1992, 32, 449-470. 
[162] Storck, S., Shukla, M., Dimitrov, S., Bouvet, P., Functions of the histone chaperone nucleolin in 
diseases. Subcell Biochem 2007, 41, 125-144. 
[163] Bonello, T. T., Stehn, J. R., Gunning, P. W., New approaches to targeting the actin cytoskeleton for 
chemotherapy. Future Med Chem 2009, 1, 1311-1331. 
[164] Oikonomou, K. G., Zachou, K., Dalekos, G. N., Alpha-actinin: a multidisciplinary protein with 
important role in B-cell driven autoimmunity. Autoimmun Rev 2011, 10, 389-396. 
[165] Yang, Y. X., Sun, X. F., Cheng, A. L., Zhang, G. Y., et al., Increased expression of HSP27 linked 
to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol 2009, 135, 181-189. 
[166] Zhang, L. H., Zhang, X., Roles of GRP78 in physiology and cancer. J Cell Biochem 2010, 110, 
1299-1305. 
[167] Kubota, H., Hynes, G., Willison, K., The chaperonin containing t-complex polypeptide 1 (TCP-1). 
Multisubunit machinery assisting in protein folding and assembly in the eukaryotic cytosol. Eur J 
Biochem 1995, 230, 3-16. 
[168] Kazerounian, S., Yee, K. O., Lawler, J., Thrombospondins in cancer. Cell Mol Life Sci 2008, 65, 
700-712. 
[169] Piccard, H., Van den Steen, P. E., Opdenakker, G., Hemopexin domains as multifunctional 
liganding modules in matrix metalloproteinases and other proteins. J Leukoc Biol 2007, 81, 870-892. 
[170] Hempel, N., Carrico, P. M., Melendez, J. A., Manganese superoxide dismutase (Sod2) and redox-
control of signaling events that drive metastasis. Anticancer Agents Med Chem 2011, 11, 191-201. 
[171] Yen, H. C., Oberley, T. D., Vichitbandha, S., Ho, Y. S., St Clair, D. K., The protective role of 
manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J 
Clin Invest 1996, 98, 1253-1260. 
[172] Tokarska-Schlattner, M., Wallimann, T., Schlattner, U., Alterations in myocardial energy 
metabolism induced by the anti-cancer drug doxorubicin. C R Biol 2006, 329, 657-668. 
167 
 
[173] Lee, J. R., Lee, S. J., Kim, T. W., Kim, J. K., et al., Chemical approach for specific enrichment and 
mass analysis of nitrated peptides. Anal Chem 2009, 81, 6620-6626. 
[174] Yamakura, F., Taka, H., Fujimura, T., Murayama, K., Inactivation of human manganese-superoxide 
dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem 
1998, 273, 14085-14089. 
[175] Ferrante, R. J., Shinobu, L. A., Schulz, J. B., Matthews, R. T., et al., Increased 3-nitrotyrosine and 
oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997, 
42, 326-334. 
[176] Kong, S. K., Yim, M. B., Stadtman, E. R., Chock, P. B., Peroxynitrite disables the tyrosine 
phosphorylation regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to phosphorylate 
nitrated cdc2(6-20)NH2 peptide. Proc Natl Acad Sci U S A 1996, 93, 3377-3382. 
[177] Squier, T. C., Oxidative stress and protein aggregation during biological aging. Exp Gerontol 2001, 
36, 1539-1550. 
[178] Peluffo, G., Radi, R., Biochemistry of protein tyrosine nitration in cardiovascular pathology. 
Cardiovasc Res 2007, 75, 291-302. 
[179] Nemirovskiy, O. V., Radabaugh, M. R., Aggarwal, P., Funckes-Shippy, C. L., et al., Plasma 3-
nitrotyrosine is a biomarker in animal models of arthritis: Pharmacological dissection of iNOS' role in 
disease. Nitric Oxide 2009, 20, 150-156. 
[180] Butterfield, D. A., Reed, T., Sultana, R., Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified 
brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic Res 2011, 45, 59-
72. 
[181] Reynolds, M. R., Berry, R. W., Binder, L. I., Nitration in neurodegeneration: deciphering the 
"Hows" "nYs". Biochemistry 2007, 46, 7325-7336. 
[182] Good, P. F., Hsu, A., Werner, P., Perl, D. P., Olanow, C. W., Protein nitration in Parkinson's 
disease. J Neuropathol Exp Neurol 1998, 57, 338-342. 
168 
 
[183] Butterfield, D. A., Reed, T., Newman, S. F., Sultana, R., Roles of amyloid beta-peptide-associated 
oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild 
cognitive impairment. Free Radic Biol Med 2007, 43, 658-677. 
[184] Sowell, R. A. B., D.A., in: Landow, M. L. (Ed.), Cognitive Impairment:  Causes, Diagnosis and 
Treatment, Nova Science Publishers Inc, Hauppauge, NY 2010. 
[185] Sultana, R., Reed, T., Perluigi, M., Coccia, R., et al., Proteomic identification of nitrated brain 
proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 2007, 11, 839-851. 
[186] Reed, T. T., Pierce, W. M., Jr., Turner, D. M., Markesbery, W. R., Butterfield, D. A., Proteomic 
identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol 
Med 2009, 13, 2019-2029. 
[187] Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., et al., Proteomic identification of nitrated 
proteins in Alzheimer's disease brain. J Neurochem 2003, 85, 1394-1401. 
[188] Mazzola, J. L., Sirover, M. A., Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in 
Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem 2001, 76, 442-449. 
[189] Aksenova, M., Butterfield, D. A., Zhang, S. X., Underwood, M., Geddes, J. W., Increased protein 
oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. J 
Neurotrauma 2002, 19, 491-502. 
[190] Sultana, R. S., R.A.; Butterfield, D.A., in: Veasey, S. C. (Ed.), Oxidative Neural Injury, Humana 
Press Inc., New York, NY 2009, pp. 137-157. 
[191] Coleman, P. D., Flood, D. G., Neuron numbers and dendritic extent in normal aging and 
Alzheimer's disease. Neurobiol Aging 1987, 8, 521-545. 
[192] Sly, W. S., Hu, P. Y., Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev 
Biochem 1995, 64, 375-401. 
[193] Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., Gibson, G. E., Mitochondrial abnormalities in 
Alzheimer brain: mechanistic implications. Ann Neurol 2005, 57, 695-703. 
169 
 
[194] Castegna, A., Lauderback, C. M., Mohmmad-Abdul, H., Butterfield, D. A., Modulation of 
phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-
hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res 2004, 1004, 193-197. 
[195] Danielson, S. R., Held, J. M., Schilling, B., Oo, M., et al., Preferentially increased nitration of 
alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal Chem 2009, 81, 
7823-7828. 
[196] Jovanovic, S. V., Clements, D., MacLeod, K., Biomarkers of oxidative stress are significantly 
elevated in Down syndrome. Free Radic Biol Med 1998, 25, 1044-1048. 
[197] Browne, S. E., Ferrante, R. J., Beal, M. F., Oxidative stress in Huntington's disease. Brain Pathol 
1999, 9, 147-163. 
[198] Cookson, M. R., Shaw, P. J., Oxidative stress and motor neurone disease. Brain Pathol 1999, 9, 
165-186. 
[199] Abe, K., Pan, L. H., Watanabe, M., Kato, T., Itoyama, Y., Induction of nitrotyrosine-like 
immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 1995, 199, 
152-154. 
[200] Horiguchi, T., Uryu, K., Giasson, B. I., Ischiropoulos, H., et al., Nitration of tau protein is linked to 
neurodegeneration in tauopathies. Am J Pathol 2003, 163, 1021-1031. 
[201] Turko, I. V., Murad, F., Protein nitration in cardiovascular diseases. Pharmacol Rev 2002, 54, 619-
634. 
[202] Lee, J. R., Kim, J. K., Lee, S. J., Kim, K. P., Role of protein tyrosine nitration in neurodegenerative 
diseases and atherosclerosis. Arch Pharm Res 2009, 32, 1109-1118. 
[203] Upmacis, R. K., Atherosclerosis:  A Link Between Lipid Intake and Protein Tyrosine Nitration. 
Lipid Insights 2008, 2, 75-88. 
[204] Surmeli, N. B., Litterman, N. K., Miller, A. F., Groves, J. T., Peroxynitrite Mediates Active Site 
Tyrosine Nitration in Manganese Superoxide Dismutase. Evidence of a Role for the Carbonate Radical 
Anion. J Am Chem Soc 2010. 
170 
 
[205] Leeuwenburgh, C., Hardy, M. M., Hazen, S. L., Wagner, P., et al., Reactive nitrogen intermediates 
promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997, 272, 1433-
1436. 
[206] Sandhu, J. K., Robertson, S., Birnboim, H. C., Goldstein, R., Distribution of protein nitrotyrosine in 
synovial tissues of patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2003, 30, 1173-1181. 
[207] Turko, I. V., Li, L., Aulak, K. S., Stuehr, D. J., et al., Protein tyrosine nitration in the mitochondria 
from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes. J Biol Chem 2003, 
278, 33972-33977. 
[208] Azad, N., Rojanasakul, Y., Vallyathan, V., Inflammation and lung cancer: roles of reactive 
oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev 2008, 11, 1-15. 
[209] Pacher, P., Beckman, J. S., Liaudet, L., Nitric oxide and peroxynitrite in health and disease. Physiol 
Rev 2007, 87, 315-424. 
[210] Marshall, A., Lutfeaili, R., Raval, A., Chakravarti, D. N., Chakravarti, B., Differential hepatic 
protein tyrosine nitration of mouse due to aging - Effect on mitochondrial energy metabolism, quality 
control machinery of the endoplasmic reticulum and metabolism of drugs. Biochem Biophys Res Commun 
2012. 
[211] Zingarelli, B., Szabo, C., Salzman, A. L., Reduced oxidative and nitrosative damage in murine 
experimental colitis in the absence of inducible nitric oxide synthase. Gut 1999, 45, 199-209. 
[212] Thangaswamy, S., Bridenbaugh, E. A., Gashev, A. A., Evidence of increased oxidative stress in 
aged mesenteric lymphatic vessels. Lymphat Res Biol 2012, 10, 53-62. 
[213] Bronte, V., Kasic, T., Gri, G., Gallana, K., et al., Boosting antitumor responses of T lymphocytes 
infiltrating human prostate cancers. J Exp Med 2005, 201, 1257-1268. 
[214] Birnboim, H. C., Lemay, A. M., Lam, D. K., Goldstein, R., Webb, J. R., Cutting edge: MHC class 
II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central 
tolerance and elicit a robust cell-mediated immune response. J Immunol 2003, 171, 528-532. 
171 
 
[215] Bayden, A. S., Yakovlev, V. A., Graves, P. R., Mikkelsen, R. B., Kellogg, G. E., Factors 
influencing protein tyrosine nitration--structure-based predictive models. Free Radic Biol Med 2011, 50, 
749-762. 
[216] Kissner, R., Nauser, T., Bugnon, P., Lye, P. G., Koppenol, W. H., Formation and properties of 
peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse 
radiolysis. Chem Res Toxicol 1997, 10, 1285-1292. 
[217] Radi, R., Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci U S A 2004, 101, 
4003-4008. 
[218] Abello, N., Kerstjens, H. A., Postma, D. S., Bischoff, R., Protein tyrosine nitration: selectivity, 
physicochemical and biological consequences, denitration, and proteomics methods for the identification 
of tyrosine-nitrated proteins. J Proteome Res 2009, 8, 3222-3238. 
[219] Alvarez, B., Radi, R., Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003, 25, 
295-311. 
[220] Radi, R., Protein tyrosine nitration: biochemical mechanisms and structural basis of functional 
effects. Acc Chem Res 2013, 46, 550-559. 
[221] Monteiro, H. P., Arai, R. J., Travassos, L. R., Protein tyrosine phosphorylation and protein tyrosine 
nitration in redox signaling. Antioxid Redox Signal 2008, 10, 843-889. 
[222] Guo, W., Adachi, T., Matsui, R., Xu, S., et al., Quantitative assessment of tyrosine nitration of 
manganese superoxide dismutase in angiotensin II-infused rat kidney. Am J Physiol Heart Circ Physiol 
2003, 285, H1396-1403. 
[223] Rubbo, H., Radi, R., Protein and lipid nitration: role in redox signaling and injury. Biochim Biophys 
Acta 2008, 1780, 1318-1324. 
[224] Spickett, C. M., Pitt, A. R., Protein oxidation: role in signalling and detection by mass 
spectrometry. Amino Acids 2012, 42, 5-21. 
[225] Sokolovsky, M., Riordan, J. F., Vallee, B. L., Conversion of 3-nitrotyrosine to 3-aminotyrosine in 
peptides and proteins. Biochem Biophys Res Commun 1967, 27, 20-25. 
172 
 
[226] Souza, J. M., Peluffo, G., Radi, R., Protein tyrosine nitration--functional alteration or just a 
biomarker? Free Radic Biol Med 2008, 45, 357-366. 
[227] Casagrande, S., Bonetto, V., Fratelli, M., Gianazza, E., et al., Glutathionylation of human 
thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U 
S A 2002, 99, 9745-9749. 
[228] Uchida, K., Stadtman, E. R., Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-
phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J 
Biol Chem 1993, 268, 6388-6393. 
[229] Adibhatla, R. M., Hatcher, J. F., Lipid oxidation and peroxidation in CNS health and disease: from 
molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010, 12, 125-169. 
[230] Yates, J. R., Ruse, C. I., Nakorchevsky, A., Proteomics by mass spectrometry: approaches, 
advances, and applications. Annu Rev Biomed Eng 2009, 11, 49-79. 
[231] Li, B., Held, J. M., Schilling, B., Danielson, S. R., Gibson, B. W., Confident identification of 3-
nitrotyrosine modifications in mass spectral data across multiple mass spectrometry platforms. J 
Proteomics 2011, 74, 2510-2521. 
[232] Dekker, F., Abello, N., Wisastra, R., Bischoff, R., Enrichment and detection of tyrosine-nitrated 
proteins. Curr Protoc Protein Sci 2012, Chapter 14, Unit 14 13. 
[233] Helman, M., Givol, D., Isolation of nitrotyrosine-containing peptides by using an insoluble-
antibody column. Biochem J 1971, 125, 971-974. 
[234] Zhan, X., Desiderio, D. M., Nitroproteins from a human pituitary adenoma tissue discovered with a 
nitrotyrosine affinity column and tandem mass spectrometry. Anal Biochem 2006, 354, 279-289. 
[235] Nuriel, T., Deeb, R. S., Hajjar, D. P., Gross, S. S., Protein 3-nitrotyrosine in complex biological 
samples: quantification by high-pressure liquid chromatography/electrochemical detection and emergence 
of proteomic approaches for unbiased identification of modification sites. Methods Enzymol 2008, 441, 1-
17. 
173 
 
[236] Nikov, G., Bhat, V., Wishnok, J. S., Tannenbaum, S. R., Analysis of nitrated proteins by 
nitrotyrosine-specific affinity probes and mass spectrometry. Anal Biochem 2003, 320, 214-222. 
[237] Abello, N., Barroso, B., Kerstjens, H. A., Postma, D. S., Bischoff, R., Chemical labeling and 
enrichment of nitrotyrosine-containing peptides. Talanta 2010, 80, 1503-1512. 
[238] Zhang, Q., Qian, W. J., Knyushko, T. V., Clauss, T. R., et al., A method for selective enrichment 
and analysis of nitrotyrosine-containing peptides in complex proteome samples. J Proteome Res 2007, 6, 
2257-2268. 
[239] Kim, J. K., Lee, J. R., Kang, J. W., Lee, S. J., et al., Selective enrichment and mass spectrometric 
identification of nitrated peptides using fluorinated carbon tags. Anal Chem 2011, 83, 157-163. 
[240] Amoresano, A., Chiappetta, G., Pucci, P., D'Ischia, M., Marino, G., Bidimensional tandem mass 
spectrometry for selective identification of nitration sites in proteins. Anal Chem 2007, 79, 2109-2117. 
[241] Dremina, E. S., Li, X., Galeva, N. A., Sharov, V. S., et al., A methodology for simultaneous 
fluorogenic derivatization and boronate affinity enrichment of 3-nitrotyrosine-containing peptides. Anal 
Biochem 2011, 418, 184-196. 
[242] Ghesquiere, B., Colaert, N., Helsens, K., Dejager, L., et al., In vitro and in vivo protein-bound 
tyrosine nitration characterized by diagonal chromatography. Mol Cell Proteomics 2009, 8, 2642-2652. 
[243] Brown, J. R., Hartley, B. S., Location of disulphide bridges by diagonal paper electrophoresis. The 
disulphide bridges of bovine chymotrypsinogen A. Biochem J 1966, 101, 214-228. 
[244] Oldreive, C., Bradley, N., Bruckdorfer, R., Rice-Evans, C., Lack of influence of dietary 
nitrate/nitrite on plasma nitrotyrosine levels measured using a competitive inhibition of binding ELISA 
assay. Free Radic Res 2001, 35, 377-386. 
[245] Khan, J., Brennand, D. M., Bradley, N., Gao, B., et al., 3-Nitrotyrosine in the proteins of human 
plasma determined by an ELISA method. Biochem J 1998, 330 ( Pt 2), 795-801. 
[246] Wayenberg, J. L., Ransy, V., Vermeylen, D., Damis, E., Bottari, S. P., Nitrated plasma albumin as a 
marker of nitrative stress and neonatal encephalopathy in perinatal asphyxia. Free Radic Biol Med 2009, 
47, 975-982. 
174 
 
[247] Bayir, H., Kagan, V. E., Clark, R. S., Janesko-Feldman, K., et al., Neuronal NOS-mediated 
nitration and inactivation of manganese superoxide dismutase in brain after experimental and human 
brain injury. J Neurochem 2007, 101, 168-181. 
[248] Ceriello, A., Mercuri, F., Quagliaro, L., Assaloni, R., et al., Detection of nitrotyrosine in the 
diabetic plasma: evidence of oxidative stress. Diabetologia 2001, 44, 834-838. 
[249] Jin, H., Webb-Robertson, B. J., Peterson, E. S., Tan, R., et al., Smoking, COPD, and 3-nitrotyrosine 
levels of plasma proteins. Environ Health Perspect 2011, 119, 1314-1320. 
[250] Weber, D., Kneschke, N., Grimm, S., Bergheim, I., et al., Rapid and sensitive determination of 
protein-nitrotyrosine by ELISA: Application to human plasma. Free Radic Res 2012, 46, 276-285. 
[251] Qu, L. N., Yang, T. B., Yuan, Y. H., Zhong, P., et al., A novel competitive ELISA for both free and 
protein-bound nitrotyrosine. Hybrid Hybridomics 2003, 22, 401-406. 
[252] Pan, S., Aebersold, R., Chen, R., Rush, J., et al., Mass spectrometry based targeted protein 
quantification: methods and applications. J Proteome Res 2009, 8, 787-797. 
[253] Duncan, M. W., A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids 2003, 25, 
351-361. 
[254] Righetti, P. G. A., P.; Simo, C.; Citterio, A., in: Agrawal, G. K. R., R. (Ed.), Plant Proteomics:  
Technologies, Strategies, and Applications 2008, pp. 9-31. 
[255] Liu, F., Xiong, J., Huang, G. Y., Wang, W., [Study on the underlying mechanism of acupuncture in 
regulating neuroendocrine activity in dysmenorrhea rats]. Zhen Ci Yan Jiu 2009, 34, 3-8. 
[256] Viera, L., Ye, Y. Z., Estevez, A. G., Beckman, J. S., Immunohistochemical methods to detect 
nitrotyrosine. Methods Enzymol 1999, 301, 373-381. 
[257] Franco Mdo, C., Fortes, Z. B., Akamine, E. H., Kawamoto, E. M., et al., Tetrahydrobiopterin 
improves endothelial dysfunction and vascular oxidative stress in microvessels of intrauterine 
undernourished rats. J Physiol 2004, 558, 239-248. 
[258] Morrissey, B. M., Schilling, K., Weil, J. V., Silkoff, P. E., Rodman, D. M., Nitric oxide and protein 
nitration in the cystic fibrosis airway. Arch Biochem Biophys 2002, 406, 33-39. 
175 
 
[259] Soderling, A. S., Hultman, L., Delbro, D., Hojrup, P., Caidahl, K., Reduction of the nitro group 
during sample preparation may cause underestimation of the nitration level in 3-nitrotyrosine 
immunoblotting. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 851, 277-286. 
[260] Bigelow, D. J., Qian, W. J., Quantitative proteome mapping of nitrotyrosines. Methods Enzymol 
2008, 440, 191-205. 
[261] Wisastra, R., Poelstra, K., Bischoff, R., Maarsingh, H., et al., Antibody-free detection of protein 
tyrosine nitration in tissue sections. Chembiochem 2011, 12, 2016-2020. 
[262] Liu, H., Sadygov, R. G., Yates, J. R., 3rd, A model for random sampling and estimation of relative 
protein abundance in shotgun proteomics. Anal Chem 2004, 76, 4193-4201. 
[263] Smith, R. D., Anderson, G. A., Lipton, M. S., Pasa-Tolic, L., et al., An accurate mass tag strategy 
for quantitative and high-throughput proteome measurements. Proteomics 2002, 2, 513-523. 
[264] Willard, B. B., Ruse, C. I., Keightley, J. A., Bond, M., Kinter, M., Site-specific quantitation of 
protein nitration using liquid chromatography/tandem mass spectrometry. Anal Chem 2003, 75, 2370-
2376. 
[265] Ruse, C. I., Willard, B., Jin, J. P., Haas, T., et al., Quantitative dynamics of site-specific protein 
phosphorylation determined using liquid chromatography electrospray ionization mass spectrometry. Anal 
Chem 2002, 74, 1658-1664. 
[266] Chen, H. J., Chiu, W. L., Simultaneous detection and quantification of 3-nitrotyrosine and 3-
bromotyrosine in human urine by stable isotope dilution liquid chromatography tandem mass 
spectrometry. Toxicol Lett 2008, 181, 31-39. 
[267] Chen, H. J., Chen, Y. C., Reactive nitrogen oxide species-induced post-translational modifications 
in human hemoglobin and the association with cigarette smoking. Anal Chem 2012, 84, 7881-7890. 
[268] Riggs, L., Seeley, E. H., Regnier, F. E., Quantification of phosphoproteins with global internal 
standard technology. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 817, 89-96. 
176 
 
[269] Tsumoto, H., Taguchi, R., Kohda, K., Efficient identification and quantification of peptides 
containing nitrotyrosine by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
after derivatization. Chem Pharm Bull (Tokyo) 2010, 58, 488-494. 
[270] Feeney, M. B., Schoneich, C., Proteomic Approaches to Analyze Protein Tyrosine Nitration. 
Antioxid Redox Signal 2012. 
[271] Haandel, L. V. K., J.; Li, X.; Schoneich, C.; Stobaugh, J.F., Phenylisothiocyanate as a Multiple 
Chemical Dimension Reagent for the Relative Quantitation of Protein Nitrotyrosine. Chromatographia 
008, 68, 507-516. 
[272] Zhang, R., Regnier, F. E., Minimizing resolution of isotopically coded peptides in comparative 
proteomics. J Proteome Res 2002, 1, 139-147. 
[273] Thompson, A., Schafer, J., Kuhn, K., Kienle, S., et al., Tandem mass tags: a novel quantification 
strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 2003, 75, 1895-
1904. 
[274] Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., et al., Multiplexed protein quantitation 
in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 
3, 1154-1169. 
[275] Chiappetta, G., Corbo, C., Palmese, A., Galli, F., et al., Quantitative identification of protein 
nitration sites. Proteomics 2009, 9, 1524-1537. 
[276] Petersson, A. S., Steen, H., Kalume, D. E., Caidahl, K., Roepstorff, P., Investigation of tyrosine 
nitration in proteins by mass spectrometry. J Mass Spectrom 2001, 36, 616-625. 
[277] Sarver, A., Scheffler, N. K., Shetlar, M. D., Gibson, B. W., Analysis of peptides and proteins 
containing nitrotyrosine by matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass 
Spectrom 2001, 12, 439-448. 
[278] Gokulrangan, G., Zaidi, A., Michaelis, M. L., Schoneich, C., Proteomic analysis of protein nitration 
in rat cerebellum: effect of biological aging. J Neurochem 2007, 100, 1494-1504. 
177 
 
[279] Kanski, J., Hong, S. J., Schoneich, C., Proteomic analysis of protein nitration in aging skeletal 
muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization 
tandem mass spectrometry. J Biol Chem 2005, 280, 24261-24266. 
[280] Jiao, K., Mandapati, S., Skipper, P. L., Tannenbaum, S. R., Wishnok, J. S., Site-selective nitration 
of tyrosine in human serum albumin by peroxynitrite. Anal Biochem 2001, 293, 43-52. 
[281] Sacksteder, C. A., Qian, W. J., Knyushko, T. V., Wang, H., et al., Endogenously nitrated proteins in 
mouse brain: links to neurodegenerative disease. Biochemistry 2006, 45, 8009-8022. 
[282] van Haandel, L. K., J.; Li, X.; Schoneich, C.; Stobaugh, J. F., Phenylisothiocyanate as a Multiple 
Chemical Dimension Reagent for the Relative Quantitation of Protein Nitrotyrosine. Chromatographia 
2008, 68, 507-516. 
[283] Stevens, S. M., Jr., Prokai-Tatrai, K., Prokai, L., Factors that contribute to the misidentification of 
tyrosine nitration by shotgun proteomics. Mol Cell Proteomics 2008, 7, 2442-2451. 
[284] Ghesquiere, B., Goethals, M., Van Damme, J., Staes, A., et al., Improved tandem mass 
spectrometric characterization of 3-nitrotyrosine sites in peptides. Rapid Commun Mass Spectrom 2006, 
20, 2885-2893. 
[285] Ghesquiere, B., Helsens, K., Vandekerckhove, J., Gevaert, K., A stringent approach to improve the 
quality of nitrotyrosine peptide identifications. Proteomics 2011, 11, 1094-1098. 
[286] Zhang, Y., Yang, H., Poschl, U., Analysis of nitrated proteins and tryptic peptides by HPLC-chip-
MS/MS: site-specific quantification, nitration degree, and reactivity of tyrosine residues. Anal Bioanal 
Chem 2011, 399, 459-471. 
[287] Kim, J. Y., Kim, K. W., Kwon, H. J., Lee, D. W., Yoo, J. S., Probing lysine acetylation with a 
modification-specific marker ion using high-performance liquid chromatography/electrospray-mass 
spectrometry with collision-induced dissociation. Anal Chem 2002, 74, 5443-5449. 
[288] Kuzyk, M. A., Ohlund, L. B., Elliott, M. H., Smith, D., et al., A comparison of MS/MS-based, 
stable-isotope-labeled, quantitation performance on ESI-quadrupole TOF and MALDI-TOF/TOF mass 
spectrometers. Proteomics 2009, 9, 3328-3340. 
178 
 
[289] Ow, S. Y., Salim, M., Noirel, J., Evans, C., et al., iTRAQ underestimation in simple and complex 
mixtures: "the good, the bad and the ugly". J Proteome Res 2009, 8, 5347-5355. 
[290] Vincent, C. E. L., A. R.; Westphall, M. S.; Coon, J. J., 59th ASMS Conference on Mass 
Specttrometry and Allied Topics, American Society of Mass Spectrometry, Denver, CO 2011. 
[291] Pichler, P., Kocher, T., Holzmann, J., Mazanek, M., et al., Peptide labeling with isobaric tags yields 
higher identification rates using iTRAQ 4-plex compared to TMT 6-plex and iTRAQ 8-plex on LTQ 
Orbitrap. Anal Chem 2010, 82, 6549-6558. 
[292] Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S., et al., Eight-channel iTRAQ enables 
comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 2008, 7, 853-863. 
[293] Koehler, C. J., Arntzen, M. O., de Souza, G. A., Thiede, B., An approach for triplex-isobaric 
peptide termini labeling (triplex-IPTL). Anal Chem 2013, 85, 2478-2485. 
[294] Dayon, L., Sonderegger, B., Kussmann, M., Combination of gas-phase fractionation and MS(3) 
acquisition modes for relative protein quantification with isobaric tagging. J Proteome Res 2012, 11, 
5081-5089. 
[295] Thingholm, T. E., Palmisano, G., Kjeldsen, F., Larsen, M. R., Undesirable charge-enhancement of 
isobaric tagged phosphopeptides leads to reduced identification efficiency. J Proteome Res 2010, 9, 4045-
4052. 
[296] Association, A. s., 2013 Alzheimer's Disease Facts and Figures. Alzheimer's Dementia 2013, 9. 
[297] Duyckaerts, C., Delatour, B., Potier, M. C., Classification and basic pathology of Alzheimer 
disease. Acta Neuropathol 2009, 118, 5-36. 
[298] Wolfe, M. S., The gamma-secretase complex: membrane-embedded proteolytic ensemble. 
Biochemistry 2006, 45, 7931-7939. 
[299] Papassotiropoulos, A., Fountoulakis, M., Dunckley, T., Stephan, D. A., Reiman, E. M., Genetics, 
transcriptomics, and proteomics of Alzheimer's disease. J Clin Psychiatry 2006, 67, 652-670. 
[300] Hall, A. M., Roberson, E. D., Mouse models of Alzheimer's disease. Brain Res Bull 2012, 88, 3-12. 
179 
 
[301] Saito, T., Matsuba, Y., Mihira, N., Takano, J., et al., Single App knock-in mouse models of 
Alzheimer's disease. Nat Neurosci 2014, 17, 661-663. 
[302] Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., et al., ApoE promotes the proteolytic 
degradation of Abeta. Neuron 2008, 58, 681-693. 
[303] Hooijmans, C. R., Kiliaan, A. J., Fatty acids, lipid metabolism and Alzheimer pathology. Eur J 
Pharmacol 2008, 585, 176-196. 
[304] Grimm, M. O., Rothhaar, T. L., Hartmann, T., The role of APP proteolytic processing in lipid 
metabolism. Exp Brain Res 2012, 217, 365-375. 
[305] Xiong, H., Callaghan, D., Jones, A., Walker, D. G., et al., Cholesterol retention in Alzheimer's brain 
is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 2008, 
29, 422-437. 
[306] Chen, Z., Zhong, C., Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: 
implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013, 108, 21-43. 
[307] Steculorum, S. M., Solas, M., Bruning, J. C., The paradox of neuronal insulin action and resistance 
in the development of aging-associated diseases. Alzheimers Dement 2014, 10, S3-11. 
[308] Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., et al., Brain fuel metabolism, aging, and 
Alzheimer's disease. Nutrition 2011, 27, 3-20. 
[309] Lin, M. T., Beal, M. F., Mitochondrial dysfunction and oxidative stress in neurodegenerative 
diseases. Nature 2006, 443, 787-795. 
[310] Sutcliffe, J. G., Hedlund, P. B., Thomas, E. A., Bloom, F. E., Hilbush, B. S., Peripheral reduction of 
beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci 
Res 2011, 89, 808-814. 
[311] Zhang, Y., Zhou, B., Zhang, F., Wu, J., et al., Amyloid-beta induces hepatic insulin resistance by 
activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012, 61, 1434-1443. 
[312] Veszelka, S., Toth, A. E., Walter, F. R., Datki, Z., et al., Docosahexaenoic acid reduces amyloid-
beta induced toxicity in cells of the neurovascular unit. J Alzheimers Dis 2013, 36, 487-501. 
180 
 
[313] Astarita, G., Jung, K. M., Berchtold, N. C., Nguyen, V. Q., et al., Deficient liver biosynthesis of 
docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 2010, 5, 
e12538. 
[314] Hooijmans, C. R., Rutters, F., Dederen, P. J., Gambarota, G., et al., Changes in cerebral blood 
volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet 
or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 2007, 28, 16-29. 
[315] Ghiso, J., Shayo, M., Calero, M., Ng, D., et al., Systemic catabolism of Alzheimer's Abeta40 and 
Abeta42. J Biol Chem 2004, 279, 45897-45908. 
[316] Sagare, A., Deane, R., Bell, R. D., Johnson, B., et al., Clearance of amyloid-beta by circulating 
lipoprotein receptors. Nat Med 2007, 13, 1029-1031. 
[317] Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., et al., Major involvement of low-density 
lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. 
Pharm Res 2006, 23, 1407-1416. 
[318] Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., et al., Withania somnifera reverses Alzheimer's 
disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad 
Sci U S A 2012, 109, 3510-3515. 
[319] Sagare, A. P., Deane, R., Zetterberg, H., Wallin, A., et al., Impaired lipoprotein receptor-mediated 
peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding 
Alzheimer's disease. J Alzheimers Dis 2011, 24, 25-34. 
[320] Reddy, J. K., Rao, M. S., Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty 
acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006, 290, G852-858. 
[321] Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., et al., Characterization of 
amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24, 
516-524. 
[322] Robinson, R. A., Joshi, G., Huang, Q., Sultana, R., et al., Proteomic analysis of brain proteins in 
APP/PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights 
181 
 
into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild 
cognitive impairment and Alzheimer's disease. Proteomics 2011, 11, 4243-4256. 
[323] Sultana, R., Robinson, R. A., Di Domenico, F., Abdul, H. M., et al., Proteomic identification of 
specifically carbonylated brain proteins in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human 
double mutant knock-in mice model of Alzheimer disease as a function of age. J Proteomics 2011, 74, 
2430-2440. 
[324] Cao, Z., Robinson, R. A., Proteome characterization of splenocytes from an Abetapp/ps-1 
Alzheimer's disease model. Proteomics 2013. 
[325] Lv, J., Ma, S., Zhang, X., Zheng, L., et al., Quantitative proteomics reveals that PEA15 regulates 
astroglial Abeta phagocytosis in an Alzheimer's disease mouse model. J Proteomics 2014, 110C, 45-58. 
[326] Gu, L., Evans, A.; Robinson, R.A.S, Sample Multiplexing with Cysteine-selective Approaches: 
cysDML and cPILOT. J. Amer. Soc. Mass Spec., Manuscript Submitted. 
[327] Cao, Z., Yende, S., Kellum, J. A., Robinson, R. A., Additions to the Human Plasma Proteome via a 
Tandem MARS Depletion iTRAQ-Based Workflow. Int J Proteomics 2013, 2013, 654356. 
[328] Mi, H., Muruganujan, A., Thomas, P. D., PANTHER in 2013: modeling the evolution of gene 
function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013, 41, 
D377-386. 
[329] Dayon, L., Hainard, A., Licker, V., Turck, N., et al., Relative quantification of proteins in human 
cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 2008, 80, 2921-2931. 
[330] McAlister, G. C., Nusinow, D. P., Jedrychowski, M. P., Wuhr, M., et al., MultiNotch MS3 enables 
accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. 
Anal Chem 2014, 86, 7150-7158. 
[331] Fang, R., Elias, D. A., Monroe, M. E., Shen, Y., et al., Differential label-free quantitative proteomic 
analysis of Shewanella oneidensis cultured under aerobic and suboxic conditions by accurate mass and 
time tag approach. Mol Cell Proteomics 2006, 5, 714-725. 
182 
 
[332] de la Monte, S. M., Tong, M., Brain metabolic dysfunction at the core of Alzheimer's disease. 
Biochem Pharmacol 2014, 88, 548-559. 
[333] Wong, B. X., Hung, Y. H., Bush, A. I., Duce, J. A., Metals and cholesterol: two sides of the same 
coin in Alzheimer's disease pathology. Front Aging Neurosci 2014, 6, 91. 
[334] Sowell, R. A., Owen, J. B., Butterfield, D. A., Proteomics in animal models of Alzheimer's and 
Parkinson's diseases. Ageing Res Rev 2009, 8, 1-17. 
[335] Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., et al., Mutant presenilins specifically 
elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-
specific gamma secretase. Hum Mol Genet 2004, 13, 159-170. 
[336] Bartlett, K., Eaton, S., Mitochondrial beta-oxidation. Eur J Biochem 2004, 271, 462-469. 
[337] Reddy, J. K., Hashimoto, T., Peroxisomal beta-oxidation and peroxisome proliferator-activated 
receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001, 21, 193-230. 
[338] Chou, J. L., Shenoy, D. V., Thomas, N., Choudhary, P. K., et al., Early dysregulation of the 
mitochondrial proteome in a mouse model of Alzheimer's disease. J Proteomics 2011, 74, 466-479. 
[339] Owen, O. E., Ketone Bodies as a fuel for the Brain during Starvation. Biochemistry and Molecular 
Biology Education 2005, 33, 246-251. 
[340] Henderson, S. T., Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 2008, 
5, 470-480. 
[341] Beckett, T. L., Studzinski, C. M., Keller, J. N., Paul Murphy, M., Niedowicz, D. M., A ketogenic 
diet improves motor performance but does not affect beta-amyloid levels in a mouse model of 
Alzheimer's disease. Brain Res 2013, 1505, 61-67. 
[342] Gray, L. R., Tompkins, S. C., Taylor, E. B., Regulation of pyruvate metabolism and human disease. 
Cell Mol Life Sci 2014, 71, 2577-2604. 
[343] Lai, J. C., Cooper, A. J., Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, 
regional distribution, and effects of inhibitors. J Neurochem 1986, 47, 1376-1386. 
183 
 
[344] Ott, P., Vilstrup, H., Cerebral effects of ammonia in liver disease: current hypotheses. Metab Brain 
Dis 2014. 
[345] Senior, J. R., Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, 
present, and future. Clin Pharmacol Ther 2012, 92, 332-339. 
[346] Seiler, N., Ammonia and Alzheimer's disease. Neurochem Int 2002, 41, 189-207. 
[347] Ponka, P., Cell biology of heme. Am J Med Sci 1999, 318, 241-256. 
[348] Jomova, K., Vondrakova, D., Lawson, M., Valko, M., Metals, oxidative stress and 
neurodegenerative disorders. Mol Cell Biochem 2010, 345, 91-104. 
[349] Atamna, H., Frey, W. H., 2nd, Mechanisms of mitochondrial dysfunction and energy deficiency in 
Alzheimer's disease. Mitochondrion 2007, 7, 297-310. 
[350] Foxton, R. H., Land, J. M., Heales, S. J., Tetrahydrobiopterin availability in Parkinson's and 
Alzheimer's disease; potential pathogenic mechanisms. Neurochem Res 2007, 32, 751-756. 
[351] Dumont, M., Beal, M. F., Neuroprotective strategies involving ROS in Alzheimer disease. Free 
Radic Biol Med 2011, 51, 1014-1026. 
[352] Rhein, V., Song, X., Wiesner, A., Ittner, L. M., et al., Amyloid-beta and tau synergistically impair 
the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U 
S A 2009, 106, 20057-20062. 
[353] Dringen, R., Pawlowski, P. G., Hirrlinger, J., Peroxide detoxification by brain cells. J Neurosci Res 
2005, 79, 157-165. 
[354] Erickson, J. R., Joiner, M. L., Guan, X., Kutschke, W., et al., A dynamic pathway for calcium-
independent activation of CaMKII by methionine oxidation. Cell 2008, 133, 462-474. 
[355] Ding, Q., Markesbery, W. R., Cecarini, V., Keller, J. N., Decreased RNA, and increased RNA 
oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 2006, 31, 705-710. 
[356] Myung, N. H., Zhu, X., Kruman, II, Castellani, R. J., et al., Evidence of DNA damage in Alzheimer 
disease: phosphorylation of histone H2AX in astrocytes. Age (Dordr) 2008, 30, 209-215. 
184 
 
[357] McKinnon, P. J., DNA repair deficiency and neurological disease. Nat Rev Neurosci 2009, 10, 100-
112. 
[358] Altelaar, A. F., Frese, C. K., Preisinger, C., Hennrich, M. L., et al., Benchmarking stable isotope 
labeling based quantitative proteomics. J Proteomics 2013, 88, 14-26. 
[359] Wu, Y., Wang, F., Liu, Z., Qin, H., et al., Five-plex isotope dimethyl labeling for quantitative 
proteomics. Chem Commun (Camb) 2014, 50, 1708-1710. 
[360] Li, L. X., F.; Greer, T.; Frost, D.; Liang, Z., United States 2013. 
[361] Frost, D. C., Greer, T., Li, L., High-resolution Enabled 12-Plex DiLeu Isobaric Tags for 
Quantitative Proteomics. Anal Chem 2014. 
[362] Kaminski, Z. J., Kolesinska, B., Kolesinska, J., Sabatino, G., et al., N-triazinylammonium 
tetrafluoroborates. A new generation of efficient coupling reagents useful for peptide synthesis. J Am 
Chem Soc 2005, 127, 16912-16920. 
[363] Hu, W., Tedesco, S., Faedda, R., Petrone, G., et al., Covalent selection of the thiol proteome on 
activated thiol sepharose: a robust tool for redox proteomics. Talanta 2010, 80, 1569-1575. 
[364] Weston, L. A., Bauer, K. M., Skube, S. B., Hummon, A. B., Selective, bead-based global peptide 
capture using a bifunctional cross-linker. Anal Chem 2013, 85, 10675-10679. 
[365] McClatchy, D. B. Y., J. R., in: Martins-de-Souza, D. (Ed.), Shotgun Proteomics:  Methods in 
Molecular Biology, Springer, New York 2014, pp. 133-146. 
[366] Hebert, A. S. M., A. E.; Richards, A. L.; MacGilvray, M. E.; Kwiecien, N. W.; Rose, C. M.; Bailey, 
D. J.; Coon, J., NeuCode Mouse and One Hour Proteomics. Mol Cell Proteomics 2014, 13, S31-S32. 
[367] Saveliev, S. E., L.; Strauss, E.; Jones, R.; Rosenblatt, M., in: Note, P. T. (Ed.) 2012. 
[368] Kellermann, J., ICPL--isotope-coded protein label. Methods Mol Biol 2008, 424, 113-123. 
[369] Com, E., Clavreul, A., Lagarrigue, M., Michalak, S., et al., Quantitative proteomic Isotope-Coded 
Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J 
Proteomics 2012, 75, 3898-3913. 
185 
 
[370] Lange, O. D., E.; Wieghaus, A.; Makarov, A., ENhanced Fourier Transform for Orbitrap Mass 
Spectrometry. International Journal of Mass Spectrometry 2014, 369, 16-22. 
[371] Cherrington, A. D. E., D.; Sindelar, D. K., The Direct and Indirect Effects of Insulin on Hepatic 
Glucose Production in Vivo. Diabetologia 1998, 41, 987-996. 
[372] Brosnan, J. T., Glutamate, at the interface between amino acid and carbohydrate metabolism. J Nutr 
2000, 130, 988S-990S. 
[373] Moore, J. K., Love, E., Craig, D. G., Hayes, P. C., Simpson, K. J., Acute kidney injury in acute 
liver failure: a review. Expert Rev Gastroenterol Hepatol 2013, 7, 701-712. 
[374] Wang, X. L., Suzuki, R., Lee, K., Tran, T., et al., Ablation of ARNT/HIF1beta in liver alters 
gluconeogenesis, lipogenic gene expression, and serum ketones. Cell Metab 2009, 9, 428-439. 
[375] Schooneman, M. G., Vaz, F. M., Houten, S. M., Soeters, M. R., Acylcarnitines: reflecting or 
inflicting insulin resistance? Diabetes 2013, 62, 1-8. 
[376] Mansour, F. R., Wei, W., Danielson, N. D., Separation of carnitine and acylcarnitines in biological 
samples: a review. Biomed Chromatogr 2013, 27, 1339-1353. 
[377] Santa, T., Derivatization reagents in liquid chromatography/electrospray ionization tandem mass 
spectrometry. Biomed Chromatogr 2011, 25, 1-10. 
[378] Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., Coon, J. J., Parallel reaction 
monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell 
Proteomics 2012, 11, 1475-1488. 
 
 
186 
 
